TY - JOUR TI - 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024 JF - DIABETES CARE J2 - DIABETES CARE VL - 47 PY - 2024 SP - S179 EP - S218 SN - 0149-5992 DO - 10.2337/dc24-S010 UR - https://m2.mtmt.hu/api/publication/34444102 ID - 34444102 N1 - Export Date: 19 December 2023 CODEN: DICAD AB - The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an in-terprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA stand-ards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. © 2023 by the American Diabetes Association. LA - English DB - MTMT ER - TY - JOUR AU - Abdin, Amr AU - Boehm, Michael TI - Therapy of heart failure with reduced pump function JF - DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT J2 - DEUT MED WOCHENSCHR VL - 149 PY - 2024 IS - 04 SP - 157 EP - 165 PG - 9 SN - 0012-0472 DO - 10.1055/a-2054-9636 UR - https://m2.mtmt.hu/api/publication/34582822 ID - 34582822 N1 - Export Date: 29 February 2024 CODEN: DMWOA Correspondence Address: Abdin, A.; Klinik für Innere Medizin III-Kardiologie, Kirrberger Straβe 100, Germany; email: amr.abdin@uks.eu AB - HFrEF causes significant morbidity and mortality and represents a major public health burden. Recently, there have been significant scientific advances in the treatment of HFrEF, with ARNI, BB, MRA, and SGLT-2i forming the GDMT for HFrEF. Basic quadruple therapy has been shown to significantly reduce of HF hospitalizations, all-cause mortality, and cardiovascular mortality. In addition, new initiation and titration procedures have recently been introduced that may progressively improve the management and prognosis of HFrEF. Further efforts are also needed to improve the use of GDMT, which is currently underutilized. LA - German DB - MTMT ER - TY - JOUR AU - Aldafas, Rami AU - Crabtree, Tomas AU - Alkharaiji, Mohammed AU - Vinogradova, Yana AU - Idris, Iskandar TI - Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis JF - AGE AND AGEING J2 - AGE AGEING VL - 53 PY - 2024 IS - 1 PG - 13 SN - 0002-0729 DO - 10.1093/ageing/afad254 UR - https://m2.mtmt.hu/api/publication/34623850 ID - 34623850 N1 - Export Date: 17 April 2024 CODEN: AANGA Correspondence Address: Idris, I.; Division of Graduate Entry Medicine, Uttoxeter Road, United Kingdom; email: iskandar.idris@nottingham.ac.uk Chemicals/CAS: canagliflozin, 842133-18-0, 928672-86-0; dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; hemoglobin A1c, 62572-11-6; ipragliflozin, 761423-87-4; luseogliflozin, 898537-18-3; sotagliflozin, 1018899-04-1; glucose, 50-99-7, 84778-64-3, 8027-56-3; glycated hemoglobin, 9062-63-9; sodium, 7440-23-5; Glucose; Glycated Hemoglobin; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors LA - English DB - MTMT ER - TY - JOUR AU - Ali, M.U. AU - Mancini, G.B.J. AU - Fitzpatrick-Lewis, D. AU - Connelly, K.A. AU - O’Meara, E. AU - Zieroth, S. AU - Sherifali, D. TI - The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis JF - CARDIOVASCULAR DIABETOLOGY J2 - CARDIOVASC DIABETOL VL - 23 PY - 2024 IS - 1 SN - 1475-2840 DO - 10.1186/s12933-024-02154-w UR - https://m2.mtmt.hu/api/publication/34728497 ID - 34728497 N1 - Department of Clinical Epidemiology & amp; Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton, Canada Division of Cardiology, Centre for Cardiovascular Innovation, Department of Medicine, University of British Columbia, Vancouver, BC, Canada School of Nursing, Faculty of Health Sciences, McMaster University, Hamilton, Canada Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON M5B 1W8, Canada Division of Cardiology, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada Export Date: 10 March 2024 CODEN: CDAIA Correspondence Address: Sherifali, D.; School of Nursing, Canada; email: dsherif@mcmaster.ca Chemicals/CAS: glucagon like peptide 1, 89750-14-1; glucose, 50-99-7, 84778-64-3, 8027-56-3; sodium, 7440-23-5; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Hypoglycemic Agents; Sodium; Symporters AB - Background: The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, additional trials of relevance for SGLT2i have been published. This update re-evaluates the clinical recommendations for using SGLTi and their indirect comparison with existing evidence on GLP-1RA as compared to the standard of care to reduce cardiorenal morbidity and mortality. Methods: We updated our existing search and screening of the literature from September 2021 to April 2023 for randomized controlled trials of SGLT2i and GLP-1RA with placebo control. We conducted risk of bias assessment, data extraction and updated our meta-analysis of studies with similar interventions and components. The certainty of the evidence was determined using GRADE. Results: Evidence from three new trials and additional results from an updated existing trial on SGLT2i met our inclusion criteria after an updated search. Across all the included studies, the total sample size was 151,023 adults, with 90,943 in SGLT2i trials and 60,080 in GLP-1 RA trials. The mean age ranged from 59.9 to 68.4 years. Compared with standard care, the use of SGLT2i and GLP-1 RA showed significant reductions in the outcomes of cardiovascular (CV) mortality (14% & 13%), any-cause mortality (12% & 12%), major adverse CV events (MACE) (11% & 14%), heart failure (HF) hospitalization (30% & 9%), CV death or HF hospitalization (23% & 11%), and kidney composite outcome (32% & 22%). In participants with T2D, both classes demonstrated significant cardiorenal protection. But, only GLP-1RA showed a reduction in non-fatal stroke (16%) and only SGLT2i showed a reduction in HF hospitalization (30%) in this population of people living with T2D. Conclusions: This updated and comprehensive meta-analysis substantiates and strengthens the clinical recommendations of the CCS cardiorenal guidelines. © The Author(s) 2024. LA - English DB - MTMT ER - TY - JOUR AU - Allen, L.A. TI - CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure JF - JACC-HEART FAILURE J2 - JACC HEART FAILURE VL - 12 PY - 2024 IS - 4 SP - 719 EP - 721 PG - 3 SN - 2213-1779 DO - 10.1016/j.jchf.2024.02.010 UR - https://m2.mtmt.hu/api/publication/34766677 ID - 34766677 N1 - Export Date: 3 April 2024 Correspondence Address: Allen, L.A.; University of Colorado, 12631 East 17th Avenue, Academic Office One, #7121, Mailstop B130, United States; email: larry.allen@cuanschutz.edu LA - English DB - MTMT ER - TY - JOUR AU - Al, Namat R. AU - Duceac, L.D. AU - Chelaru, L. AU - Dabija, M.G. AU - Guțu, C. AU - Marcu, C. AU - Popa, M.V. AU - Popa, F. AU - Bogdan, Goroftei E.R. AU - Țarcă, E. TI - Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis JF - DIAGNOSTICS J2 - DIAGNOSTICS VL - 14 PY - 2024 IS - 1 SN - 2075-4418 DO - 10.3390/diagnostics14010016 UR - https://m2.mtmt.hu/api/publication/34536415 ID - 34536415 N1 - Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy Iași, Iași, 700115, Romania Faculty of Medicine and Pharmacy, “Dunărea de Jos” University, Galați, 800008, Romania Department of Surgery II—Pediatric Surgery, “Grigore T. Popa” University of Medicine and Pharmacy, Iași, 700115, Romania Export Date: 27 January 2024 Correspondence Address: Dabija, M.G.; Faculty of Medicine, Romania; email: mariusdabija.md@gmail.com Correspondence Address: Duceac, L.D.; Faculty of Medicine and Pharmacy, Romania; email: letimedr@yahoo.com AB - Introduction: Increasingly, SGLT2 inhibitors save patients with heart failure and comorbidities such as type-2 diabetes mellitus (T2DM) and chronic kidney disease (CKD); the inhibition of sodium-glucose cotransporter 2 (SGLT2) was first studied in patients with diabetes as a solution to lower glucose levels by preventing glucose reabsorption and facilitating its elimination; in the process, researchers took notice of how SGLT2 inhibitors also seemed to have beneficial cardiovascular effects in patients with both diabetes and cardiovascular disease. Aim: Our single-center prospective study assesses outcomes of post-coronary artery bypass grafting (CABG) rehabilitation and SLGT2 inhibition in CABG patients with/without T2DM and with/without CKD. Materials and Methods: One hundred twenty consecutive patients undergoing CABG were included in the analysis. Patients were divided into four subgroups: diabetes patients with chronic kidney disease (T2DM + CKD), diabetes patients without chronic kidney disease (T2DM−CKD), prediabetes patients with chronic kidney disease (PreD+CKD), and prediabetes patients without chronic kidney disease (PreD−CKD). Echocardiographic and laboratory investigations post-surgery (phase I) and 6 months later (phase II) included markers for cardiac ischemia, glycemic status, and renal function, and metabolic equivalents were investigated. Results: One hundred twenty patients participated, mostly men, overweight/obese, hypertensive, smokers; 65 had T2DM (18 with CKD), and 55 were prediabetic (17 with CKD). The mean ejection fraction increased by 8.43% overall but significantly more in the prediabetes group compared to the T2DM group (10.14% vs. 6.98%, p < 0.05). Overall, mean heart-type fatty-acid-binding protein (H-FABP) levels returned to normal levels, dropping from 68.40 ng/mL to 4.82 ng/mL (p = 0.000), and troponin data were more nuanced relative to an overall, strongly significant decrease of 44,458 ng/L (p = 0.000). Troponin levels in patients with CKD dropped more, both in the presence of T2DM (by 82,500 ng/L, p = 0.000) and in patients without T2DM (by 73,294 ng/L, p = 0.047). As expected, the overall glycated hemoglobin (HbA1c) levels improved significantly in those with prediabetes (from 6.54% to 5.55%, p = 0.000); on the other hand, the mean HbA1c changed from 7.06% to 6.06% (p = 0.000) in T2DM, and the presence or absence of CKD did not seem to make any difference: T2DM+CKD 7.01–6.08% (p = 0.000), T2DM−CKD 7.08–6.04% (p = 0.000), PreD+CKD 5.66–4.98% (p = 0.014), and PreD−CKD 6.03–4.94% (p = 0.00). Compared to an overall gain of 11.51, the GFRs of patients with CKD improved by 18.93 (68.15–87.07%, p = 0.000) in the presence of established diabetes and 14.89 (64.75–79.64%, p = 0.000) in the prediabetes group. Conclusions: Regarding the patients’ cardiac statuses, the results from our single-center analysis revealed a significant decrease in ischemic risk (H-FABP and hs-cTnI levels) with improvements in mean ejection fraction, glycemic status, and renal function in patients post-CABG with/without T2DM, with/without CKD, and with SGLT2 inhibitor dapagliflozin treatment while undergoing cardiac rehabilitation. © 2023 by the authors. LA - English DB - MTMT ER - TY - JOUR AU - American, Diabetes Association Professional Practice Committee TI - 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024 JF - DIABETES CARE J2 - DIABETES CARE VL - 47 PY - 2024 SP - S219 EP - S230 SN - 0149-5992 DO - 10.2337/dc24-S011 UR - https://m2.mtmt.hu/api/publication/34517163 ID - 34517163 N1 - Export Date: 19 January 2024 CODEN: DICAD Chemicals/CAS: canagliflozin, 842133-18-0, 928672-86-0; creatinine, 19230-81-0, 60-27-5; dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; finerenone, 1050477-31-0; liraglutide, 204656-20-2; metformin, 1115-70-4, 657-24-9; potassium, 7440-09-7; semaglutide, 910463-68-2 AB - The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. © 2023 by the American Diabetes Association. LA - English DB - MTMT ER - TY - JOUR AU - Andersen, C.F. AU - Larsen, J.H. AU - Jensen, J. AU - Omar, M. AU - Nouhravesh, N. AU - Kistorp, C. AU - Tuxen, C. AU - Gustafsson, F. AU - Knop, F.K. AU - Forman, J.L. AU - Davidovski, F.S. AU - Jensen, L.T. AU - Højlund, K. AU - Køber, L. AU - Antonsen, L. AU - Poulsen, M.K. AU - Schou, M. AU - Møller, J.E. TI - Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program JF - AMERICAN HEART JOURNAL J2 - AM HEART J VL - 271 PY - 2024 SP - 84 EP - 96 PG - 13 SN - 0002-8703 DO - 10.1016/j.ahj.2024.02.005 UR - https://m2.mtmt.hu/api/publication/34766673 ID - 34766673 N1 - Department of Cardiology, Herlev-Gentofte University Hospital, Denmark Faculty of Health and Medical Sciences, Copenhagen University, Denmark Department of Cardiology, Odense University Hospital, Denmark Faculty of Health Sciences, University of Southern Denmark, Denmark Department of Endocrinology and Metabolism, Copenhagen University Hospital Rigshospitalet, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark Department of Cardiology, Frederiksberg-Bispebjerg University Hospital, Denmark Department of Cardiology, The Heart Center, Copenhagen University Hospital Rigshospitalet, Denmark Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Steno Diabetes Center Copenhagen, Herlev, Denmark Section of Biostatistics, Department of Public Health, University of Copenhagen, Denmark Department of Clinical Physiology and Nuclear Medicine, Herlev Gentofte University Hospital, Copenhagen, Denmark Steno Diabetes Center Odense, Odense University Hospital, Denmark Department of Clinical Research, University of Southern Denmark, Odense, Denmark Export Date: 3 April 2024 CODEN: AHJOA Correspondence Address: Andersen, C.F.; Department of Cardiology, Herlev Ringvej 75, Denmark; email: camilla.fuchs.andersen@regionh.dk AB - Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The Empire Prevent trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing HF, but without diabetes or established HF. Methods: The Empire Prevent trial program is an investigator-initiated, double-blind, randomized clinical trial program including elderly and obese patients (60-84 years, body mass index >28 kg/m2) with at least one manifestation of hypertension, cardiovascular or chronic kidney disease, but no history of diabetes or HF. The aims are to investigate the effects of empagliflozin on 1) physical capacity and left ventricular and atrial structural changes with peak oxygen consumption and left ventricular mass as primary endpoints (Empire Prevent Cardiac), and 2) cardiac-adipose tissue interaction and volume homeostasis with primary endpoints of changes in epicardial adipose tissue and estimated extracellular volume (Empire Prevent Metabolic). At present, 138 of 204 patients have been randomized in the Empire Prevent trial program. Patients are randomized 1:1 to 180 days treatment with empagliflozin 10 mg daily or placebo, while undergoing a comprehensive examination program at baseline and follow-up. Discussion: The Empire Prevent trial program will mark the first step towards elucidating the potential of SGLT2 inhibition for HF prevention in an outpatient setting in elderly and obese patients with increased risk of developing HF, but with no history of diabetes or established HF. Furthermore, the Empire Prevent trial program will supplement the larger event-driven trials by providing mechanistic insights to the beneficial effects of SGLT2 inhibition. Trial Registration: Both parts of the trial program have been registered on September 13th 2021 (Clinical Trial Registration numbers: NCT05084235 and NCT05042973) before enrollment of the first patient. All patients will provide oral and written informed consent. The trial is approved by The Regional Committee on Health Research Ethics and the Danish Medicines Agency. Data will be disseminated through scientific meetings and peer-reviewed journals irrespective of outcome. © 2024 The Author(s) LA - English DB - MTMT ER - TY - JOUR AU - Arbel, R. AU - Azab, A.N. AU - Oberoi, M. AU - Aboalhasan, E. AU - Star, A. AU - Elhaj, K. AU - Khalil, F. AU - Alnsasra, H. TI - Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 15 PY - 2024 SN - 1663-9812 DO - 10.3389/fphar.2024.1357673 UR - https://m2.mtmt.hu/api/publication/34799347 ID - 34799347 N1 - Maximizing Health Outcomes Research Lab, Sapir College, Ashkelon, Israel Department of Cardiology, Soroka University Medical Center, Beersheba, Israel Department of Nursing, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben Gurion University of the Negev, Be’er Sheva, Israel University of Nebraska Medical Center, Omaha, NE, United States Faculty of Health Sciences, Ben Gurion University of the Negev, Be’er Sheva, Israel Export Date: 19 April 2024 Correspondence Address: Azab, A.N.; Department of Cardiology, Israel; email: azab@bgu.ac.il Correspondence Address: Alnsasra, H.; Department of Cardiology, Israel; email: h.alnsasra@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Avula, V. AU - Sharma, G. AU - Kosiborod, M.N. AU - Vaduganathan, M. AU - Neilan, T.G. AU - Lopez, T. AU - Dent, S. AU - Baldassarre, L. AU - Scherrer-Crosbie, M. AU - Barac, A. AU - Liu, J. AU - Deswal, A. AU - Khadke, S. AU - Yang, E.H. AU - Ky, B. AU - Lenihan, D. AU - Nohria, A. AU - Dani, S.S. AU - Ganatra, S. TI - SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction JF - JACC-HEART FAILURE J2 - JACC HEART FAILURE VL - 12 PY - 2024 IS - 1 SP - 67 EP - 78 PG - 12 SN - 2213-1779 DO - 10.1016/j.jchf.2023.08.026 UR - https://m2.mtmt.hu/api/publication/34476864 ID - 34476864 N1 - Johns Hopkins School of Medicine, Baltimore, MD, United States Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, United States Saint Luke's Mid America Heart Institute, Kansas City, MO, United States University of Missouri, Kansas City, MO, United States Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, United States Cardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Boston, MA, United States Department of Cardiology, La Paz University Hospital, Madrid, Spain Duke Cancer Institute, Department of Medicine, Duke University, Durham, NC, United States Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, United States Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States Cardio-Oncology Program, Division of Cardiology, MedStar Washington Hospital Center, Washington, DC, United States Cardio-Oncology Program, Memorial Sloan Kettering Cancer Center, New York City, NY, United States Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX, United States Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA, United States Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, United States International Cardio-Oncology Society, Tampa, FL, United States St. Francis Healthcare, Cape Girardeau, MO, United States Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States Cited By :1 Export Date: 4 January 2024 Correspondence Address: Ganatra, S.; Division of Cardiology, 41 Mall Road, United States; email: Sarju.Ganatra@lahey.org LA - English DB - MTMT ER - TY - JOUR AU - Badimon, J. AU - Santos-Gallego, C.G. TI - Men are from mars, but women are not from venus: The benefits of SGLT2 inhibitors after myocardial infarction are independent of gender JF - HELLENIC JOURNAL OF CARDIOLOGY J2 - HELL J CARDIOL VL - 75 PY - 2024 SP - 93 EP - 95 PG - 3 SN - 1109-9666 DO - 10.1016/j.hjc.2023.09.015 UR - https://m2.mtmt.hu/api/publication/34477037 ID - 34477037 N1 - Export Date: 4 January 2024 CODEN: HLKEA Correspondence Address: Badimon, J.; Atherothrombosis Research Unit, United States; email: juan.badimon@mssm.edu LA - English DB - MTMT ER - TY - JOUR AU - Ballister, Briana AU - Hernandez, Rebecca L. AU - Quffa, Lieth H. AU - Franck, Andrew J. TI - Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit JF - JOURNAL OF PHARMACY PRACTICE J2 - J PHARM PRACTICE VL - 37 PY - 2024 IS - 2 SP - 435 EP - 441 PG - 7 SN - 0897-1900 DO - 10.1177/08971900221144399 UR - https://m2.mtmt.hu/api/publication/33419113 ID - 33419113 N1 - Export Date: 16 January 2023 CODEN: JPPRE Correspondence Address: Franck, A.J.; VA North Florida South Georgia Veterans Health SystemUnited States; email: Andrew.Franck@va.gov AB - Background Involvement of Clinical Pharmacy Specialists (CPS) in the care of patients with diabetes mellitus (DM) has been demonstrated to be beneficial. Whether this positive impact applies to increased use of cardiovascular risk-reducing medications is less well established. Objective To determine the association of CPS co-management on the prescription of diabetes medications with proven cardiovascular benefits for patients with DM and established cardiovascular disease in the primary care setting. Methods This retrospective cohort study evaluated patients in a Veterans Affairs health-system in primary care settings from February 1, 2019, through January 31, 2020. Patients were included if they had type 2 DM treated with at least one medication and had CVD. Patients were grouped into two cohorts for comparison, those with CPS co-management and those without. The primary outcome was the proportion of patients in each group with new prescriptions for empagliflozin or liraglutide initiated during the study timeframe. Results In total, 8058 patients were found eligible for inclusion in the study. Clinical co-management by a CPS was provided to 2099 patients. Study medications were prescribed, approved, and initiated in 596 patients during the study period, including 391 (18.6%) in the CPS group and 205 (3.4%) in the non-CPS group (P < .001). Conclusion This study showed CPS involvement is associated with increased prescribing of diabetes medications with proven cardiovascular benefits. LA - English DB - MTMT ER - TY - JOUR AU - Banerjee, M. AU - Pal, R. AU - Maisnam, I. AU - Mukhopadhyay, S. TI - GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis JF - DIABETES AND METABOLIC SYNDROME: CLINICAL RESEARCH AND REVIEWS J2 - DIABETES AND METABOLIC SYNDROME: CLINICAL RESEARCH AND REVIEWS VL - 18 PY - 2024 IS - 1 SN - 1871-4021 DO - 10.1016/j.dsx.2024.102943 UR - https://m2.mtmt.hu/api/publication/34536413 ID - 34536413 N1 - Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, 700020, India Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India Export Date: 27 January 2024 Correspondence Address: Banerjee, M.; Department of Endocrinology and Metabolism Institute of Post Graduate Medical Education and ResearchIndia; email: mainak18y@gmail.com Correspondence Address: Mukhopadhyay, S.; Department of Endocrinology and Metabolism Institute of Post Graduate Medical Education and ResearchIndia; email: satinath.Mukhopadhyay@gmail.com AB - Objective: Type-2 diabetes (T2D) poses a higher risk of noncardiovascular mortality in addition to the burden of cardiovascular mortality. The well-established cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) could solely explain their apparent effects on all-cause mortality in T2D. The present meta-analysis aims to pool their effects on noncardiovascular mortality in T2D and summarize the recent evidence on plausible pathways mediating these effects. Methods: PubMed, Embase, Web of Science, and clinical trial registries were searched for randomized controlled trials (RCTs) with ≥1-year duration in adults with T2D reporting both cardiovascular and all-cause mortality in treatment versus placebo arms (PROSPERO: CRD42022337559). Noncardiovascular mortality was calculated by subtracting cardiovascular mortality events from all-cause mortality and risk ratios (RRs) were calculated. Random-effects meta-analysis was done. GRADE framework was used to assess evidence quality. Results: We identified 17 eligible RCTs pooling data retrieved from 109,892 patients. Randomization to GLP-1 RA treatment versus placebo was associated with reduced noncardiovascular mortality (RR = 0.90; 95%CI: 0.81–0.99; I2 = 0 %; p < 0.05), consistent with their effects on cardiovascular mortality (RR = 0.88; 95%CI: 0.81–0.95; I2 = 0 %; p < 0.01) in T2D. Compared to placebo, SGLT2i significantly reduced noncardiovascular mortality (RR = 0.90; 95%CI: 0.82–0.99; I2 = 0 %; p < 0.05) along with cardiovascular mortality (RR = 0.84; 95%CI: 0.77–0.92; I2 = 28 %; p < 0.001). Subgroup analysis showed no significant effects of heart failure or renal function on treatment benefits of SGLT2i on noncardiovascular mortality (p value > 0.2 for subgroup differences). Conclusion: The impact of GLP-1RAs and SGLT2i on mortality in people with T2D extends beyond their cardiovascular benefits. © 2024 LA - English DB - MTMT ER - TY - JOUR AU - Bánfi‐Bacsárdi, Fanni AU - Pilecky, Dávid AU - Vámos, Máté AU - Majoros, Zsuzsanna AU - Török, Gábor Márton AU - Borsányi, Tünde Dóra AU - Dékány, Miklós AU - Solymossi, Balázs AU - Andréka, Péter AU - Duray, Gábor Zoltán AU - Kiss, Róbert Gábor AU - Nyolczas, Noémi AU - Muk, Balázs TI - The effect of kidney function on guideline‐directed medical therapy implementation and prognosis in heart failure with reduced ejection fraction JF - CLINICAL CARDIOLOGY J2 - CLIN CARDIOL VL - 47 PY - 2024 IS - 2 PG - 11 SN - 0160-9289 DO - 10.1002/clc.24244 UR - https://m2.mtmt.hu/api/publication/34684418 ID - 34684418 N1 - Department of Cardiology, Central Hospital of Northern Pest - Military Hospital, Budapest, Hungary Department of Adult Cardiology, Gottsegen National Cardiovascular Center, Budapest, Hungary Doctoral School of Clinical Medicine, University of Szeged, Szeged, Hungary Cardiac Electrophysiology Division, Cardiology Center, Department of Internal Medicine, University of Szeged, Szeged, Hungary Heart and Vascular Center, Semmelweis University, Budapest, Hungary Export Date: 19 April 2024 CODEN: CLCAD Correspondence Address: Bánfi-Bacsárdi, F.; Department of Adult Cardiology, 1096 Haller Str. 29, Hungary; email: bacsardifanni@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Bauersachs, J. AU - Soltani, S. TI - Heart failure: update of the ESC 2023 guidelines JF - HERZ J2 - HERZ VL - 49 PY - 2024 SP - 19 EP - 21 PG - 3 SN - 0340-9937 DO - 10.1007/s00059-023-05221-2 UR - https://m2.mtmt.hu/api/publication/34434950 ID - 34434950 N1 - Export Date: 14 December 2023 CODEN: HERZD Correspondence Address: Bauersachs, J.; Klinik für Kardiologie und Angiologie, Carl-Neuberg-Str. 1, Germany; email: bauersachs.johann@mh-hannover.de LA - German DB - MTMT ER - TY - JOUR AU - Bawaskar, P. AU - Thomas, N. AU - Ismail, K. AU - Guo, Y. AU - Chhikara, S. AU - Athwal, P.S.S. AU - Ranum, A. AU - Jadhav, A. AU - Mendez, A.H. AU - Nadkarni, I. AU - Frerichs, D. AU - Velangi, P. AU - Ergando, T. AU - Akram, H. AU - Kanda, A. AU - Shenoy, C. TI - Nonischemic or Dual Cardiomyopathy in Patients With Coronary Artery Disease JF - CIRCULATION J2 - CIRCULATION VL - 149 PY - 2024 IS - 11 SP - 807 EP - 821 PG - 15 SN - 0009-7322 DO - 10.1161/CIRCULATIONAHA.123.067032 UR - https://m2.mtmt.hu/api/publication/34749923 ID - 34749923 N1 - Export Date: 21 March 2024 CODEN: CIRCA Correspondence Address: Shenoy, C.; University of Minnesota Medical School, 420 Delaware St SE, MMC 508, United States; email: cshenoy@umn.edu LA - English DB - MTMT ER - TY - JOUR AU - Berezin, Alexander E. AU - Berezina, Tetiana A. TI - Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases JF - JOURNAL OF INTERNATIONAL MEDICAL RESEARCH J2 - J INT MED RES VL - 52 PY - 2024 IS - 2 PG - 16 SN - 0300-0605 DO - 10.1177/03000605241227659 UR - https://m2.mtmt.hu/api/publication/34644991 ID - 34644991 N1 - Export Date: 29 February 2024 CODEN: JIMRB Correspondence Address: Berezin, A.E.; Department of Internal Medicine II, Austria; email: aeberezin@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Bhatt, A.S. AU - Vaduganathan, M. AU - Claggett, B.L. AU - Kulac, I.J. AU - Anand, I.S. AU - Desai, A.S. AU - Fang, J.C. AU - Hernandez, A.F. AU - Jhund, P.S. AU - Kosiborod, M.N. AU - Sabatine, M.S. AU - Shah, S.J. AU - Vardeny, O. AU - McMurray, J.J.V. AU - Solomon, S.D. AU - Gaziano, T.A. TI - Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials JF - JOURNAL OF THE AMERICAN HEART ASSOCIATION J2 - J AM HEART ASSOC VL - 13 PY - 2024 IS - 5 SN - 2047-9980 DO - 10.1161/JAHA.123.032279 UR - https://m2.mtmt.hu/api/publication/34777746 ID - 34777746 N1 - Export Date: 8 April 2024 LA - English DB - MTMT ER - TY - JOUR AU - Bhave, N.M. AU - Han, Y. AU - Steffick, D. AU - Bragg-Gresham, J. AU - Zivin, K. AU - Burrows, N.R. AU - Pavkov, M.E. AU - Tuot, D. AU - Powe, N.R. AU - Saran, R. TI - Assessing trends and variability in outpatient dual testing for chronic kidney disease with urine albumin and serum creatinine, 2009-2018: A retrospective cohort study in the Veterans Health Administration System JF - BMJ OPEN J2 - BMJ OPEN VL - 14 PY - 2024 IS - 2 SN - 2044-6055 DO - 10.1136/bmjopen-2023-073136 UR - https://m2.mtmt.hu/api/publication/34742585 ID - 34742585 N1 - Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, United States Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, United States Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, United States Department of Psychiatry, University of Michigan, Ann Arbor, MI, United States Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, United States Department of Medicine, Division of Nephrology, University of California San Francisco, San Francisco, CA, United States Export Date: 18 March 2024 Correspondence Address: Han, Y.; Department of Internal Medicine, United States; email: hanyun@umich.edu Correspondence Address: Saran, R.; Department of Internal Medicine, United States; email: rsaran@umich.edu Chemicals/CAS: creatinine, 19230-81-0, 60-27-5; Creatinine Funding text 1: This study was done under the auspices of the Supporting, Maintaining and Improving the Surveillance System for Chronic Kidney Disease in the USA, Cooperative Agreement Number, U58 DP006254, funded by the Centers for Disease Control and Prevention. AB - Background Simultaneous urine testing for albumin (UAlb) and serum creatinine (SCr), that is, 'dual testing,' is an accepted quality measure in the management of diabetes. As chronic kidney disease (CKD) is defined by both UAlb and SCr testing, this approach could be more widely adopted in kidney care. Objective We assessed time trends and facility-level variation in the performance of outpatient dual testing in the integrated Veterans Health Administration (VHA) system. Design, subjects and main measures This retrospective cohort study included patients with any inpatient or outpatient visit to the VHA system during the period 2009-2018. Dual testing was defined as UAlb and SCr testing in the outpatient setting within a calendar year. We assessed time trends in dual testing by demographics, comorbidities, high-risk (eg, diabetes) specialty care and facilities. A generalised linear mixed-effects model was applied to explore individual and facility-level predictors of receiving dual testing. Key results We analysed data from approximately 6.9 million veterans per year. Dual testing increased, on average, from 17.4% to 21.2%, but varied substantially among VHA centres (0.3%-43.7% in 2018). Dual testing was strongly associated with diabetes (OR 10.4, 95% CI 10.3 to 10.5, p<0.0001) and not associated with VHA centre complexity level. However, among patients with high-risk conditions including diabetes, <50% received dual testing in any given year. As compared with white veterans, black veterans were less likely to be tested after adjusting for other individual and facility characteristics (OR 0.93, 95% CI 0.92 to 0.93, p<0.0001). Conclusions Dual testing for CKD in high-risk specialties is increasing but remains low. This appears primarily due to low rates of testing for albuminuria. Promoting dual testing in high-risk patients will help to improve disease management and patient outcomes. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. LA - English DB - MTMT ER - TY - JOUR AU - Bismpos, Dimitrios AU - Wintrich, Jan AU - Hoevelmann, Julian AU - Boehm, Michael TI - Latest pharmaceutical approaches across the spectrum of heart failure JF - HEART FAILURE REVIEWS J2 - HEART FAIL REV VL - 29 PY - 2024 SP - 675 EP - 687 PG - 13 SN - 1382-4147 DO - 10.1007/s10741-024-10389-8 UR - https://m2.mtmt.hu/api/publication/34639437 ID - 34639437 N1 - Funding Agency and Grant Number: Universittsklinikum des Saarlandes und Medizinische Fakultt der Universitt des Saarlandes (8981) Funding text: No Statement Available LA - English DB - MTMT ER - TY - JOUR AU - Borrelli, S. AU - Garofalo, C. AU - Liberti, M.E. AU - Ruotolo, C. AU - Capozzi, F. AU - Yavorskiy, P. AU - De, Nicola L. TI - Sodium-glucose cotransporter-2 inhibition in a CKD patient with severe heart failure treated by high-dose diuretics and peritoneal ultrafiltration: lesson for the clinical nephrologist JF - JOURNAL OF NEPHROLOGY J2 - J NEPHROL VL - 37 PY - 2024 SP - 199 EP - 201 PG - 3 SN - 1121-8428 DO - 10.1007/s40620-023-01766-x UR - https://m2.mtmt.hu/api/publication/34170056 ID - 34170056 N1 - Export Date: 3 October 2023 CODEN: JLNEE Correspondence Address: Garofalo, C.; Unit of Nephrology and Dialysis, Italy; email: carlo.garofalo@unicampania.it LA - English DB - MTMT ER - TY - JOUR AU - Bozkurt, B. TI - Contemporary pharmacological treatment and management of heart failure JF - NATURE REVIEWS CARDIOLOGY J2 - NAT REV CARDIOL VL - In press PY - 2024 SP - In press SN - 1759-5002 DO - 10.1038/s41569-024-00997-0 UR - https://m2.mtmt.hu/api/publication/34766715 ID - 34766715 N1 - Export Date: 3 April 2024 Correspondence Address: Bozkurt, B.; Winters Center for Heart Failure Research, United States; email: bbozkurt@bcm.edu AB - The prevention and treatment strategies for heart failure (HF) have evolved in the past two decades. The stages of HF have been redefined, with recognition of the pre-HF state, which encompasses asymptomatic patients who have developed either structural or functional cardiac abnormalities or have elevated plasma levels of natriuretic peptides or cardiac troponin. The first-line treatment of patients with HF with reduced ejection fraction includes foundational therapies with angiotensin receptor–neprilysin inhibitors, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, mineralocorticoid receptor antagonists, sodium–glucose cotransporter 2 (SGLT2) inhibitors and diuretics. The first-line treatment of patients with HF with mildly reduced ejection fraction or with HF with preserved ejection fraction includes SGLT2 inhibitors and diuretics. The timely initiation of these disease-modifying therapies and the optimization of treatment are crucial in all patients with HF. Reassessment after initiation of these therapies is recommended to evaluate patient symptoms, health status and left ventricular function, and timely referral to a HF specialist is necessary if a patient has persistent advanced HF symptoms or worsening HF. Lifestyle modification and treatment of comorbidities such as diabetes mellitus, ischaemic heart disease and atrial fibrillation are crucial through each stage of HF. This Review provides an overview of the management strategies for HF according to disease stages that are derived from the recommendations in the latest US and European HF guidelines. © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. LA - English DB - MTMT ER - TY - JOUR AU - Brockmeyer, M. AU - Parco, C. AU - Vargas, K.G. AU - Westenfeld, R. AU - Jung, C. AU - Kelm, M. AU - Roden, M. AU - Akbulut, C. AU - Schlesinger, S. AU - Wolff, G. AU - Kuss, O. TI - Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data JF - JOURNAL OF NEPHROLOGY J2 - J NEPHROL VL - In press PY - 2024 SN - 1121-8428 DO - 10.1007/s40620-023-01858-8 UR - https://m2.mtmt.hu/api/publication/34536404 ID - 34536404 N1 - Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom Cardiovascular Research Institute Düsseldorf (CARID), Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Division of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany German Center for Diabetes Research, Partner Düsseldorf, Munich-Neuherberg, Germany Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany Center for Health and Society, Faculty of Medicine, Heinrich Heine University Düsseldorf, Düsseldorf, Germany Division of Cardiology, Pulmonology and Vascular Medicine, Department of Conservative Medicine, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, Düsseldorf, 40225, Germany Export Date: 27 January 2024 CODEN: JLNEE Correspondence Address: Wolff, G.; Division of Cardiology, Moorenstr. 5, Germany; email: georg.wolff@med.uni-duesseldorf.de AB - Background: Absolute treatment benefits—expressed as numbers needed to treat—of the glucose lowering and cardiovascular drugs, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose transporter 2 (SGLT2) inhibitors on renal outcomes remain uncertain. With the present meta-analysis of digitalized individual patient data, we aimed to display and compare numbers needed to treat of both drugs on a composite renal outcome. Methods: From Kaplan–Meier plots of major cardiovascular outcome trials of GLP-1 receptor agonists and SGLT2 inhibitors vs. placebo, we digitalized individual patient time-to-event information on composite renal outcomes with WebPlotDigitizer 4.2; numbers needed to treat from individual cardiovascular outcome trials were estimated using parametric Weibull regression models and compared to original data. Random-effects meta-analysis generated meta-numbers needed to treat with 95% confidence intervals (CI). Results: Twelve cardiovascular outcome trials (three for GLP-1 receptor agonists, nine for SGLT2 inhibitors) comprising 90,865 participants were included. Eight trials were conducted in primary type 2 diabetes populations, two in a primary heart failure and two in a primary chronic kidney disease population. Mean estimated glomerular filtration rate at baseline ranged between 37.3 and 85.3 ml/min/1.73 m2. Meta-analyses estimated meta-numbers needed to treat of 85 (95% CI 60; 145) for GLP-1 receptor agonists and 104 (95% CI 81; 147) for SGLT2 inhibitors for the composite renal outcome at the overall median follow-up time of 36 months. Conclusion: The present meta-analysis of digitalized individual patient data revealed moderate and similar absolute treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors compared to placebo for a composite renal outcome. Graphical Abstract: [Figure not available: see fulltext.] © 2024, The Author(s). LA - English DB - MTMT ER - TY - JOUR AU - Burchill, L.J. AU - Jain, C.C. AU - Miranda, W.R. TI - Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure JF - JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY J2 - J AM COLL CARDIOL VL - 83 PY - 2024 IS - 15 SP - 1415 EP - 1417 PG - 3 SN - 0735-1097 DO - 10.1016/j.jacc.2024.03.002 UR - https://m2.mtmt.hu/api/publication/34799296 ID - 34799296 N1 - Export Date: 19 April 2024 CODEN: JACCD Correspondence Address: Burchill, L.J.; Department of Cardiovascular Medicine, 200 First Street SW, United States; email: Burchill.luke@mayo.edu LA - English DB - MTMT ER - TY - JOUR AU - Byrne, R.A. AU - Rossello, X. AU - Coughlan, J.J. AU - Barbato, E. AU - Berry, C. AU - Chieffo, A. AU - Claeys, M.J. AU - Dan, G.-A. AU - Dweck, M.R. AU - Galbraith, M. AU - Gilard, M. AU - Hinterbuchner, L. AU - Jankowska, E.A. AU - Jüni, P. AU - Kimura, T. AU - Kunadian, V. AU - Leosdottir, M. AU - Lorusso, R. AU - Pedretti, R.F.E. AU - Rigopoulos, A.G. AU - Gimenez, M.R. AU - Thiele, H. AU - Vranckx, P. AU - Wassmann, S. AU - Wenger, N.K. AU - Ibanez, B. AU - Halvorsen, S. AU - James, S. AU - Abdelhamid, M. AU - Aboyans, V. AU - Marsan, N.A. AU - Antoniou, S. AU - Asteggiano, R. AU - Bäck, M. AU - Capodanno, D. AU - Casado-Arroyo, R. AU - Cassese, S. AU - Čelutkiene, J. AU - Cikes, M. AU - Collet, J.-P. AU - Ducrocq, G. AU - Falk, V. AU - Fauchier, L. AU - Geisler, T. AU - Gorog, D.A. AU - Holmvang, L. AU - Jaarsma, T. AU - Jones, H.W. AU - Køber, L. AU - Koskinas, K.C. AU - Kotecha, D. AU - Krychtiuk, K.A. AU - Landmesser, U. AU - Lazaros, G. AU - Lewis, B.S. AU - Lindahl, B. AU - Linhart, A. AU - Løchen, M.-L. AU - Mamas, M.A. AU - McEvoy, J.W. AU - Mihaylova, B. AU - Mindham, R. AU - Mueller, C. AU - Neubeck, L. AU - Niebauer, J. AU - Nielsen, J.C. AU - Niessner, A. AU - Paradies, V. AU - Pasquet, A.A. AU - Petersen, S.E. AU - Prescott, E. AU - Rakisheva, A. AU - Rocca, B. AU - Rosano, G.M.C. AU - Sade, L.E. AU - Schiele, F. AU - Siller-Matula, J.M. AU - Sticherling, C. AU - Storey, R.F. AU - Thielmann, M. AU - Vrints, C. AU - Windecker, S. AU - Wiseth, R. AU - Witkowski, A. AU - ESC, Scientific Document Group TI - 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC) JF - EUROPEAN HEART JOURNAL: ACUTE CARDIOVASCULAR CARE J2 - EUR HEART J-ACUTE CA VL - 13 PY - 2024 IS - 1 SP - 55 EP - 161 PG - 107 SN - 2048-8726 DO - 10.1093/ehjacc/zuad107 UR - https://m2.mtmt.hu/api/publication/34668108 ID - 34668108 N1 - Department of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland Clinical Research Department, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain Cardiology Department, IIS-Fundación Jiménez Díaz University Hospital, Madrid, Spain, CIBERCV, ISCIII, Madrid, Spain Cardiology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain Clinical Research Department Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain Health Research Institute of the Balearic Islands (IdiSBa), Universitat de les Illes Balears (UIB), Palma de Mallorca, Spain Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland Clinical and Molecular Medicine, Sapienza University, Rome, Italy British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom NHS Golden Jubilee, Clydebank, United Kingdom NHS Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom IRCCS San Raffaele Scientific Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy University Vita-Salute San Raffaele, Milan, Italy Antwerp University Hospital, Edegem, Belgium Colentina University Hospital, Cardiology Dpt., "carol Davila" University of Medicine Bucharest, Romania British Heart Foundation Centre for Cardiovascular Sciences, Chancellors Building, Little France Crescent, Little France, Edinburgh, United Kingdom ESC Patient Forum, Sophia Antipolis, France INSERM UMR 1304 GETBO- Brest University, Brest, France Department of Cardiology, Clinic of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland Institute of Heart Diseases, University Hospital in Wroclaw, Wroclaw, Poland Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom Department of Cardiology, Hirakata Kohsai Hospital, Osaka, Japan Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom Cardiothoracic Centre, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom Department of Cardiology, Skane University Hospital, Malmö, Sweden Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden Cardio-Thoracic Surgery, Maastricht University Medical Centre, Maastricht, Netherlands Cardiovascular Research Institute Maastricht, Maastricht, Netherlands Cardiovascular Department, IRCCS MultiMedica, Milan, Italy Adult Cardiology, Mitera General Hospital-Hygeia Group, Athens, Greece Department of Internal Medicine and Cardiology, Heart Center Leipzig, University of Leipzig, Leipzig, Germany Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland Heart Center Leipzig, University of Leipzig, Leipzig, Germany Leipzig Heart Science, Leipzig, Germany Cardiology and Critical Care Medicine, Jessa Ziekenhuis, Hasselt, Belgium Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium Cardiology Pasing, Munich, Germany Faculty of Medicine, University of the Saarland, Homburg/Saar, Germany Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, United States Emory Heart and Vascular Center Emory University, School of Medicine, Atlanta, GA, United States Emory Women's Heart Center, Emory University School of Medicine, Atlanta, GA, United States Export Date: 22 February 2024 Correspondence Address: Byrne, R.A.; Department of Cardiology, Ireland; email: robertabyrne@rcsi.ie Correspondence Address: Ibanez, B.; Clinical Research Department, Spain; email: bibanez@cnic.es LA - English DB - MTMT ER - TY - JOUR AU - Cai, Dabei AU - Chen, Qianwen AU - Mao, Lipeng AU - Xiao, Tingting AU - Wang, Yu AU - Gu, Qingqing AU - Wang, Qingjie AU - Ji, Yuan AU - Sun, Ling TI - Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients JF - EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY J2 - EUR J CLIN PHARMACOL VL - 80 PY - 2024 SP - 613 EP - 620 PG - 8 SN - 0031-6970 DO - 10.1007/s00228-024-03623-7 UR - https://m2.mtmt.hu/api/publication/34600815 ID - 34600815 N1 - Department of Cardiology, the Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Jiangsu, Changzhou, 213000, China Dalian Medical University, Dalian, Liaoning, 116000, China Export Date: 29 February 2024 CODEN: EJCPA Correspondence Address: Wang, Q.; Department of Cardiology, Jiangsu, China; email: wang-qingjie@hotmail.com Correspondence Address: Ji, Y.; Department of Cardiology, Jiangsu, China; email: jiyuan1213@aliyun.com Correspondence Address: Sun, L.; Department of Cardiology, Jiangsu, China; email: sunling85125@hotmail.com AB - Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects in reducing hospitalization or cardiovascular mortality, while the association of SGLT2 inhibitor dapagliflozin (DAPA) and the risk of acute kidney injury (AKI) in acute myocardial infarction (AMI) patients has not been comprehensively investigated. Therefore, we aimed to assess the association between DAPA and AKI risk in AMI patients after percutaneous coronary intervention (PCI) therapy. Methods: Using the Changzhou Acute Myocardial Infarction Registry database, we retrospectively included AMI patients from January 2017 to August 2021 and analyzed the risk of AKI and all-cause mortality after PCI therapy. The patients were divided into two groups according to the use of DAPA (DAPA group and Ctrl group). Patients in the DAPA group started to use DAPA after admission and continued its use during hospitalization and follow-up period. Baseline characteristics were balanced between the two groups with a propensity score matching (PSM) analysis. The outcome was AKI within 7 days after PCI and all-cause mortality during a follow-up of 2 years. Univariate and multivariate logistic regression analyses were used to assess the association between DAPA and AKI risk. Results: A total of 1839 AMI patients undergoing PCI were enrolled. DAPA was used in 278 (15.1%) patients. Postoperative AKI occurred in 351 (19.1%) cases. A 1:1 PSM analysis was used to reduce confounding factors. The multivariate stepwise regression analysis showed that DAPA (odds ratio, OR 0.66; 95% confidence interval, CI 0.44-0.97; P = 0.036) was an independent protective factor in the entire cohort. After matching, the use of DAPA in AMI patients was independently associated with a decline of AKI risk (OR 0.32; 95% CI, 0.19-0.53; P < 0.001) after hospital admission. Meanwhile, there were significant differences in mortality between the DAPA group and Ctrl group (2.5% vs. 7.6%, P = 0.012). Conclusion: SGLT2 inhibitor DAPA was associated with lower risks of incident AKI and all-cause mortality in AMI patients after PCI therapy. LA - English DB - MTMT ER - TY - JOUR AU - Capodanno, Davide AU - Finocchiaro, Simone TI - SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial? JF - KARDIOLOGIA POLSKA J2 - KARDIOL POL VL - 82 PY - 2024 IS - 1 SP - 3 EP - 4 PG - 2 SN - 0022-9032 DO - 10.33963/v.phj.98860 UR - https://m2.mtmt.hu/api/publication/34638158 ID - 34638158 N1 - Export Date: 29 February 2024 CODEN: KARPA Correspondence Address: Capodanno, D.; Division of Cardiology, Italy; email: dcapodanno@unict.it LA - English DB - MTMT ER - TY - JOUR AU - Cases, A. AU - Cigarrán, S. AU - Górriz, J.L. AU - Nuñez, J. TI - Effect of SGLT2 inhibitors on anemia and their possible clinical implications JF - NEFROLOGIA J2 - NEFROLOGIA VL - 44 PY - 2024 IS - 2 SP - 165 EP - 172 PG - 8 SN - 0211-6995 DO - 10.1016/j.nefro.2023.11.001 UR - https://m2.mtmt.hu/api/publication/34474391 ID - 34474391 N1 - Export Date: 3 January 2024 Correspondence Address: Górriz, J.L.; Grupo de Anemia de la S.E.N.Spain; email: jlgorriz@gmail.com AB - Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was soon seen that these drugs increased erythropoietin levels and erythropoiesis, and improved iron metabolism. Mediation studies found that the increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs. In this review, we discuss the mechanisms for improving erythropoiesis and the implication of the increase in hemoglobin on the cardiorenal prognostic benefit of these drugs. © 2023 Sociedad Española de Nefrología LA - Spanish DB - MTMT ER - TY - JOUR AU - Cepoi, Maria-Ruxandra AU - Duca, Stefania Teodora AU - Chetran, Adriana AU - Costache, Alexandru Dan AU - Spiridon, Marilena Renata AU - Afrasanie, Irina AU - Leanca, Sabina Andreea AU - Dmour, Bianca-Ana AU - Matei, Iulian Theodor AU - Miftode, Radu Stefan AU - Miftode, Larisa AU - Prepeliuc, Cristian Sorin AU - Haba, Mihai Stefan Cristian AU - Badescu, Minerva Codruta AU - Costache, Irina Iuliana TI - Chronic Kidney Disease Associated with Ischemic Heart Disease: To What Extent Do Biomarkers Help? JF - LIFE-BASEL J2 - LIFE-BASEL VL - 14 PY - 2024 IS - 1 PG - 27 SN - 2075-1729 DO - 10.3390/life14010034 UR - https://m2.mtmt.hu/api/publication/34638161 ID - 34638161 LA - English DB - MTMT ER - TY - JOUR AU - Cersosimo, A. AU - Salerno, N. AU - Sabatino, J. AU - Scatteia, A. AU - Bisaccia, G. AU - De, Rosa S. AU - Dellegrottaglie, S. AU - Bucciarelli-Ducci, C. AU - Torella, D. AU - Leo, I. TI - Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance JF - CARDIOVASCULAR DIABETOLOGY J2 - CARDIOVASC DIABETOL VL - 23 PY - 2024 IS - 1 SN - 1475-2840 DO - 10.1186/s12933-024-02181-7 UR - https://m2.mtmt.hu/api/publication/34747983 ID - 34747983 N1 - Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy Advanced Cardiovascular Imaging Unit, Ospedale Medico-Chirurgico Accreditato Villa dei Fiori, Naples, Italy Department of Neuroscience, Imaging and Clinical Sciences, Institute for Advanced Biomedical Technologies “G. d’Annunzio”, University of Chieti-Pescara, Chieti, Italy Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy CMR Unit, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, Kings College London, London, United Kingdom Export Date: 20 March 2024 CODEN: CDAIA Correspondence Address: Torella, D.; Department of Experimental and Clinical Medicine, Italy; email: dtorella@unicz.it Correspondence Address: Leo, I.; Department of Experimental and Clinical Medicine, Italy; email: isabella.leo@unicz.it Chemicals/CAS: canagliflozin, 842133-18-0, 928672-86-0; dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; exendin 4, 141732-76-5, 141758-74-9, 286014-72-0, 335149-21-8; liraglutide, 204656-20-2; sotagliflozin, 1018899-04-1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors Funding text 1: This work was supported by grants from the Italian Ministry of University and Research: PRIN 2020L45ZWA_005, and PNRR-National Center for Gene Therapy and Drugs based on RNA Technology (CN00000041), and from the Italian Ministry of Health: PSC SALUTE 2014–2020 - POS4 “Cal-Hub-Ria” (T4-AN-09), and PNRR MAD-2022-12376814. AB - Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have been proposed, the exact pathophysiology behind these effects is not yet fully understood. Cardiovascular imaging is key for the evaluation of diabetic patients, with an established role from the identification of early subclinical changes to long-term follow up and prognostic assessment. Among the different imaging modalities, CMR may have a key-role being the gold standard for volumes and function assessment and having the unique ability to provide tissue characterization. Novel techniques are also implementing the possibility to evaluate cardiac metabolism through CMR and thereby further increasing the potential role of the modality in this context. Aim of this paper is to provide a comprehensive review of changes in CMR parameters and novel CMR techniques applied in both pre-clinical and clinical studies evaluating the effects of SGLT2i and GLP-1Ra, and their potential role in better understanding the underlying CV mechanisms of these drugs. © The Author(s) 2024. LA - English DB - MTMT ER - TY - JOUR AU - Çetin, Güvenç R. AU - Güvenç, T.S. AU - Çağlar, M.E. AU - Al, Arfaj A.A. AU - Behrad, A. AU - Yılmaz, M.B. TI - Digoxin is Not Related to Mortality in Patients with Heart Failure: Results from the SELFIE-TR Registry JF - AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS J2 - AM J CARDIOVASC DRUG PY - 2024 SN - 1175-3277 DO - 10.1007/s40256-024-00639-3 UR - https://m2.mtmt.hu/api/publication/34799343 ID - 34799343 N1 - Division of Cardiology, Department of Internal Medical Sciences, Istanbul Okan University School of Medicine, Tepeören Mahallesi Tuzla Kampüsü, Istanbul, 34959, Turkey Division of Cardiology, Department of Internal Medical Sciences, Istinye University School of Medicine, Istanbul, Turkey Division of Cardiology, Department of Internal Medical Sciences, Dokuz Eylul University School of Medicine, Istanbul, Turkey Export Date: 19 April 2024 CODEN: AJCDD Correspondence Address: Çetin Güvenç, R.; Division of Cardiology, Tepeören Mahallesi Tuzla Kampüsü, Turkey; email: rcguvenc1@gmail.com LA - English DB - MTMT ER - TY - CHAP AU - Chaikijurajai, T. AU - Rincon-Choles, H. AU - Tang, W.H.W. TI - Natriuretic peptide testing strategies in heart failure: A 2023 update T2 - Advances in Clinical Chemistry VL - 118 PB - Academic Press Inc. T3 - Advances in Clinical Chemistry, ISSN 0065-2423 ; 118. PY - 2024 SP - 155 EP - 203 PG - 49 DO - 10.1016/bs.acc.2023.11.005 UR - https://m2.mtmt.hu/api/publication/34795794 ID - 34795794 N1 - Export Date: 17 April 2024 Correspondence Address: Tang, W.H.W.; Kaufman Center for Heart Failure Treatment and Recovery, United States; email: tangw@ccf.org Chemicals/CAS: brain natriuretic peptide, 114471-18-0; Biomarkers; Natriuretic Peptide, Brain; Peptide Fragments AB - Natriuretic peptides (NPs), including B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), have been recommended as standard biomarkers for diagnosing heart failure (HF), and one of the strongest risk predictors for mortality and HF hospitalization regardless of ejection fraction (EF) and etiology of HF. BNP is an active neurohormone opposing renin-angiotensin-aldosterone and sympathetic nervous system overactivated in HF, whereas NT-proBNP is an inactive prohormone released from cardiomyocytes in response to wall stress. Despite substantial advances in the development of guideline-directed medical therapy (GDMT) for HF with reduced EF, studies demonstrating direct benefits of NP-guided chronic HF therapy on mortality, HF hospitalization, and GDMT optimization have yielded conflicting results. However, accumulating evidence shows that achieving prespecified BNP or NT-proBNP target over time is significantly associated with favorable outcomes, suggesting that benefits of serially measured NPs may be limited to particular groups of HF patients, such as those with extreme levels of baseline BNP or NT-proBNP, which could represent severe phenotypes of HF associated with natriuretic peptide resistance or cardiorenal syndrome. Over the past decade, clinical utilization of BNP and NT-proBNP has been expanded, especially using serial NP measurements for guiding HF therapy, optimizing GDMT and identifying at-risk patients with HF phenotypes who may be minimally symptomatic or asymptomatic. © 2024 LA - English DB - MTMT ER - TY - JOUR AU - Chen, Chih-Wei AU - Su, Fu-You AU - Wang, Ping-Ping AU - Chuang, Ming-Tsang AU - Lin, Yi-Cheng AU - Kao, Chih-Chin AU - Huang, Chun-Yao TI - Renal outcomes after contrast exposure in patients with diabetes who use sodium-glucose cotransporter 2 inhibitors JF - POSTGRADUATE MEDICAL JOURNAL J2 - POSTGRAD MED J VL - 100 PY - 2024 IS - 1181 SP - 142 EP - 150 PG - 9 SN - 0032-5473 DO - 10.1093/postmj/qgad118 UR - https://m2.mtmt.hu/api/publication/34623869 ID - 34623869 N1 - Export Date: 28 February 2024 LA - English DB - MTMT ER - TY - JOUR AU - Cheng, X. AU - Huang, P. AU - Liu, H. AU - Bi, X. AU - Gao, Y. AU - Lu, R. AU - Gao, Y. AU - Liu, Y. AU - Deng, Y. TI - Improvements of myocardial strain and work in diabetes patients with normal ejection fraction after empagliflozin treatment JF - JOURNAL OF DIABETES INVESTIGATION J2 - J DIABETES INVEST PY - 2024 SN - 2040-1116 DO - 10.1111/jdi.14199 UR - https://m2.mtmt.hu/api/publication/34799342 ID - 34799342 N1 - Export Date: 19 April 2024 Correspondence Address: Deng, Y.; Department of Medical Ultrasound, China; email: ybdeng2007@hotmail.com LA - English DB - MTMT ER - TY - JOUR AU - Chen, J. AU - Jiang, C. AU - Guo, M. AU - Zeng, Y. AU - Jiang, Z. AU - Zhang, D. AU - Tu, M. AU - Tan, X. AU - Yan, P. AU - Xu, X.M. AU - Long, Y. AU - Xu, Y. TI - Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis JF - CARDIOVASCULAR DIABETOLOGY J2 - CARDIOVASC DIABETOL VL - 23 PY - 2024 IS - 1 SN - 1475-2840 DO - 10.1186/s12933-023-02042-9 UR - https://m2.mtmt.hu/api/publication/34502113 ID - 34502113 N1 - Department of Endocrinology and Metabolism, the Affiliated Hospital of Southwest Medical University, Sichuan, Luzhou, China Department of Endocrinology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Sichuan, Mianyang, China Sichuan Clinical Research Center for Nephropathy, Sichuan, Luzhou, China Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, China State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau Faculty of Chinese Medicine, Macau University of Science and Technology, Macau Export Date: 15 January 2024 CODEN: CDAIA Correspondence Address: Long, Y.; Department of Endocrinology and Metabolism, Sichuan, China; email: longyang0217@swmu.edu.cn Correspondence Address: Xu, Y.; Department of Endocrinology and Metabolism, Sichuan, China; email: xywyll@swmu.edu.cn Correspondence Address: Xu, X.M.; Department of Endocrinology, Sichuan, China; email: 764681378@qq.com Chemicals/CAS: brain natriuretic peptide, 114471-18-0; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors Funding text 1: This study was funded by grants from the National Natural Science Foundation of China (grant number U22A20286), the grants from Key Research and Development Program of Science and Technology Department of Sichuan Province (grant number 2022YFS0612) and Mianyang Health Committee project (202040). AB - Purpose: Numerous clinical studies have explored sodium–glucose cotransporter 2 inhibitor (SGLT2i) in patients with chronic heart failure (CHF), with or without type 2 diabetes mellitus (T2DM), and SGLT2i were proved to significantly reduce CHF hospitalization, cardiovascular death, cardiovascular mortality, all-cause mortality and myocardial infarction in patients with or without T2DM. However, only a limited few have investigated the effects of SGLT-2i on HF disease-specific health status and cardiac function. This meta-analysis aims to assess the effects of SGLT2i on disease-specific health status and cardiac function in CHF patients. Methods: A comprehensive search was conducted of trials by searching in PubMed, EMBASE, CENTRAL, Scopus, and Web of Science, and two Chinese databases (CNKI and Wanfang), Clinical Trials (http://www.clinicaltrials.gov) were also searched. Results: A total of 18 randomized controlled trials (RCTs) involving 23,953 participants were included in the meta-analysis. The effects of SGLT2 inhibitors were compared with control or placebo groups in CHF with or without T2DM. The SGLT2 inhibitors group exhibited a significant reduction in pro b-type natriuretic peptide (NT-proBNP) levels by 136.03 pg/ml (95% confidence interval [CI]: −253.36, − 18.70; P = 0.02). Additionally, a greater proportion of patients in the SGLT2 inhibitors group showed a ≥ 20% decrease in NT-proBNP (RR = 1.45, 95% CI [0.92, 2.29], p = 0.072). However, no statistically significant difference was observed for the effects on B-type natriuretic peptide (BNP). The use of SGLT-2 inhibitors led to a noteworthy improvement in LVEF by 2.79% (95% CI [0.18, 5.39];P = 0.036). In terms of health status, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6-minute walk distance, SGLT2 inhibitors led to a significant improvement in KCCQ clinical summary (KCCQ-CS) score (WMD = 1.7, 95% CI [1.67, 1.73], P < 0.00001), KCCQ overall summary (KCCQ-OS) score (WMD = 1.73, 95% CI [0.94, 2.52], P < 0.00001), and KCCQ total symptom (KCCQ-TS) score (WMD = 2.88, 95% CI [1.7, 4.06], P < 0.00001). Furthermore, the occurrence of KCCQ-CS and KCCQ-OS score increases ≥ 5 points had relative risks (RR) of 1.25 (95% CI [1.11, 1.42], P < 0.00001) and 1.15 (95% CI [1.09, 1.22], P < 0.00001), respectively. Overall, SGLT2 inhibitors increased the 6-minute walk distance by 23.98 m (95% CI [8.34, 39.62]; P = 0.003) compared to control/placebo from baseline. Conclusions: The SGLT2 inhibitors treatment offers an effective strategy for improving NT-proBNP levels, Kansas City Cardiomyopathy Questionnaire scores and 6-minute walk distance in CHF with or without T2DM. These findings indicate that SGLT2i improve cardiac function and health status in CHF with or without T2DM, and provide valuable guidance for clinicians making treatment decisions for patients with CHF. © 2023, The Author(s). LA - English DB - MTMT ER - TY - JOUR AU - Chioncel, O. AU - Čelutkienė, J. AU - Bělohlávek, J. AU - Kamzola, G. AU - Lainscak, M. AU - Merkely, Béla Péter AU - Miličić, D. AU - Nessler, J. AU - Ristić, A.D. AU - Sawiełajc, L. AU - Uchmanowicz, I. AU - Uuetoa, T. AU - Turgonyi, E. AU - Yotov, Y. AU - Ponikowski, P. TI - Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement JF - ESC HEART FAILURE J2 - ESC HEART FAIL PY - 2024 SN - 2055-5822 DO - 10.1002/ehf2.14687 UR - https://m2.mtmt.hu/api/publication/34766718 ID - 34766718 N1 - Emergency Institute for Cardiovascular Diseases ‘Prof. Dr. C.C. Iliescu’, Bucharest, Romania Carol Davila University of Medicine, Bucharest, Romania Clinic of Cardiac and Vascular Diseases, Faculty of Medicine, Vilnius University/State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania Second Department of Medicine, Cardiovascular Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic Latvian Centre of Cardiology, Pauls Stradiņš Clinical University Hospital, Riga, Latvia Faculty of Medicine, University of Latvia, Riga, Latvia Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia Faculty of Natural Sciences and Mathematics, University of Maribor, Maribor, Slovenia Heart and Vascular Centre, Semmelweis University, Budapest, Hungary Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland Department of Cardiology, University Clinical Centre of Serbia, Belgrade, Serbia Faculty of Medicine, University of Belgrade, Belgrade, Serbia AstraZeneca, Warsaw, Poland Department of Nursing and Obstetrics, Faculty of Health Sciences, Wrocław Medical University, Wrocław, Poland Institute of Heart Diseases, University Hospital, Wrocław, Poland Confido Healthcare Centre, Tallinn, Estonia AstraZeneca GCC, Dubai, United Arab Emirates First Department of Internal Diseases, Faculty of Medicine, Medical University of Varna, Varna, Bulgaria Wrocław Medical University, Wrocław, Poland Export Date: 17 April 2024 Correspondence Address: Chioncel, O.; Emergency Institute for Cardiovascular Diseases ‘Prof. Dr. C.C. Iliescu’Romania; email: ochioncel@yahoo.co.uk AB - Despite improvements over recent years, morbidity and mortality associated with heart failure (HF) are higher in countries in the Central and Eastern Europe and Baltic region than in Western Europe. With the goal of improving the standard of HF care and patient outcomes in the Central and Eastern Europe and Baltic region, this review aimed to identify the main barriers to optimal HF care and potential areas for improvement. This information was used to suggest methods to improve HF management and decrease the burden of HF in the region that can be implemented at the national and regional levels. We performed a literature search to collect information about HF epidemiology in 11 countries in the region (Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Serbia, and Slovenia). The prevalence of HF in the region was 1.6–4.7%, and incidence was 3.1–6.0 per 1000 person-years. Owing to the scarcity of published data on HF management in these countries, we also collected insights on local HF care and management practices via two surveys of 11 HF experts representing the 11 countries. Based on the combined results of the literature review and surveys, we created national HF care and management profiles for each country and developed a common patient pathway for HF for the region. We identified five main barriers to optimal HF care: (i) lack of epidemiological data, (ii) low awareness of HF, (iii) lack of national HF strategies, (iv) infrastructure and system gaps, and (v) poor access to novel HF treatments. To overcome these barriers, we propose the following routes to improvement: (i) establish regional and national prospective HF registries for the systematic collection of epidemiological data; (ii) establish education campaigns for the public, patients, caregivers, and healthcare professionals; (iii) establish formal HF strategies to set clear and measurable policy goals and support budget planning; (iv) improve access to quality-of-care centres, multidisciplinary care teams, diagnostic tests, and telemedicine/telemonitoring; and (v) establish national treatment monitoring programmes to develop policies that ensure that adequate proportions of healthcare budgets are reserved for novel therapies. These routes to improvement represent a first step towards improving outcomes in patients with HF in the Central and Eastern Europe and Baltic region by decreasing disparities in HF care within the region and between the region and Western Europe. © 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. LA - English DB - MTMT ER - TY - JOUR AU - Chong, J.H. AU - Chang, W.-T. AU - Chan, J.J. AU - Tan, T.J.Y. AU - Chan, J.W.K. AU - Wong, M. AU - Wong, F.Y. AU - Chuah, C.T.H. TI - The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction – A systematic review JF - CURRENT PROBLEMS IN CARDIOLOGY J2 - CURR PROB CARDIOLOGY VL - 49 PY - 2024 IS - 3 SN - 0146-2806 DO - 10.1016/j.cpcardiol.2024.102372 UR - https://m2.mtmt.hu/api/publication/34694303 ID - 34694303 N1 - National Heart Centre Singapore, Singapore General Hospital, 5 Hospital Dr169609, Singapore Duke-NUS Medical School, 8 College Rd169857, Singapore School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan National Cancer Centre Singapore, Singapore General Hospital, 30 Hospital Blvd168583, Singapore Singapore General Hospital, Outram Road169608, Singapore Export Date: 29 February 2024 CODEN: CPCAE Correspondence Address: Chong, J.H.; National Heart Centre Singapore, 5 Hospital Dr, Singapore; email: e0483553@u.duke.nus.edu AB - Background: Sodium–glucose cotransporter 2-inhibitors (SGLT2i) improve cardiovascular outcomes including reduction in risk of first hospitalisation for heart failure (HF), worsening HF and cardiovascular death regardless of HF or diabetes mellitus (DM) status. It is not known whether SGLT2i can prevent the development of incident HF or reduce the risk of HF in patients receiving trastuzumab with or without other concurrent anti-HER2 agent or sequential anthracycline for treatment of HER2 positive breast cancer. Patients with active malignancy or recent history of malignancy were excluded from participating in the main cardiovascular outcome trials involving SGLT2i. Aim: A systematic review was performed to objectively assess published literature on the cardioprotective effects of SGLT2i in breast cancer treatment-related cardiotoxicity. Methods: Systematic searches of Embase, Medline, The Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov databases were performed. Titles and abstracts were screened separately by two cardio-oncologists (JHC, WTC). Full texts of potentially eligible records were then assessed separately by JHC and WTC before inclusion into review upon joint agreement. Results: 479 records were identified from 3 databases (MEDLINE=51, EMBASE=408, CENTRAL=13) and 1 registry (Clinicaltrials.gov=7). 460 records were excluded based on title and abstract (including duplicates). 19 full text reports were assessed for eligibility and included in review (basic science/animal study paper 2, Clinicaltrials.gov randomised controlled trial submission 1 (currently recruiting), basic science/animal study conference abstract 5, case report 2, review 3, editorial comment 2, clinical guidelines 1, retrospective/registry-based conference abstract 3). Conclusion: Cardiotoxicity is the most common dose-limiting toxicity associated with trastuzumab. Discontinuation of trastuzumab however, can lead to worse cancer outcomes. There have been case reports, registry-based, retrospective cohort-based and mechanistic studies suggesting the cardioprotective potential of SGLT2i in cancer therapy-related cardiac dysfunction (CTRCD). Based on these, there is now a call for randomised controlled trials to be performed in this patient cohort to advise guideline-directed therapy for CTRCD, which will in turn also provide detailed safety information and improve cancer and cardiovascular outcomes. © 2024 LA - English DB - MTMT ER - TY - JOUR AU - Chong, K. AU - Chang, J.K.-J. AU - Chuang, L.-M. TI - Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies JF - KAOHSIUNG JOURNAL OF MEDICAL SCIENCES J2 - KAOHSIUNG J MED SCI VL - 40 PY - 2024 IS - 3 SP - 212 EP - 220 PG - 9 SN - 1607-551X DO - 10.1002/kjm2.12800 UR - https://m2.mtmt.hu/api/publication/34502121 ID - 34502121 N1 - Department of Internal Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan Department of Nursing, Yuanpei University of Medical Technology, Hsinchu, Taiwan Biological Programs for Younger Scholar, Academia Sinica, Taipei, Taiwan Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Export Date: 15 January 2024 CODEN: KHHCE Correspondence Address: Chuang, L.-M.; Department of Internal Medicine, Taiwan; email: leeming@ntu.edu.tw AB - Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person-centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing glucose for patients with T2DM. A glucose-reduction treatment regimen must consider weight management. Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events. Glucagon-like peptide-1 (GLP-1) receptor agonists allow better control of glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which activate GIP and GLP-1 receptors improve glycemic control and promote greater weight loss than GLP-1 receptor agonists. Several novel drugs are in the clinical development phase. This review pertains to recent advances in pharmacological management of type 2 diabetes. © 2024 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University. LA - English DB - MTMT ER - TY - JOUR AU - Chopra, H.K. AU - Nair, T. AU - Wander, G.S. AU - Ponde, C.K. AU - Ray, S. AU - Khullar, D. AU - Nanda, N.C. AU - Narula, J. AU - Kasliwal, R.R. AU - Rana, D.S. AU - Kirpalani, A. AU - Sawhney, J.P.S. AU - Chandra, P. AU - Mehta, Y. AU - Kumar, V. AU - Tewari, S. AU - Pancholia, A.K. AU - Kher, V. AU - Bansal, S. AU - Mittal, S. AU - Kerkar, P. AU - Sahoo, P.K. AU - Hotchandani, R. AU - Prakash, S. AU - Chauhan, N. AU - Rastogi, V. AU - Jabir, A. AU - Shanmugasundaram, S. AU - Tiwaskar, M. AU - Sinha, A. AU - Gupta, V. AU - Mishra, S.S. AU - Routray, S.N. AU - Omar, A.K. AU - Swami, O.C. AU - Jaswal, A. AU - Alam, S. AU - Passey, R. AU - Rajput, R. AU - Paul, J. AU - Kapoor, A. AU - Prabhakar, D. AU - Chandra, S. AU - Malhotra, P. AU - Singh, V.P. AU - Bansal, M. AU - Shah, P. AU - Jain, S. AU - Bhargava, M. AU - Vijayalakshmi, I.B. AU - Varghaese, K. AU - Jain, D. AU - Goel, A. AU - Mehmood, K. AU - Gaur, N. AU - Tandon, R. AU - Moorthy, A. AU - George, S. AU - Katyal, V.K. AU - Mantri, R.R. AU - Mehrotra, R. AU - Bhalla, D. AU - Mittal, V. AU - Rao, S. AU - Jagia, M. AU - Singh, H. AU - Awasthi, S. AU - Sattur, A. AU - Mishra, R. AU - Pandey, A. AU - Chawla, R. AU - Jaggi, S. AU - Sehgal, B. AU - Sehgal, A. AU - Goel, N. AU - Gupta, R. AU - Kubba, S. AU - Chhabra, A. AU - Bagga, S. AU - Shastry, N.R. TI - Current Place of SGLT2i in the Management of Heart Failure: An Expert Opinion from India JF - JOURNAL OF ASSOCIATION OF PHYSICIANS OF INDIA J2 - J ASSOC PHYS INDIA VL - 72 PY - 2024 IS - 1 SP - 63 EP - 73 PG - 11 SN - 0004-5772 DO - 10.59556/japi.71.0440 UR - https://m2.mtmt.hu/api/publication/34742642 ID - 34742642 N1 - Department of Cardiology, Medanta Moolchand Heart Center, Delhi, India Department of Cardiology, PRS Hospital, Kerala, Trivandrum, India Department of Cardiology, Dayanand Medical College & Hospital (DMCH), Hero DMC Heart Institute, Punjab, Ludhiana, India Department of Cardiology, PD Hinduja National Hospital, Medical Research Centre, Maharashtra, Mumbai, India Department of Invasive Cardiology, AMRI Hospital, West Bengal, Kolkata, India Nephrology and Renal Transplant Medicine, Department of Nephrology and Renal Transplant Medicine, Max Super Speciality Hospital, Delhi, India Department of Medicine and Cardiovascular Disease, Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, United States University of Texas, Houston K. Lance Gould, Distinguished University Chair for Coronary Pathophysiology, Medicine & Cardiology McGovern Medical School, Houston, TX, United States Department of Clinical and Preventive Cardiology, Medanta-The Medicity, Haryana, Gurugram, India Department of Nephrology, Sir Ganga Ram Hospital, Delhi, India Bombay Hospital, Maharashtra, Mumbai, India Department of Cardiology, Sir Gangaram Hospital, Delhi, India Department of Interventional and Structural Heart Cardiology, Medanta-The Medicity, Haryana, Gurugram, India Department of Critical Care Medicine, Medanta Institute of Critical Care Anaesthesiology, Medanta, The Medicity, Haryana, Gurugram, India Department of Cardiac Sciences, Max Hospital, Delhi, India Department of Cardiology, SGPGIMS, Uttar Pradesh, Lucknow, India Department of Clinical and Preventive Cardiology, Arihant Hospital and Research Centre, Madhya Pradesh, Indore, India Department of Nephrology, Department of Kidney Transplant, Epitome Kidney Urology Institute, Lions Hospital, Delhi, India Department of Cardiology, Vardhaman Mahavir Medical College, Safdarjung Hospital, Delhi, India Medanta-The Medicity, Haryana, Gurugram, India Asian Heart Institute, Maharashtra, Mumbai, India Department of Cardiology, Apollo Hospital, Odisha, Bhubaneshwar, India Department of Nephrology, Moolchand Centre for Renal Care and Dialysis, Moolchand Hospital, Delhi, India Department of Nephrology and Renal Transplantation, BLK-Max Super Speciality Hospital, Delhi, India Department of Interventional Cardiology, Head of Advanced Heart Failure Program, Fortis Escort Heart Institute, Delhi, India Lisie Hospital, Kerala, Cochin, India Billroth Hospitals, Tamil Nadu, Chennai, India Shilpa Medical Research Centre, Maharashtra, Mumbai, India Department of Cardiology, Medanta Heart Institute, Bihar, Patna, India Department of Internal Medicine, Kishori Ram Hospital and Diabetes Care Centre, Punjab, Bhatinda, India Med N Heart Clinic, Odisha, Cuttack, India Department of Cardiology, SCB Medical College, Odisha, Cuttack, India Fortis Escorts Heart Institute, Department of Non-invasive Cardiology, Delhi, India Medical Services, Alembic Pharmaceuticals Ltd., Maharashtra, Mumbai, India Department of Cardiac Pacing and Electrophysiology, Fortis Escorts Heart Institute, Delhi, India Jayprabha Medanta Super Speciality Hospital, Bihar, Patna, India Sir Ganga Ram Hospital, Delhi, India Apollo Hospitals, Delhi, India Madras Medical College, Tamil Nadu, Chennai, India Department of Cardiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Uttar Pradesh, Lucknow, India Ashwin Clinic, Tamil Nadu, Chennai, India Department of Cardiology and Structural Heart Disease, BLK Max Super Speciality Hospital, Delhi, India Department of Cardiac Anaesthesia, All India Institute of Medical Sciences, Delhi, India Fortis Escort Heart Institute, Delhi, India Max Hospital, Delhi, India Former Head Cardiology, Shri Jayadeva Institute of Cardiovascular Sciences and Research, Karnataka, Bengaluru, India Department of Cardiology, St. John’s Medical College, Karnataka, Bengaluru, India Department of Cardiology, IMS, BHU, Uttar Pradesh, Varanasi, India Interventional Cardiology, Max Super-speciality hospital, Delhi, India Department of Medicine and Cardiology, Icahn School of Medicine at Mount Sinai, Heart Failure Program, Mount Sinai Morningside Hospital, New York, United States CVTS, AIIMS Rishikesh, Uttarakhand, Rishikesh, India Department of Cardiology, Dayanand Medical College and Hospital, Punjab, Ludhiana, India SIMS Hospital, Tamil Nadu, Chennai, India Department of Interventional Cardiology, Jubilee Memorial Hospital, Kerala, Trivandrum, India Department of General Medicine, Positron Hospital, Department of Medicine, Pt BD Sharma Post Graduate Institute of Medical Sciences, Haryana, Rohtak, India Department of Cardiology, Sir Ganga Ram Hospital, Delhi, India Department of Non-invasive Cardiology, Max Super Speciality Hospital, Delhi, India Department of Nephrology and Renal Transplant, Max Super Speciality Hospital, India Centre for Diabetes and Metabolic Diseases, Heart and Lung Institute, Delhi, India Apollo Hospital, Madhya Pradesh, Indore, India Department of Anaesthesia and Critical care, Moolchand Hospital, Delhi, India Max Super Speciality Hospital, Uttar Pradesh, Ghaziabad, India Moolchand Hospital, Delhi, India Cath Lab HCG, Suchiraya Hospital, Karnataka, Hubli, India Apollo Hospital, Delhi, India Department of Cardiology, Kailash Deepak Hospital, India North Delhi Diabetes and Cardiac Centre, Delhi, India Dr Mohan Diabetes Specialities Centre, Delhi, India Shree Balaji Action Medical Institute, Delhi, India Yeshoda Super Speciality Hospital, Uttar Pradesh, Ghaziabad, India Department of Cardiology and HF, Fortis Shalimar Bagh Hospital, Delhi, India Max Super Speciality Hospital, Delhi, India Department of Cardiology, Dharmshila Narayana Superspeciality Hospital, Delhi, India Fortis Hospital, Delhi, India Medanta Moolchand Heart Center, Delhi, India Export Date: 18 March 2024 Correspondence Address: Wander, G.S.; Department of Cardiology, Punjab, India Funding text 1: Funding for medical writing support was provided by Alembic Pharmaceuticals Ltd. AB - Heart failure (HF) is a global health concern that is prevalent in India as well. HF is reported at a younger age in Indian patients with comorbidity of type 2 diabetes (T2DM) in approximately 50% of patients. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally approved for T2DM, are new guideline-recommended and approved treatment strategies for HF. Extensive evidence highlights that SGLT2i exhibits profound cardiovascular (CV) benefits beyond glycemic control. SGLT2i, in conjunction with other guideline-directed medical therapies (GMDT), has additive effects in improving heart function and reducing adverse HF outcomes. The benefits of SGLT2i are across a spectrum of patients, with and without diabetes, suggesting their potential place in broader HF populations irrespective of ejection fraction (EF). This consensus builds on the updated evidence of the efficacy and safety of SGLT2i in HF and recommends its place in therapy with a focus on Indian patients with HF. ©The Author(s). 2024. LA - English DB - MTMT ER - TY - JOUR AU - Christa, M. AU - Maack, C. TI - Heart failure is a systemic disease JF - KARDIOLOGIE J2 - KARDIOLOGIE VL - 18 PY - 2024 SP - 135 EP - 142 PG - 8 SN - 2731-7129 DO - 10.1007/s12181-024-00677-w UR - https://m2.mtmt.hu/api/publication/34742629 ID - 34742629 N1 - Export Date: 18 March 2024 Correspondence Address: Maack, C.; Medizinische Klinik 1, Germany; email: Maack_C@ukw.de AB - Heart failure affects approximately 4% of the German population, is the most common reason for hospitalization and is associated with a high morbidity and mortality. The prevalence increases with age, and older patients also frequently have diseases of other organ systems, such as chronic kidney disease, anemia, obesity, and type 2 diabetes mellitus. The number of comorbidities has a significant impact on the prognosis. Therefore, heart failure is no longer regarded as an isolated organ disease but as a systemic disease in which the heart is in communication with other organs. This communication is governed in particular through neuroendocrine activation, inflammation and metabolism. While previous treatments mainly focused on the neuroendocrine activation, more recent approaches target metabolism and inflammation. Depending on the approach, the clinical results of these interventions show that not only the heart, but also the kidneys, metabolic and possibly also tumor diseases can be favorably influenced. This illustrates that the treatment of heart failure is an interdisciplinary approach, in which cardiologists should work closely with other disciplines of internal medicine. The present review focuses on the cardiorenal metabolic system in patients with heart failure, and how therapeutic interventions targeting this system impact the generation and course heart failure. © Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. Published by Springer Medizin Verlag GmbH, ein Teil von Springer Nature - all rights reserved 2024. LA - German DB - MTMT ER - TY - JOUR AU - Chrysopoulou, M. AU - Rinschen, M.M. TI - Metabolic Rewiring and Communication: An Integrative View of Kidney Proximal Tubule Function JF - ANNUAL REVIEW OF PHYSIOLOGY J2 - ANNU REV PHYSIOL VL - 86 PY - 2024 SP - 405 EP - 427 PG - 23 SN - 0066-4278 DO - 10.1146/annurev-physiol-042222-024724 UR - https://m2.mtmt.hu/api/publication/34777770 ID - 34777770 N1 - Cited By :1 Export Date: 8 April 2024 CODEN: ARPHA LA - English DB - MTMT ER - TY - JOUR AU - Chyou, J.Y. AU - Qin, H. AU - Butler, J. AU - Voors, A.A. AU - Lam, C.S.P. TI - Sex-related similarities and differences in responses to heart failure therapies JF - NATURE REVIEWS CARDIOLOGY J2 - NAT REV CARDIOL VL - In press PY - 2024 SN - 1759-5002 DO - 10.1038/s41569-024-00996-1 UR - https://m2.mtmt.hu/api/publication/34740411 ID - 34740411 N1 - Export Date: 14 March 2024 Correspondence Address: Lam, C.S.P.; National Heart Centre Singapore and Duke-NUS Medical SchoolSingapore; email: carolyn.lam@duke-nus.edu.sg AB - Although sex-related differences in the epidemiology, risk factors, clinical characteristics and outcomes of heart failure are well known, investigations in the past decade have shed light on an often overlooked aspect of heart failure: the influence of sex on treatment response. Sex-related differences in anatomy, physiology, pharmacokinetics, pharmacodynamics and psychosocial factors might influence the response to pharmacological agents, device therapy and cardiac rehabilitation in patients with heart failure. In this Review, we discuss the similarities between men and women in their response to heart failure therapies, as well as the sex-related differences in treatment benefits, dose–response relationships, and tolerability and safety of guideline-directed medical therapy, device therapy and cardiac rehabilitation. We provide insights into the unique challenges faced by men and women with heart failure, highlight potential avenues for tailored therapeutic approaches and call for sex-specific evaluation of treatment efficacy and safety in future research. © Springer Nature Limited 2024. LA - English DB - MTMT ER - TY - JOUR AU - Ciampi, C.M. AU - Sultana, A. AU - Ossola, P. AU - Farina, A. AU - Fragasso, G. AU - Spoladore, R. TI - Current experimental and early investigational agents for cardiac fibrosis: where are we at? JF - EXPERT OPINION ON INVESTIGATIONAL DRUGS J2 - EXPERT OPIN INV DRUG VL - 33 PY - 2024 IS - 4 SP - 389 EP - 404 PG - 16 SN - 1354-3784 DO - 10.1080/13543784.2024.2326024 UR - https://m2.mtmt.hu/api/publication/34742604 ID - 34742604 N1 - Health Science Department, University of Milan Bicocca, Milano, Italy Division of Cardiology, Alessandro Manzoni Hospital, ASST- Lecco, Italy Heart Failure Unit Head, Division of Cardiology, IRCCS Vita-Salute San Raffaele University Hospital, Milan, Italy Export Date: 18 March 2024 CODEN: EOIDE Correspondence Address: Spoladore, R.; Division of Cardiology, Italy; email: ambulatorio.rscardiologia@gmail.com AB - Introduction: Myocardial fibrosis (MF) is induced by factors activating pro-fibrotic pathways such as acute and prolonged inflammation, myocardial ischemic events, hypertension, aging process, and genetically-linked cardiomyopathies. Dynamics and characteristics of myocardial fibrosis development are very different. The broad range of myocardial fibrosis presentations suggests the presence of multiple potential targets. Area covered: Heart failure treatment involves medications primarily aimed at counteracting neurohormonal activation. While these drugs have demonstrated efficacy against MF, not all specifically target inflammation or fibrosis progression with some exceptions such as RAAS inhibitors. Consequently, new therapies are being developed to address this issue. This article is aimed to describe anti-fibrotic drugs currently employed in clinical practice and emerging agents that target specific pathways, supported by evidence from both preclinical and clinical studies. Expert opinion: Despite various preclinical findings suggesting the potential utility of new drugs and molecules for treating cardiac fibrosis in animal models, there is a notable scarcity of clinical trials investigating these effects. However, the pathology of damage and repair in the heart muscle involves a complex network of interconnected inflammatory pathways and various types of immune cells. Our comprehension of the positive and negative roles played by specific immune cells and cytokines is an emerging area of research. © 2024 Informa UK Limited, trading as Taylor & Francis Group. LA - English DB - MTMT ER - TY - JOUR AU - Ciardullo, S. AU - Savaré, L. AU - Rea, F. AU - Perseghin, G. AU - Corrao, G. TI - Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes JF - DIABETES-METABOLISM RESEARCH AND REVIEWS J2 - DIABETES-METAB RES VL - 40 PY - 2024 IS - 4 SN - 1520-7552 DO - 10.1002/dmrr.3791 UR - https://m2.mtmt.hu/api/publication/34799293 ID - 34799293 N1 - Department of Internal Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy Department of Medicine and Surgery, Università degli Studi di Milano-Bicocca, Monza, Italy National Centre for Healthcare Research & Pharmacoepidemiology, at the University of Milano-Bicocca, Milan, Italy MOX - Laboratory for Modeling and Scientific Computing, Department of Mathematics, Politecnico di Milano, Milan, Italy CHDS - Center for Health data Science, Human Technopole, Milan, Italy Laboratory of Healthcare Research & Pharmacoepidemiology, Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy Export Date: 19 April 2024 CODEN: DMRRF Correspondence Address: Ciardullo, S.; Department of Medicine and Surgery, Via Modigliani 10, MB, Italy; email: stefano.ciardullo@policlinicodimonza.it LA - English DB - MTMT ER - TY - JOUR AU - Clark, K.M. AU - Mahboob, F. AU - Evans, J. AU - Sun, J.H. AU - Wang, N. TI - Efficacy of Guideline-Directed Medical Therapy in Heart Failure Patients With and Without Chronic Kidney Disease: A Meta-Analysis of 63,677 Patients JF - HEART LUNG AND CIRCULATION J2 - HEART LUNG CIRC VL - 33 PY - 2024 IS - 3 SP - 281 EP - 291 PG - 11 SN - 1443-9506 DO - 10.1016/j.hlc.2023.12.013 UR - https://m2.mtmt.hu/api/publication/34750144 ID - 34750144 N1 - Sydney Medical School, University of Sydney, Sydney, NSW, Australia Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia Cardiovascular Division, The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia Export Date: 21 March 2024 CODEN: HLCEA Correspondence Address: Wang, N.; Department of Cardiology, Australia; email: nelson.wang@sydney.edu.au AB - Background: Chronic kidney disease (CKD) coexists in up to 50% of heart failure (HF) patients, affecting both those with reduced ejection fraction (HFrEF) and those with preserved ejection fraction (HFpEF). Although the efficacy of several guideline-directed medical therapies (GDMT) has been well established, the treatment recommendations are similar for those patients with HF with and without CKD. We aimed to investigate the efficacy of GDMT in patients with HF with versus those without CKD. Method: This systematic review and meta-analysis included randomised controlled trials that compared the efficacy of GDMT (angiotensin-converting enzyme inhibitor [ACE-I], beta blocker, sodium-glucose cotransporter-2 inhibitor, mineralocorticoid receptor antagonist, angiotensin receptor-neprilysin inhibitor) in patients with HF with and without CKD. The primary outcome was the composite of cardiovascular death and HF hospitalisation. Risk ratios (RR) were pooled using random-effects meta-analysis. Results: A total of 19 trials (15 trials in HFrEF and four trials in HFpEF) enrolling 63,677 (38% had CKD) participants were included. Among HFrEF patients, GDMT reduced the primary endpoint in those with CKD (RR 0.77, 95% confidence interval [CI] 0.72-0.82) and without CKD (RR 0.79, 95% CI 0.74–0.84). Among HFpEF patients, the pooled summary RR for GDMT reducing the primary endpoint was 0.82 (95% CI 0.74-0.91) among those with CKD and 0.88 (95% CI 0.77-0.99) among those without CKD. There was no significant difference in the efficacy of GDMT in head-to-head comparisons between those with and without CKD in HFrEF (ratio of RR 0.97, 95% CI 0.88-1.06) and HFpEF (ratio of RR 0.94, 95% CI 0.80-1.11). Conclusions: Among patients with HF, GDMT had a consistent effect in reducing adverse cardiovascular events in those with and without CKD. Future studies should investigate the best strategy to ensure patients with HF with CKD receive and tolerate GDMT when indicated. © 2024 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) LA - English DB - MTMT ER - TY - JOUR AU - Cohen, B. AU - Harris, Y.T. AU - Schulman-Rosenbaum, R. TI - Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia JF - ENDOCRINE PRACTICE J2 - ENDOCR PRACT VL - 30 PY - 2024 IS - 4 SP - 402 EP - 408 PG - 7 SN - 1530-891X DO - 10.1016/j.eprac.2023.11.014 UR - https://m2.mtmt.hu/api/publication/34502124 ID - 34502124 N1 - Export Date: 15 January 2024 CODEN: EPNRA Correspondence Address: Schulman-Rosenbaum, R.; Division of Endocrinology, 270-05 76th Ave, United States; email: rschulma@northwell.edu AB - Objective: Hyperglycemia in patients with type 2 diabetes mellitus is frequently encountered in the hospital setting. The recent guidelines for the management of inpatient hyperglycemia have included the use of dipeptidyl peptidase 4 inhibitors as an alternative to standard insulin therapy in select patients. This raises the question of the inpatient use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), which have gained increasing popularity in the outpatient setting because of beneficial cardiovascular and renal outcomes. This article describes the risks associated with the use of SGLT2i for the management of inpatient hyperglycemia. Methods: A literature review was performed using PubMed and Google Scholar for studies assessing the inpatient use of SGLT2i. Search terms included “SGLT2 inhibitors,” “euglycemic DKA,” “inpatient hyperglycemia,” “DPP4 inhibitors,” “hypovolemia,” and “urinary tract infections.” Studies not written in English were excluded. Forty-eight articles were included. Results: Review of the literature showed significant safety concerns with the use of SGLT2i for the inpatient management of hyperglycemia. Hospitalized patients treated with SGLT2i were at increased risk of diabetic ketoacidosis, euglycemic diabetic ketoacidosis, hypovolemia, and urinary tract infections. When compared head-to-head, SGLT2i were not more effective for inpatient glycemic control than dipeptidyl peptidase 4 inhibitors and did not reduce insulin requirements when used in combination with insulin. Although SGLT2i can be considered for the treatment of congestive heart failure, they should be started close to or at the time of discharge. Conclusion: Although SGLT2i are a preferred pharmacotherapy class for the outpatient management of type 2 diabetes mellitus, there are considerable safety concerns when using them in a hospital setting, and avoidance is recommended. © 2023 AACE LA - English DB - MTMT ER - TY - JOUR AU - Cowart, Kevin AU - Coon, Scott AU - Carris, Nicholas W. W. TI - A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes JF - ANNALS OF PHARMACOTHERAPY J2 - ANN PHARMACOTHER VL - 58 PY - 2024 IS - 5 SP - 514 EP - 522 PG - 9 SN - 1060-0280 DO - 10.1177/10600280231190443 UR - https://m2.mtmt.hu/api/publication/34123049 ID - 34123049 N1 - Taneja College of Pharmacy, Morsani College of Medicine, College of Public Health, University of South Florida, Tampa, FL, United States Taneja College of Pharmacy and Morsani College of Medicine, University of South Florida, Tampa, FL, United States Export Date: 1 September 2023 CODEN: APHRE Correspondence Address: Cowart, K.; Taneja College of Pharmacy, United States; email: kcowart2@usf.edu AB - Objective: To review the pharmacology of bexagliflozin in addition to its safety and efficacy from available clinical trials used for its approval, as well as available clinical evidence to date. Data Sources: A search of the National Institutes of Health Clinical Trials Registry (http://www.clinicaltrials.gov) and PubMed database was performed from inception through June 1, 2023. Study Selection and Data Extraction Quantification: The following study designs were included: metaanalyses, systematic review, clinical trial, or observational study design. Abstracts and drug monographs were also reviewed. Narrative or scoping reviews were excluded. Only articles in the English language and those evaluating the pharmacology, pharmacokinetics, safety, or efficacy of bexaglifozin in humans were included. Data Synthesis: Bexagliflozin reduces hemoglobin A1c similar to 0.5% with similar reductions in systolic blood pressure and body weight to other SGLT2 inhibitors. No cardiovascular outcomes trial is published, nor ongoing at this time. Adverse effects are similar to other SGLT2 inhibitors (genital mycotic and urinary tract infections, increased urination) including a warning for lower extremity amputation similar to canagliflozin. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Although no cost-effectiveness data are available, statements from the manufacturer suggest a competitive price point. Given limited trial data, lower cost, if chosen, may create a temporary niche for bexagliflozin pending generic availability of other SGLT2 inhibitors. However, given lack of cardiovascular and renal outcome data, empagliflozin, dapagliflozin, or canagliflozin may be preferred. Conclusion: Bexagliflozin appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2D. LA - English DB - MTMT ER - TY - JOUR AU - Cuthbert, J.J. AU - Brown, O.I. AU - Pellicori, P. AU - Dobbs, K. AU - Bulemfu, J. AU - Kazmi, S. AU - Sokoreli, I. AU - Pauws, S.C. AU - Riistama, J.M. AU - Cleland, J.G.F. AU - Clark, A.L. TI - Medicines optimization prior to discharge in patients admitted to hospital with heart failure JF - ESC HEART FAILURE J2 - ESC HEART FAIL VL - 11 PY - 2024 IS - 2 SP - 950 EP - 961 PG - 12 SN - 2055-5822 DO - 10.1002/ehf2.14638 UR - https://m2.mtmt.hu/api/publication/34536407 ID - 34536407 N1 - Clinical Sciences Centre, Hull York Medical School, University of Hull, East Riding of Yorkshire, Kingston upon Hull, United Kingdom Department of Cardiology, Hull University Teaching Hospital Trust, Castle Hill Hospital, East Riding of Yorkshire, Kingston upon Hull, United Kingdom British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Place, Glasgow, Lanarkshire, Glasgow, G12 8TA, United Kingdom Remote Patient Management and Chronic Care, Philips Research Eindhoven, Eindhoven, Netherlands Department of Communication and Cognition, Tilburg University, Tilburg, Netherlands Philips Image Guided Therapy Devices, Best, Netherlands Export Date: 27 January 2024 Correspondence Address: Cuthbert, J.J.; Clinical Sciences Centre, East Riding of Yorkshire, United Kingdom; email: joe.cuthbert@hyms.ac.uk Correspondence Address: Cleland, J.G.F.; Clinical Sciences Centre, East Riding of Yorkshire, United Kingdom; email: john.cleland@glasgow.ac.uk Funding text 1: J.G.F.C. is supported by a British Heart Foundation Centre of Research Excellence (grant number RE/18/6/34217). AB - Aims: Approximately half of patients with heart failure and a reduced ejection fraction (HeFREF) are discharged from hospital on triple therapy [angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), beta-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs)]. We investigated what proportion of patients are on optimal doses prior to discharge and how many might be eligible for initiation of sacubitril–valsartan or sodium-glucose co-transporter-2 inhibitors (SGLT2Is). Methods and results: Between 2012 and 2017, 1277 patients admitted with suspected heart failure were enrolled at a single hospital serving a local community around Kingston upon Hull, UK. Eligibility for sacubitril–valsartan or SGLT2I was based on entry criteria for the PIONEER-HF, DAPA-HF, and EMPEROR-Reduced trials. Four hundred fifty-five patients had HeFREF with complete data on renal function, heart rate, and systolic blood pressure (SBP) prior to discharge. Eighty-three per cent of patients were taking an ACE-I or ARB, 85% a BB, and 63% an MRA at discharge. More than 60% of patients were eligible for sacubitril–valsartan and >70% for SGLT2I. Among those not already receiving a prescription, 37%, 28%, and 49% were eligible to start ACE-I or ARB, BB, and MRA, respectively. Low SBP (≤105 mmHg) was the most frequent explanation for failure to initiate or up-titrate therapy. Conclusions: Most patients admitted for heart failure are eligible for initiation of life-prolonging medications prior to discharge. A hospital admission may be a common missed opportunity to improve treatment for patients with HeFREF. © 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. LA - English DB - MTMT ER - TY - JOUR AU - Dabour, M.S. AU - George, M.Y. AU - Daniel, M.R. AU - Blaes, A.H. AU - Zordoky, B.N. TI - The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review JF - JACC. CARDIOONCOLOGY J2 - JACC-CARDIOONCOL VL - 6 PY - 2024 IS - 2 SP - 159 EP - 182 PG - 24 SN - 2666-0873 DO - 10.1016/j.jaccao.2024.01.007 UR - https://m2.mtmt.hu/api/publication/34777796 ID - 34777796 N1 - Export Date: 8 April 2024 LA - English DB - MTMT ER - TY - JOUR AU - D’Amato, Andrea AU - Prosperi, Silvia AU - Severino, Paolo AU - Myftari, Vincenzo AU - Labbro Francia, Aurora AU - Cestiè, Claudia AU - Pierucci, Nicola AU - Marek-Iannucci, Stefanie AU - Mariani, Marco Valerio AU - Germanò, Rosanna AU - Fanisio, Francesca AU - Lavalle, Carlo AU - Maestrini, Viviana AU - Badagliacca, Roberto AU - Mancone, Massimo AU - Fedele, Francesco AU - Vizza, Carmine Dario TI - Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 3 PG - 21 SN - 1661-6596 DO - 10.3390/ijms25031574 UR - https://m2.mtmt.hu/api/publication/34549777 ID - 34549777 N1 - Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, 00161, Italy Division of Cardiology, Policlinico Casilino, Rome, 00169, Italy San Raffaele Cassino, Cassino, 03043, Italy Export Date: 29 February 2024 Correspondence Address: Severino, P.; Department of Clinical, Italy; email: paolo.severino@uniroma1.it AB - Worsening heart failure (WHF) is a severe and dynamic condition characterized by significant clinical and hemodynamic deterioration. It is characterized by worsening HF signs, symptoms and biomarkers, despite the achievement of an optimized medical therapy. It remains a significant challenge in cardiology, as it evolves into advanced and end-stage HF. The hyperactivation of the neurohormonal, adrenergic and renin-angiotensin-aldosterone system are well known pathophysiological pathways involved in HF. Several drugs have been developed to inhibit the latter, resulting in an improvement in life expectancy. Nevertheless, patients are exposed to a residual risk of adverse events, and the exploration of new molecular pathways and therapeutic targets is required. This review explores the current landscape of WHF, highlighting the complexities and factors contributing to this critical condition. Most recent medical advances have introduced cutting-edge pharmacological agents, such as guanylate cyclase stimulators and myosin activators. Regarding device-based therapies, invasive pulmonary pressure measurement and cardiac contractility modulation have emerged as promising tools to increase the quality of life and reduce hospitalizations due to HF exacerbations. Recent innovations in terms of WHF management emphasize the need for a multifaceted and patient-centric approach to address the complex HF syndrome. LA - English DB - MTMT ER - TY - JOUR AU - Dattani, Abhishek AU - Singh, Anvesha AU - Mccann, Gerry P. AU - Gulsin, Gaurav S. TI - Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target JF - JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE J2 - J CARDIOVASC DEV DIS VL - 11 PY - 2024 IS - 1 PG - 19 SN - 2308-3425 DO - 10.3390/jcdd11010012 UR - https://m2.mtmt.hu/api/publication/34607569 ID - 34607569 AB - Type 2 diabetes (T2D) is a multisystem disease with rapidly increasing global prevalence. Heart failure has emerged as a major complication of T2D. Dysregulated myocardial calcium handling is evident in the failing heart and this may be a key driver of cardiomyopathy in T2D, but until recently this has only been demonstrated in animal models. In this review, we describe the physiological concepts behind calcium handling within the cardiomyocyte and the application of novel imaging techniques for the quantification of myocardial calcium uptake. We take an in-depth look at the evidence for the impairment of calcium handling in T2D using pre-clinical models as well as in vivo studies, following which we discuss potential novel therapeutic approaches targeting dysregulated myocardial calcium handling in T2D. LA - English DB - MTMT ER - TY - JOUR AU - de Germay, Sibylle AU - Pambrun, Elodie AU - Pariente, Antoine AU - Grenet, Guillaume AU - Bezin, Julien AU - Faillie, Jean-Luc TI - Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database JF - DIABETES OBESITY & METABOLISM J2 - DIABETES OBES METAB VL - 26 PY - 2024 IS - 5 SP - 1678 EP - 1686 PG - 9 SN - 1462-8902 DO - 10.1111/dom.15472 UR - https://m2.mtmt.hu/api/publication/34639873 ID - 34639873 N1 - Univ. Bordeaux, INSERM, BPH, U1219 Team AHeaD, Bordeaux, France Department of Medical Pharmacology, CHU de Bordeaux, Bordeaux, France Department of Medical Pharmacotoxicology, Hospices Civils de Lyon, Lyon, France Department of Medical Pharmacology and Toxicology, CHU Montpellier; Univ Montpellier, IDESP INSERM, Montpellier, France Export Date: 29 February 2024 CODEN: DOMEF Correspondence Address: Faillie, J.-L.; Department of Medical Pharmacology and Toxicology, France; email: jean-luc.faillie@umontpellier.fr LA - English DB - MTMT ER - TY - JOUR AU - Dehghani, P. AU - Srivatsav, V. AU - Vardeny, O. AU - Grewal, J. AU - Opotowsky, A.R. AU - Muhll, I.V. AU - Keir, M. AU - Ducas, R. AU - Singh, J. AU - Kim, K. AU - Joseph, J. AU - Aboulhosn, J. AU - Havighurst, T. AU - Hegde, S.M. AU - Bhatt, D.L. AU - Solomon, S. AU - Farkouh, M. AU - Goodman, S.G. AU - Moe, T.G. AU - Udell, J.A. TI - Feasibility and Findings of Including Self-Identified Adult Congenital Heart Disease Patients in the INVESTED Trial JF - JACC: ADVANCES J2 - JACC: ADVANCES VL - 3 PY - 2024 IS - 4 SN - 2772-963X DO - 10.1016/j.jacadv.2024.100897 UR - https://m2.mtmt.hu/api/publication/34799299 ID - 34799299 N1 - Division of Cardiology, Department of Medicine, Prairie Vascular Research Inc, Regina, SK, Canada Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis, MN, United States Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada Department of Pediatrics, Heart Institute, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States Division of Cardiology, University of Alberta, Edmonton, AB, Canada Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada Section of Cardiology, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, United States Cardiology Section, VA Providence Healthcare System, Providence, RI, United States Ahmanson/UCLA Adult Congenital Heart Center, Ronald Reagan/UCLA Medical Center, Los Angeles, CA, United States Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, United States Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY, United States Academic Affairs, Cedars-Sinai Health System, Los Angeles, CA, United States Division of Cardiology, St. Michael's Hospital, Unity Health Toronto, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto, ON, Canada Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada Arizona Cardiology Group, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States Faculty of Medicine, Division of Cardiology, Department of Medicine, Women's College Hospital, University of Toronto, Toronto, ON, Canada Cited By :1 Export Date: 19 April 2024 Correspondence Address: Dehghani, P.; Department of Cardio-neurosciences, 3rd Floor Regina General Hospital 1440 14th Ave., Canada; email: p.dehghani@usask.ca LA - English DB - MTMT ER - TY - JOUR AU - Dent, Susan AU - Rader, Ryan K. AU - White, Olivia AU - Patterson, Brandy AU - Moore, Heather N. TI - Moving Beyond Cardiotoxicity Detection to Prevention: A Pharmacologic Review JF - CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE J2 - CURR TREAT OPTIONS CARDIOVASC MED VL - 26 PY - 2024 SP - 1 EP - 12 PG - 12 SN - 1092-8464 DO - 10.1007/s11936-023-01030-2 UR - https://m2.mtmt.hu/api/publication/34495176 ID - 34495176 N1 - Export Date: 11 January 2024 CODEN: CTOCC Correspondence Address: Dent, S.; Duke University HospitalUnited States; email: susan.dent@duke.edu AB - Purpose of reviewCardio-oncology is a subspecialty of medicine focused on minimizing the risk of cardiovascular (CV) toxicity in patients receiving potentially cardiotoxic cancer therapy. While the literature has previously focused on detection of CV toxicity, there has been growing interest in primary prevention strategies for cancer therapy-related cardiovascular toxicity (CTR-CVT).Recent findingsSeveral trials have investigated the role of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and/or beta-blockers with mixed results, prompting researchers to assess alternatives, e.g., statins and sodium-glucose co-transporter-2 inhibitors (SGLT-2i). In this review, we discuss the positive and negative clinical trial results relating to these two drug classes. Ongoing prevention-focused clinical trials include ARBs in combination with neprilysin inhibitors (ARNis), azeliragon, and ivabradine. Further research is needed to discern the true benefit of novel agents and, importantly, the specific populations that would derive the most benefit.SummaryIn this review, we focus on results from recently reported studies exploring the potential benefit of pharmacologic approaches in primary prevention. There are currently no definitive signals strongly recommending a specific class of drugs for primary prevention in patients with cancer. Further research is required to determine which subset of patients might benefit from primary prevention strategies. LA - English DB - MTMT ER - TY - JOUR AU - Devadoss, Ramprakash AU - Dhillon, Gagandeep AU - Sharma, Pranjal AU - Verma, Ram Kishun AU - Munjal, Ripudaman AU - Kashyap, Rahul TI - Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment JF - JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE J2 - J CARDIOVASC DEV DIS VL - 11 PY - 2024 IS - 1 SN - 2308-3425 DO - 10.3390/jcdd11010015 UR - https://m2.mtmt.hu/api/publication/34549392 ID - 34549392 N1 - Export Date: 26 February 2024 Correspondence Address: Kashyap, R.; WellSpan Health, 1001 S George St., United States; email: kashyapmd@gmail.com AB - Heart failure is a cardiovascular condition, leading to fatigue, breathlessness, and fluid retention. It affects around 56 million people globally and is a leading cause of hospitalization and mortality. Its prevalence is rising due to aging populations and lifestyle factors. Managing heart failure demands a multidisciplinary approach, encompassing medications, lifestyle modifications, and often medical devices or surgeries. The treatment burden is substantial, impacting patients’ daily lives and straining healthcare systems. Improving early detection, novel therapies, and patient education are crucial for alleviating the burden and enhancing the quality of life. There are notable advancements in the field of heart failure treatment and prevention. We will discuss significant pharmacological and device advances related to heart failure, including angiotensin receptor–neprilysin inhibitor, sodium–glucose co-transporter inhibition, glucagon-like peptide-1 agonist, cardiac resynchronization therapy, cardiac contractility modulation, mechanical circulatory support devices, and transcatheter valve interventions. We will also review novel therapies on the horizon, emerging technologies like CRISPR-based treatments for genetic anomalies, and the involvement of artificial intelligence in heart failure detection and management. LA - English DB - MTMT ER - TY - JOUR AU - Dhingra, N.K. AU - Verma, S. AU - Butler, J. AU - Anker, S.D. AU - Ferreira, J.P. AU - Filippatos, G. AU - Januzzi, J.L. AU - Lam, C.S.P. AU - Sattar, N. AU - Zaremba-Pechmann, L. AU - Böhm, M. AU - Nordaby, M. AU - Brueckmann, M. AU - Pocock, S.J. AU - Zannad, F. AU - Packer, M. AU - EMPEROR-Reduced, Trial Committees and Investigators TI - Efficacy and Safety of Empagliflozin According to Background Diuretic Use in Heart Failure With Reduced Ejection Fraction: Post-Hoc Analysis of EMPEROR-Reduced JF - JACC-HEART FAILURE J2 - JACC HEART FAILURE VL - 12 PY - 2024 IS - 1 SP - 35 EP - 46 PG - 12 SN - 2213-1779 DO - 10.1016/j.jchf.2023.06.036 UR - https://m2.mtmt.hu/api/publication/34213291 ID - 34213291 N1 - Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Canada Baylor Scott and White Research Institute, Dallas, TX, United States University of Mississippi, Jackson, MS, United States Department of Cardiology of German Heart Center Charité, Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research, partner site Berlin, Charité Universitätsmedizin, Berlin, Germany Université de Lorraine, Inserm, Centre d'Investigations Cliniques–Plurithématique 14-33, Nancy, France Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Portugal National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Boston, MA, United States National Heart Centre Singapore, Duke-NUS Medical School, Singapore School of Cardiovascular and Metabolic Health, University of Glasgow, Scotland, United Kingdom Elderbrook Solutions GmbH, Krakow, Poland Boehringer Ingelheim International GmbH, Ingelheim, Germany First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, United States Imperial College, London, United Kingdom Export Date: 24 October 2023 Correspondence Address: Verma, S.; St. Michael's Hospital, 30 Bond Street, Canada; email: Subodh.Verma@unityhealth.to Funding text 1: The authors acknowledge editorial support provided by Elevate Scientific Solutions and graphical assistance provided by 7.4 Limited, which were contracted and compensated by Boehringer Ingelheim. AB - Background: The EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) trial established the efficacy of empagliflozin in reducing heart failure (HF) outcomes among patients with heart failure with reduced ejection fraction (HFrEF). Objectives: The authors examined the outcomes of EMPEROR-Reduced as a function of background diuretic therapy. Methods: The EMPEROR-Reduced trial was a double-blind, randomized controlled trial of placebo vs empagliflozin 10 mg among 3,730 HFrEF patients. Herein, the population was stratified into 4 groups: no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. Results: A total of 3,656 patients from the EMPEROR-Reduced trial were available for analysis. Of those patients, 482 (13.2%) were receiving no diuretic therapy, and 731 (20.0%), 1,411 (38.6%), and 1,032 (28.2%) were receiving <40 mg, 40 mg, and >40 mg, respectively. The efficacy of empagliflozin on the primary outcome (time to first event of hospitalization for HF or cardiovascular [CV] death) was consistent regardless of background diuretic therapy (>40 mg: HR: 0.88 [95% CI: 0.71-1.10]; 40 mg: HR: 0.65 [95% CI: 0.51-0.82]; <40 mg: HR: 0.65 [95% CI: 0.46-0.92]); no diuretic agents: HR: 0.78 [95% CI: 0.47-1.29]; Ptrend test = 0.192). Baseline diuretic doses did not influence the effect of empagliflozin on body weight, systolic blood pressure, NT-proBNP, or hematocrit at 52 weeks. The safety profile of empagliflozin vs placebo was unaffected by baseline diuretic dose; however, independently of treatment allocation, total rates of adverse events were higher among patients with higher baseline doses of diuretic agents. Conclusions: Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977) © 2023 American College of Cardiology Foundation LA - English DB - MTMT ER - TY - JOUR AU - Diallo, A. AU - Diallo, M. F. AU - Carlos-Bolumbu, M. AU - Galtier, F. TI - Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis JF - DIABETES OBESITY & METABOLISM J2 - DIABETES OBES METAB VL - 26 PY - 2024 IS - 5 SP - 1980 EP - 1985 PG - 6 SN - 1462-8902 DO - 10.1111/dom.15483 UR - https://m2.mtmt.hu/api/publication/34623846 ID - 34623846 N1 - University Gamal Abdel Nasser of Conakry, Department of Public Health, Conakry, Guinea Groupe Hospitalier du Havre, Service de Néphrologie, Havre, France APHP, Université Paris Sacly, Paris, France Clinical Investigation Center 1411, INSERM, CHU Montpellier, Univ Montpellier, Montpellier, France INSERM, F-CRIN, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Paris, France Export Date: 3 April 2024 CODEN: DOMEF Correspondence Address: Diallo, A.; University Gamal Abdel Nasser of Conakry, Guinea; email: djuhany@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Dimitrios, P Ntentakis AU - Victor, San Martin Carvalho Correa AU - Anastasia, Maria Ntentaki AU - Eleni, Delavogia AU - Toshio, Narimatsu AU - Nikolaos, E Efstathiou AU - Demetrios, G. Vavvas TI - Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review JF - GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY J2 - GRAEF ARCH CLIN EXP VL - 262 PY - 2024 SP - 717 EP - 752 PG - 36 SN - 0721-832X DO - 10.1007/s00417-023-06236-5 UR - https://m2.mtmt.hu/api/publication/34170053 ID - 34170053 N1 - Ines and Fredrick Yeatts Retina Research Laboratory, Angiogenesis Laboratory, Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Main Campus, 243 Charles Street, Harvard Medical School, Boston, MA 02114, United States Department of Pediatrics, Harvard Medical School, Boston, MA, United States Export Date: 3 October 2023 CODEN: GACOD Correspondence Address: Vavvas, D.G.; Ines and Fredrick Yeatts Retina Research Laboratory, 243 Charles Street, Harvard Medical School, United States; email: Demetrios_Vavvas@MEEI.HARVARD.EDU LA - English DB - MTMT ER - TY - JOUR AU - Doherty, Daniel J. AU - Docherty, Kieran F. AU - Gardner, Roy S. TI - Review of the National Institute for Health and Care Excellence guidelines on chronic heart failure JF - HEART J2 - HEART VL - 110 PY - 2024 SP - 466 EP - 475 PG - 10 SN - 1355-6037 DO - 10.1136/heartjnl-2022-322164 UR - https://m2.mtmt.hu/api/publication/34582826 ID - 34582826 N1 - School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom Golden Jubilee National Hospital, Scottish National Advanced Heart Failure Service, Clydebank, United Kingdom Export Date: 29 February 2024 CODEN: HEARF Correspondence Address: Doherty, D.J.; School of Cardiovascular and Metabolic Health, United Kingdom; email: daniel.doherty@glasgow.ac.Uk AB - Guidelines are more accessible than ever and represent an important tool in clinical practice. The National Institute for Health and Care Excellence (NICE) has developed recommendations for heart failure diagnosis and management based not only on morbidity and mortality trial outcome data but also in-depth economic analysis, with a focus on generalisability to UK National Health Service clinical practice. There is broad consistency in structure and content between NICE guidelines and those produced by major cardiovascular organisations such as the American College of Cardiology/American Heart Association and the European Society of Cardiology. However, important differences do exist-largely attributable to publication timing-a factor that is enhanced by the rapid pace of heart failure research. This article reviews the most recent iteration of NICE chronic heart failure guidelines and compares them with major guidelines on an international scale. Variations in recommendations will be explored including implications for NICE guideline updates in the future. LA - English DB - MTMT ER - TY - JOUR AU - Doi, S.N. AU - Thune, J.J. AU - Nielsen, J.C. AU - Haarbo, J. AU - Videbæk, L. AU - Yafasova, A. AU - Bruun, N.E. AU - Gustafsson, F. AU - Eiskjær, H. AU - Hassager, C. AU - Svendsen, J.H. AU - Høfsten, D.E. AU - Torp-Pedersen, C. AU - Pehrson, S. AU - Køber, L. AU - Butt, J.H. TI - Estimated Glomerular Filtration Rate and Implantable Cardioverter-Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow-Up of DANISH JF - JOURNAL OF THE AMERICAN HEART ASSOCIATION J2 - J AM HEART ASSOC VL - 13 PY - 2024 IS - 3 SN - 2047-9980 DO - 10.1161/JAHA.123.031977 UR - https://m2.mtmt.hu/api/publication/34742587 ID - 34742587 N1 - Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Department of Cardiology, Copenhagen University Hospital—Bispebjerg and Frederiksberg, Copenhagen, Denmark Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark Department of Clinical Medicine, Aarhus University, Aarhus, Denmark Department of Cardiology, Copenhagen University Hospital—Herlev and Gentofte, Hellerup, Denmark Department of Cardiology, Odense University Hospital, Svendborg, Denmark Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark Department of Cardiology, Zealand University Hospital, Roskilde, Denmark Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark Department of Public Health, University of Copenhagen, Copenhagen, Denmark Export Date: 18 March 2024 Correspondence Address: Butt, J.H.; Department of Cardiology, Blegdamsvej 9, Denmark; email: jawad_butt91@hotmail.com Chemicals/CAS: amiodarone, 1951-25-3, 19774-82-4, 62067-87-2; metolazone, 17560-51-9, 56436-31-8, 56436-32-9 Funding text 1: S.N. Doi was supported by the Japanese College of Cardiology Overseas Research Fellowship and Scandinavia-Japan Sasakawa Foundation. AB - BACKGROUND: Patients with heart failure and chronic kidney disease (CKD) may have an increased risk of death from causes competing with arrhythmic death, which could have implications for the efficacy of implantable cardioverter-defibrillators (ICDs). We examined the long-term effects of primary prophylactic ICD implantation, compared with usual care, according to baseline CKD status in an extended follow-up study of DANISH (Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality). METHODS AND RESULTS: In the DANISH trial, 1116 patients with nonischemic heart failure with reduced ejection fraction were randomized to receive an ICD (N=556) or usual care (N=550). Outcomes were analyzed according to CKD status (estimated glomerular filtration rate ≥/<60 mL/min per 1.73 m2) at baseline. In total, 1113 patients had an available estimated glomerular filtration rate measurement at baseline (median estimated glomerular filtration rate 73 mL/min per 1.73 m2), and 316 (28%) had CKD. During a median follow-up of 9.5 years, ICD implantation, compared with usual care, did not reduce the rate of all-cause mortality (no CKD, HR, 0.82 [95% CI, 0.64–1.04]; CKD, HR, 1.02 [95% CI, 0.75–1.38]; Pinteraction =0.31) or cardiovascular death (no CKD, HR, 0.77 [95% CI, 0.58–1.03]; CKD, HR, 1.05 [95% CI, 0.73–1.51]; Pinteraction =0.20), irrespective of baseline CKD status. Similarly, baseline CKD status did not modify the beneficial effects of ICD implantation on sudden cardiovascular death (no CKD, HR, 0.57 [95% CI, 0.32–1.00]; CKD, HR, 0.65 [95% CI, 0.34–1.24]; Pinteraction =0.70). CONCLUSIONS: ICD implantation, compared with usual care, did not reduce the overall mortality rate, but it did reduce the rate of sudden cardiovascular death, regardless of baseline kidney function in patients with nonischemic heart failure with reduced ejection fraction. © 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. LA - English DB - MTMT ER - TY - JOUR AU - Ekpo, E. AU - Balla, S. AU - Ngo, S. AU - Witting, C. AU - Sarraju, A. AU - Furst, A. AU - Rodriguez, F. TI - Underrepresentation of Women in Reduced Ejection Heart Failure Clinical Trials With Improved Mortality or Hospitalization JF - JACC: ADVANCES J2 - JACC: ADVANCES VL - 3 PY - 2024 IS - 1 SN - 2772-963X DO - 10.1016/j.jacadv.2023.100743 UR - https://m2.mtmt.hu/api/publication/34517897 ID - 34517897 N1 - Department of Cardiovascular Medicine, Scripps Clinic, La Jolla, CA, United States Department of Internal Medicine, University of California-San Francisco, Fresno, CA, United States Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, United States Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, United States Palo Alto Veterans Institute for Research (PAVIR), Palo Alto, CA, United States Cited By :1 Export Date: 19 January 2024 Correspondence Address: Rodriguez, F.; Division of Cardiovascular Medicine, 453 Quarry Road, Mail Code 5687, United States; email: frodrigu@stanford.edu AB - Background: There are established sex-specific differences in heart failure with reduced ejection fraction (HFrEF) outcomes. Randomized clinical trials (RCTs) based on cardiovascular outcome benefits, typically either reduced cardiovascular mortality or hospitalization for heart failure (HHF), influence current guidelines for therapy. Objectives: The authors evaluate the representation of women in HFrEF RCTs that observed reduced all-cause or cardiovascular mortality or HHF. Methods: We queried Cumulative Index to Nursing and Allied Health Literature, Excerpta Medica dataBASE, Medical Literature Analysis and Retrieval System Online, and PubMed for HFrEF RCTs that reported a statistically significant benefit of intervention resulting in improved mortality or HHF published from 1980 to 2021. We estimated representation using the participation-to-prevalence ratio (PPR). A PPR of 0.8 to 1.2 was considered representative. Results: The final analysis included 33 RCTs. Women represented only 23.2% of all enrolled participants (n = 24,366/104,972), ranging from 11.4% to 40.1% per trial. Overall PPR was 0.58, with per-trial PPR estimates ranging from 0.29 to 1.00. Only 5 trials (15.2%) had a PPR of women representative of the disease population. Representation did not change significantly over time. The proportion of women in North American trials was significantly greater than trials conducted in Europe (P = 0.03). The proportion of women was greater in industry trials compared to government-funded trials (P = 0.05). Conclusions: Women are underrepresented in HFrEF RCTs that have demonstrated mortality or HHF benefits and influence current guidelines. Representation is key to further delineation of sex-specific differences in major trial results. Sustained efforts are warranted to ensure equitable and appropriate inclusion of women in HFrEF trials. © 2024 The Authors LA - English DB - MTMT ER - TY - JOUR AU - EL-Andari, R. AU - Fialka, N.M. AU - Kang, J. AU - Bozso, S.J. AU - Nagendran, J. AU - Nagendran, J. TI - The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review JF - AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS J2 - AM J CARDIOVASC DRUG VL - 24 PY - 2024 SP - 55 EP - 69 PG - 15 SN - 1175-3277 DO - 10.1007/s40256-023-00618-0 UR - https://m2.mtmt.hu/api/publication/34434947 ID - 34434947 N1 - Export Date: 14 December 2023 CODEN: AJCDD Correspondence Address: Nagendran, J.; Division of Cardiac Surgery, 4-108A Li Ka Shing Health Research Centre, 8602-112 Street, Canada; email: jeevan@ualberta.ca LA - English DB - MTMT ER - TY - JOUR AU - Elkeraie, A.F. AU - Al-Ghamdi, S. AU - Abu-Alfa, A.K. AU - Alotaibi, T. AU - Alsaedi, A.J. AU - Alsuwaida, A. AU - Arici, M. AU - Ecder, T. AU - Ghnaimat, M. AU - Hafez, M.H. AU - Hassan, M.H. AU - Sqalli, T. TI - Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective JF - INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE J2 - INT J NEPHROL RENOVASC DIS VL - 17 PY - 2024 SP - 1 EP - 16 PG - 16 SN - 1178-7058 DO - 10.2147/IJNRD.S430532 UR - https://m2.mtmt.hu/api/publication/34536412 ID - 34536412 N1 - Export Date: 27 January 2024 Correspondence Address: Elkeraie, A.F.; Department of Internal Medicine and Nephrology, Egypt; email: drahmed@hotmail.com Chemicals/CAS: canagliflozin, 842133-18-0, 928672-86-0; dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; ertugliflozin, 1210344-57-2, 1210344-83-4; sotagliflozin, 1018899-04-1 Funding text 1: The preparation of this consensus manuscript and funding of the journal’s article processing charges were supported by AstraZeneca FZ, LLC. All authors had full access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analyses. Funding text 2: The authors would like to thank Dr. Dakshayani S and Dr. Soma Santra of Fortrea Scientific Pvt. Ltd. (formerly Labcorp Scientific Services & Solutions Pvt. Ltd) for medical writing support, which was funded by AstraZeneca FZ LLC in accordance with the Good Publication Practice 2022 guidelines. AB - Chronic kidney disease (CKD) is a major public health concern in the Middle East and Africa (MEA) region and a leading cause of death in patients with type 2 diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and proper sequencing with renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may result in better clinical outcomes due to their cardioprotective properties and complementary mechanisms of action. In this review, we present guideline-based consensus recommendations by experts from the MEA region, as practical algorithms for screening, early detection, nephrology referral, and treatment pathways for CKD management in patients with hypertension and diabetes mellitus. This study will help physicians take timely and appropriate actions to provide better care to patients with CKD or those at high risk of CKD. © 2024 Elkeraie et al. LA - English DB - MTMT ER - TY - JOUR AU - Faluk, M. AU - Wardhere, A. AU - Thakker, R. AU - Khan, F.A. TI - SGLT2 inhibitors in heart failure with preserved ejection fraction JF - CURRENT PROBLEMS IN CARDIOLOGY J2 - CURR PROB CARDIOLOGY VL - 49 PY - 2024 IS - 3 SN - 0146-2806 DO - 10.1016/j.cpcardiol.2024.102388 UR - https://m2.mtmt.hu/api/publication/34536399 ID - 34536399 N1 - Department of Internal Medicine, Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX 77550, United States Department of Internal Medicine, Division of Cardiovascular Medicine, Columbia University Irving Medical Center, United States Export Date: 27 January 2024 CODEN: CPCAE Correspondence Address: Faluk, M.301 University Blvd, United States; email: mofaluk@utmb.edu Chemicals/CAS: dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0 Funding text 1: This article was supported (in whole or in part) by UTMB and/or CU Irving Medical Center. The views expressed in this article represent those of the authors and do not necessarily represent the official views of the universities or any of its affiliated entities. AB - Heart failure (HF) is a clinical syndrome due to either functional or structural impairment of the ventricular pump or filling, representing a major cause of global morbidity and mortality. Heart failure with preserved ejection fraction (HFpEF), characterized by a left ventricular ejection fraction (LVEF) of ≥50%, constitutes over half of the HF population, with a rising prevalence. Until recently, therapeutic options in treating HFpEF and reducing hospitalization and mortality remained limited. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promising results in this patient population. This review article explores current literature and significant clinical trials investigating the impact of sodium- SGLT2 inhibitors in patients with HFpEF. © 2024 Elsevier Inc. LA - English DB - MTMT ER - TY - JOUR AU - Fardman, A. AU - Kodesh, A. AU - Siegel, A.J. AU - Segev, A. AU - Regev, E. AU - Maor, E. AU - Berkovitch, A. AU - Kuperstein, R. AU - Morgan, A. AU - Nahum, E. AU - Peled, Y. AU - Grupper, A. TI - The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices JF - ARTIFICIAL ORGANS J2 - ARTIF ORGANS VL - In press PY - 2024 SN - 0160-564X DO - 10.1111/aor.14733 UR - https://m2.mtmt.hu/api/publication/34742623 ID - 34742623 N1 - The Cardiovascular Division, Sheba Medical Center, Tel Hashomer, Israel The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel Department of Internal Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United States Export Date: 18 March 2024 CODEN: ARORD Correspondence Address: Fardman, A.; The Cardiovascular Division, Israel; email: alexfardman@gmail.com AB - Background: The safety and impact of sodium glucose transporter 2 inhibitors (SGLT2-I) in patients with left ventricular assist devices (LVAD) are unknown. Methods: A retrospective analysis of all consecutive patients who underwent LVAD Heart Mate 3 (HM3) implantation at a single medical center and received SGLT2-I therapy following surgery was conducted. LVAD parameters, medical therapy, laboratory tests, echocardiography, and right heart catheterization (RHC) study results were recorded and compared before and after initiation of SGLT2-I. Results: SGLT2-I medications were initiated in 29 (21%) of 138 patients following HM3 implantation (23 (79%) received Empagliflozin and 6 (21%) Dapagliflozin). The mean age at the time of LVAD implantation was 62 ± 6.7 years, 25 (86%) were male, and 23 (79%) had diabetes mellitus. The median time from HM3 implantation to SGLT2-I initiation was 108 days, IQR (26–477). Following SGLT2-I therapy, the daily dose of furosemide decreased from 47 to 23.5 mg/day (mean difference = 23.5 mg/d, 95% CI 8.2–38.7, p = 0.004) and significant weight reduction was observed (mean difference 2.5 kg, 95% CI 0.7–4.3, p = 0.008). Moreover, a significant 5.6 mm Hg reduction in systolic pulmonary artery pressure (sPAP) was measured during RHC (95% CI 0.23–11, p = 0.042) in a subgroup of 11 (38%) patients. LVAD parameters were similar before and after SGLT2-I initiation (p > 0.2 for all). No adverse events were recorded during median follow-up of 354 days, IQR (206–786). Conclusion: SGLT2-I treatment is safe in LVAD patients and might contribute to reduction in patients sPAP. © 2024 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC. LA - English DB - MTMT ER - TY - JOUR AU - Fauchier, L. AU - Lamblin, N. AU - Tardu, J. AU - Bellier, L. AU - Groyer, H. AU - Ittah, D. AU - Chollet, J. AU - Linden, S. AU - Levy, P. TI - Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial JF - PHARMACOECONOMICS-OPEN J2 - PHARMACOECON-OPEN VL - 8 PY - 2024 IS - 1 SP - 19 EP - 30 PG - 12 SN - 2509-4262 DO - 10.1007/s41669-023-00432-z UR - https://m2.mtmt.hu/api/publication/34143925 ID - 34143925 N1 - Cardiology Department, CHU de Tours, Université de Tours, Tours, France Cardiology Department, CHU de Lille, Université de Lille, Lille, France Creativ-Ceutical, Paris, France Creativ-Ceutical, London, United Kingdom Boehringer Ingelheim France, Paris, France Université Paris Dauphine, Université PSL, LEDA [LEGOS], Paris, France Export Date: 18 September 2023 Correspondence Address: Tardu, J.; Creativ-CeuticalFrance; email: Jean.Tardu@creativ-ceutical.com AB - Introduction: The efficacy and safety of empagliflozin in the treatment of heart failure with preserved ejection fraction (HFpEF) were demonstrated in the EMPEROR-Preserved trial, which showed a 21% reduction in combined risks of cardiovascular death or HF hospitalization [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.69–0.90, p < 0.001] and a 27% reduction in the total number of HF hospitalizations (HR 0.73; 95% CI 0.61–0.88, p < 0.001) compared with placebo. On the basis of these results, the present study aimed to assess the cost-effectiveness of empagliflozin + standard of care (SoC) compared with SoC alone in the treatment of HFpEF. Methods: A published Markov model was adapted to compare the health and economic outcomes in France, considering a collective perspective, in patients treated with empagliflozin in addition to SoC versus patients treated by SoC alone. The model simulated the intention-to-treat (ITT) population of the trial, transitioning between four mutually exclusive health states representing the quartiles of the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS). For each arm, the model estimated (over a lifetime time horizon) the economics and the health outcomes (HF hospitalizations avoided, and life years and quality-adjusted life years (QALYs) gained) to calculate the incremental cost-effectiveness ratios (ICERs). The resources used were derived by pairing the FREnch Survey on HF (FRESH) cohort data to French health insurance claims data, and the utilities were derived on the basis of the EQ-5D-5L questionnaire valued on the French tariff. Both economic and health outcomes were discounted at a 2.5% annual rate. Results: The model predicted that treatment of HFpEF patients with empagliflozin would prevent, for 1000 patients treated, 74 HF hospitalizations and 15 deaths attributable to cardiovascular events, resulting on average in a gain of 1 month in overall survival (7.24 versus 7.16 years with placebo) and 0.11 QALYs (6.14 versus 6.03 with placebo). Empagliflozin costs were partially offset by the cost savings from avoided hospitalizations. The ICERs were €18,597 per life year gained and €13,980 per QALY gained. The sensitivity analyses conducted showed that empagliflozin has a 65% probability to be cost-effective under the €25,000/QALY threshold. Conclusions: The base-case results showed that empagliflozin is a cost-effective strategy for management of HFpEF, in addition to the impact on public health by preventing HF-hospitalizations and deaths in France. Sensitivity analyses suggest that 65% of simulations are under the €25,000/QALY threshold. © 2023, The Author(s). LA - English DB - MTMT ER - TY - JOUR AU - Fazzini, Luca AU - Casati, Mattia AU - Martis, Alessandro AU - Perra, Ferdinando AU - Rubiolo, Paolo AU - Deidda, Martino AU - Mercuro, Giuseppe AU - Cadeddu Dessalvi, Christian TI - Gender Effect on Clinical Profiles, Pharmacological Treatments and Prognosis in Patients Hospitalized for Heart Failure JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 3 PG - 13 SN - 2077-0383 DO - 10.3390/jcm13030881 UR - https://m2.mtmt.hu/api/publication/34639861 ID - 34639861 N1 - Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, 09124, Italy Sassu Cardiologic Center, Cittadella Universitaria, Sardinia, 09033, Italy Export Date: 29 February 2024 Correspondence Address: Deidda, M.; Department of Medical Sciences and Public Health, Italy; email: martino.deidda@tiscali.it LA - English DB - MTMT ER - TY - JOUR AU - Ferreira, J.P. AU - Packer, M. AU - Sattar, N. AU - Butler, J. AU - Pocock, S.J. AU - Anker, S.D. AU - Maldonado, S.G. AU - Panova-Noeva, M. AU - Sumin, M. AU - Masson, S. AU - Zannad, F. AU - Januzzi, J.L. TI - Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme JF - EUROPEAN JOURNAL OF HEART FAILURE J2 - EUR J HEART FAIL VL - In press PY - 2024 SP - In press SN - 1388-9842 DO - 10.1002/ejhf.3166 UR - https://m2.mtmt.hu/api/publication/34766745 ID - 34766745 N1 - Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Cardiovascular Research and Development Center (UnIC@RISE), Porto, Portugal Heart Failure Clinic, Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Gaia, Portugal Centre d'Investigations Cliniques Plurithématique 14-33, Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Cardiovascular Research and Development Center, Université de Lorraine, Nancy, France Imperial College London, London, United Kingdom Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, United States School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom Baylor Scott and White Research Institute, Dallas, TX, United States University of Mississippi Medical Center, Jackson, MS, United States London School of Hygiene and Tropical Medicine, London, United Kingdom Center for Regenerative Therapies, Berlin Institute of Health, Department of Cardiology, German Centre for Cardiovascular Research, partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany Boehringer Ingelheim International GmbH, Ingelheim, Germany Roche Diagnostics International Ltd, Rotkreuz, Switzerland Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, Nancy, France Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, United States Export Date: 3 April 2024 CODEN: EJHFF Correspondence Address: Januzzi, J.L.; Cardiology Division, 55 Fruit Street, United States; email: jjanuzzi@partners.org AB - Aim: Vascular congestion may lead to an increase of carbohydrate antigen 125 (CA-125). The role of CA-125 as a biomarker of congestion or for prognosis across the full ejection fraction (EF) spectrum of chronic heart failure (HF) remains unknown. Methods and results: Serum CA-125 was measured in 1111 study participants from the EMPEROR-Reduced and EMPEROR-Preserved trials. Congestive signs and symptoms were evaluated across CA-125 tertiles. Cox regression was used to study the association with outcomes. The primary outcome was a composite of first HF hospitalization or cardiovascular (CV) death. No significant association was present between baseline CA-125 levels and congestive signs or symptoms. In the overall population, higher CA-125 levels were not associated with an increased risk of primary outcome (tertile 3 vs. tertile 1: hazard ratio [HR] 1.34; 95% confidence interval [CI] 0.91–1.96; p-trend = 0.11). However, higher CA-125 levels were associated with an increased risk of primary outcome in patients with HF and reduced EF (HFrEF; tertile 3 vs. tertile 1: HR 2.25 [95% CI 1.30–3.89]), but not among patients with preserved EF (HFpEF; tertile 3 vs. tertile 1: HR 0.68 [95% CI 0.38–1.21]); interaction-p = 0.02). Patients in the upper CA-125 tertile also showed the steepest estimated glomerular filtration rate decline over time (p-trend = 0.03). The effect of empagliflozin to reduce the risk of CV death or HF hospitalization appeared to be attenuated in those with lower baseline CA-125 levels (interaction-p-trend = 0.09). Conclusion: Across the range of EF in patients with chronic HF enrolled in the EMPEROR trials, the majority of whom did not have clinical evidence of congestion, CA-125 concentrations were not significantly associated with congestive signs or symptoms. CA-125 concentrations may predict HF hospitalization/CV death in patients with HFrEF, but not those with HFpEF. Clinical Trial Registration: EMPEROR-Reduced (NCT03057977), EMPEROR-Preserved (NCT03057951). © 2024 European Society of Cardiology. LA - English DB - MTMT ER - TY - JOUR AU - Frățilă, V.-G. AU - Lupușoru, G. AU - Sorohan, B.M. AU - Obrișcă, B. AU - Mocanu, V. AU - Lupușoru, M. AU - Ismail, G. TI - Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches JF - BIOMEDICINES J2 - BIOMEDICINES VL - 12 PY - 2024 IS - 3 SN - 2227-9059 DO - 10.3390/biomedicines12030569 UR - https://m2.mtmt.hu/api/publication/34777747 ID - 34777747 N1 - Export Date: 8 April 2024 LA - English DB - MTMT ER - TY - JOUR AU - Fukino, K. AU - Ueshima, D. AU - Yamaguchi, T. AU - Mizuno, A. AU - Tobita, K. AU - Suzuki, K. AU - Murata, N. AU - Jujo, K. AU - Kodama, T. AU - Nakamura, F. AU - Higashitani, M. TI - Prognostic Impact of Reduced Left Ventricular Ejection Fraction After Endovascular Therapy for Lower Extremities JF - CIRCULATION JOURNAL: OFFICIAL JOURNAL OF THE JAPANESE CIRCULATION SOCIETY J2 - CIRC J VL - 88 PY - 2024 IS - 3 SP - 341 EP - 350 PG - 10 SN - 1346-9843 DO - 10.1253/circj.CJ-23-0215 UR - https://m2.mtmt.hu/api/publication/34742632 ID - 34742632 N1 - The Third Department of Internal Medicine, Teikyo University, Chiba Medical Center, Chiba, Japan Department of Cardiology, Kameda Medical Center, Chiba, Japan Department of Cardiology, Toranomon Hospital, Tokyo, Japan Department of Cardiology, St. Luke’s International Hospital, Tokyo, Japan Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan Department of Cardiology, Tokyo Saiseikai Central Hospital, Tokyo, Japan Department of Cardiology, Tokyo Medical University, Tokyo, Japan Department of Cardiology, Saitama Medical Center, Saitama, Japan Department of Cardiology, Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan Export Date: 18 March 2024 CODEN: CJIOB Correspondence Address: Fukino, K.; The Third Department of Internal Medicine, 3426-3 Anesaki, Chiba, Japan; email: fukinok@gmail.com Chemicals/CAS: acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; alanine aminotransferase, 9000-86-6, 9014-30-6; aspartate aminotransferase, 9000-97-9; C reactive protein, 9007-41-4; cilostazol, 73963-72-1; creatine kinase, 9001-15-4; hemoglobin, 9008-02-0; icosapentaenoic acid, 10417-94-4, 1553-41-9, 25378-27-2, 32839-30-8; insulin, 9004-10-8; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A Tradenames: R software version 4.1.2 Funding text 1: This work was supported by the Vascular Disease Research Project of the Japan Research Promotion Society for Cardiovascular Disease, Tokyo, Japan. AB - Background: The mechanism underlying a poor prognosis in patients with lower-extremity artery disease (LEAD) with heart failure is unknown. We examined the prognostic impact of the left ventricular ejection fraction (LVEF) in patients with LEAD who underwent endovascular therapy (EVT). Methods and Results: From August 2014 to August 2016, 2,180 patients with LEAD (mean age, 73.2 years; male, 71.9%) underwent EVT and were stratified into low-LVEF (LVEF <40%; n=234, 10.7%) and not-low LVEF groups. In the low- vs. not-low LVEF groups, there was a higher prevalence of heart failure (i.e., history of heart failure hospitalization or New York Heart Association functional class III or IV symptoms) (44.0% vs. 8.3%, respectively), diabetes mellitus, chronic kidney disease, below-the-knee lesion, critical limb ischemia, and incidence of major cardiovascular and cerebrovascular events (MACCEs) and major adverse limb events (MALEs) (P<0.001, all). Low LVEF independently predicted MACCEs (hazard ratio: 2.23, 95% confidence interval: 1.63–3.03; P<0.001) and MALEs (hazard ratio: 1.85, 95% confidence interval: 1.15–2.96; P=0.011), regardless of heart failure (P value for interaction: MACCEs: 0.27; MALEs: 0.52). Conclusions: Low LVEF, but not symptomatic heart failure, increased the incidence of MACCEs and MALEs. Intensive cardiac dysfunction management may improve LEAD prognosis after EVT. © 2024 Japanese Circulation Society. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Gallo, G. AU - Volpe, M. TI - Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 5 SN - 1661-6596 DO - 10.3390/ijms25052484 UR - https://m2.mtmt.hu/api/publication/34747986 ID - 34747986 N1 - Export Date: 20 March 2024 Correspondence Address: Volpe, M.; IRCCS San Raffaele Roma, Via della Pisana 235, Italy; email: massimo.volpe@sanraffaele.it Chemicals/CAS: sodium, 7440-23-5; Glucagon-Like Peptide-1 Receptor Agonists; Glucose Transport Proteins, Facilitative; Sodium Funding text 1: M.V. is supported by a grant of the Italian Ministry of Health (Ricerca Corrente). AB - Different multifactorial pathophysiological processes are involved in the development of heart failure (HF), including neurohormonal dysfunction, the hypertrophy of cardiomyocytes, interstitial fibrosis, microvascular endothelial inflammation, pro-thrombotic states, oxidative stress, decreased nitric oxide (NO) bioavailability, energetic dysfunction, epicardial coronary artery lesions, coronary microvascular rarefaction and, finally, cardiac remodeling. While different pharmacological strategies have shown significant cardiovascular benefits in HF with reduced ejection fraction (HFrEF), there is a residual unmet need to fill the gap in terms of knowledge of mechanisms and efficacy in the outcomes of neurohormonal agents in HF with preserved ejection fraction (HFpEF). Recently, type-2 sodium–glucose transporter inhibitors (SGLT2i) have been shown to contribute to a significant reduction in the composite outcome of HF hospitalizations and cardiovascular mortality across the entire spectrum of ejection fraction. Moreover, glucagon-like peptide-1 receptor agonists (GLP1-RA) have demonstrated significant benefits in patients with high cardiovascular risk, excess body weight or obesity and HF, in particular HFpEF. In this review, we will discuss the biological pathways potentially involved in the action of SGLT2i and GLP1-RA, which may explain their effective roles in the treatment of HF, as well as the potential implications of the use of these agents, also in combination therapies with neurohormonal agents, in the clinical practice. © 2024 by the authors. LA - English DB - MTMT ER - TY - JOUR AU - Gao, M. AU - Bhatia, K. AU - Kapoor, A. AU - Badimon, J. AU - Pinney, S.P. AU - Mancini, D.M. AU - Santos-Gallego, C.G. AU - Lala, A. TI - SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure: A Systematic Review and Meta-Analysis JF - JAMA NETWORK OPEN J2 - JAMA NETW OPEN VL - 7 PY - 2024 IS - 4 SP - E245135 SN - 2574-3805 DO - 10.1001/jamanetworkopen.2024.5135 UR - https://m2.mtmt.hu/api/publication/34795700 ID - 34795700 N1 - Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States Mount Sinai Fuster Heart Hospital, Mount Sinai Morningside, New York, NY, United States Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, One Gustave Levy Pl, Box 1030, New York, NY 10029, United States Department of Population Health Science, Icahn School of Medicine at Mount Sinai, New York, NY, United States Export Date: 17 April 2024 Correspondence Address: Santos-Gallego, C.G.; Zena and Michael A. Wiener Cardiovascular Institute, One Gustave Levy Pl, Box 1030, United States; email: carlos.santos-gallego@mssm.edu Correspondence Address: Lala, A.; Zena and Michael A. Wiener Cardiovascular Institute, One Gustave Levy Pl, Box 1030, United States; email: anu.lala@mountsinai.org Chemicals/CAS: Sodium-Glucose Transporter 2 Inhibitors AB - Importance: The associations of sodium glucose cotransporter-2 inhibitors (SGLT2is) with reduction in mortality and hospitalization rates in patients with heart failure (HF) are well established. However, their association with improving functional capacity and quality of life (QOL) has been variably studied and less reported. Objective: To provide evidence on the extent to which SGLT2is are associated with improvement on objective measures of functional capacity and QOL in patients living with HF. Data Sources: The MEDLINE, EMBASE, and Cochrane databases were systematically searched for relevant articles on July 31, 2023. Study Selection: Randomized, placebo-controlled clinical trials reporting the effect of SGLT2i on functional outcomes of exercise capacity (peak oxygen consumption [peak VO2] or 6-minute walk distance [6MWD]) and/or QOL using validated questionnaires for patients with HF were included. Data Extraction and Synthesis: Data were extracted by 2 authors following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines, and a meta-analysis using the restricted maximum likelihood random-effects model was conducted. Main Outcomes and Measures: Outcomes of interest included changes in peak VO2, 6MWD, and Kansas City Cardiomyopathy Questionnaire-12 total symptom score (KCCQ-TSS), clinical summary score (KCCQ-CSS), and overall summary score (KCCQ-OSS). Results: In this meta-analysis of 17 studies, 23523 patients (mean [range] age, 69 [60-75] years) were followed over a period ranging from 12 to 52 weeks. Four studies included peak VO2 as an outcome, 7 studies included 6MWD, and 10 studies reported KCCQ scores. Mean (SD) left ventricular ejection fraction was 43.5% (12.4%). Compared with controls, patients receiving SGLT2i treatment experienced significant increases in peak VO2 (mean difference [MD], 1.61 mL/kg/min; 95% CI, 0.59-2.63 mL/kg/min; P =.002) and 6MWD (MD, 13.09 m; 95% CI, 1.20-24.97 m; P =.03). SGLT2i use was associated with increased KCCQ-TSS (MD, 2.28 points; 95% CI, 1.74-2.81 points; P <.001), KCCQ-CSS (MD, 2.14 points; 95% CI, 1.53-2.74 points; P <.001), and KCCQ-OSS (MD, 1.90 points; 95% CI, 1.41-2.39 points; P <.001) scores. Subgroup analysis and meta-regression demonstrated almost all improvements were consistent across ejection fraction, sex, and the presence of diabetes. Conclusions and Relevance: These findings suggest that in addition to known clinical associations with mortality and hospitalization outcomes, SGLT2i use is associated with improvement in outcomes of interest to patients' everyday lives as measured by objective assessments of maximal exercise capacity and validated QOL questionnaires, regardless of sex or ejection fraction. © 2024 American Medical Association. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - García-Moll, X. AU - Croci, F. AU - Solé, A. AU - Hartgers-Gubbels, E.S. AU - Calleja-Hernández, M.A. TI - A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials JF - EXPERT REVIEW OF CARDIOVASCULAR THERAPY J2 - EXP REV CARDIOVASC THER VL - In press PY - 2024 SN - 1477-9072 DO - 10.1080/14779072.2024.2324027 UR - https://m2.mtmt.hu/api/publication/34750146 ID - 34750146 N1 - Export Date: 21 March 2024 CODEN: ERCTA Correspondence Address: Croci, F.; EMEA Real World Methods & Evidence Generation, 37 North Wharf Road, Paddington, United Kingdom; email: francesco.croci@iqvia.com AB - Background: Heart failure (HF) is a chronic condition with considerable clinical burden for patients and economic burden for healthcare systems. Treatment for HF is typically based on ejection fraction (EF) phenotype. The cost-effectiveness of empagliflozin + standard of care (SoC) compared to SoC has been examined for HF phenotypes below or above 40% EF separately, but not across the full spectrum of EF in Spain. Methods: The results of two preexisting, validated, and published phenotype-specific Markov cohort models were combined using a population-weighted approach, reflecting the incidence of each phenotype in the total HF population in Spain. A probabilistic sensitivity analysis was performed by sampling each model’s probabilistic results. Results: Empagliflozin + SoC compared to SoC resulted in increased life-years (LYs) (6.48 vs. 6.35), quality-adjusted LYs (QALYs) (4.80 vs. 4.63), and healthcare costs (€19,090 vs. €18,246), over a lifetime time horizon for the combined HF population in Spain. The incremental cost-effectiveness ratio (ICER) was €5,089/QALY. All subgroup, scenario, and probabilistic ICERs were consistently below €10,000/QALY. Conclusions: Empagliflozin is the first treatment with established efficacy and cost-effectiveness for HF patients across EF from the perspective of healthcare payers in Spain. Empagliflozin also proved to be cost-effective for all subgroups of patients included in the analysis. © 2024 I am not an employee but the copyright belongs to Boehringer Ingelheim International GmbH. Published by Informa UK Limited, trading as Taylor & Francis Group. LA - English DB - MTMT ER - TY - JOUR AU - Garg, A. AU - Lavine, K.J. AU - Greenberg, M.J. TI - Assessing Cardiac Contractility From Single Molecules to Whole Hearts JF - JACC:BASIC TO TRANSLATIONAL SCIENCE J2 - JACC-BASIC TRANSL SC VL - 9 PY - 2024 IS - 3 SP - 414 EP - 439 PG - 26 SN - 2452-302X DO - 10.1016/j.jacbts.2023.07.013 UR - https://m2.mtmt.hu/api/publication/34423918 ID - 34423918 N1 - Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, United States Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States Export Date: 6 April 2024 Correspondence Address: Greenberg, M.J.; Department of Biochemistry and Molecular Biophysics, 660 S Euclid Avenue, Campus Box 8231, United States; email: greenberg@wustl.edu Funding text 1: The authors thank Aurora Scientific and Chris Rand for their images of single-myocyte and single-myofibril systems. The authors thank Lina Greenberg for the images of EHTs and related data traces. The authors thank Anthony Cammarato for sharing images of Drosophila heart tube kymography. The authors thank Jamison Leid for providing light-sheet fluorescence microscopic images of zebrafish hearts. LA - English DB - MTMT ER - TY - JOUR AU - Gass, Alan TI - Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure JF - AMERICAN JOURNAL OF MEDICINE J2 - AM J MED VL - 137 PY - 2024 IS - 2 SP - S1 EP - S2 PG - 2 SN - 0002-9343 DO - 10.1016/j.amjmed.2023.04.032 UR - https://m2.mtmt.hu/api/publication/34649627 ID - 34649627 N1 - Export Date: 29 February 2024 CODEN: AJMEA Correspondence Address: Gass, A.; Department of Cardiology, 100 Woods Road, United States; email: alan.gass@wmchealth.org LA - English DB - MTMT ER - TY - JOUR AU - Gonzalez-Franco, J. AU - Caicedo-Espinosa, J. AU - Cardona-Tobon, C. AU - Jaramillo-Jara, N. AU - Aguilar-Molina, O. AU - Jaimes-Barragan, F.-A. AU - Saldarriaga-Giraldo, C.-I. TI - Application of eligibility criteria from DAPA-HF, EMPEROR-Reduced, and PARADIGM-HF trials to a population with heart failure with reduced ejection fraction at a specialized cardiology Clinic in Medellin, Colombia: A retrospective cohort study JF - CURRENT PROBLEMS IN CARDIOLOGY J2 - CURR PROB CARDIOLOGY VL - 49 PY - 2024 IS - 2 SN - 0146-2806 DO - 10.1016/j.cpcardiol.2023.102193 UR - https://m2.mtmt.hu/api/publication/34434785 ID - 34434785 N1 - CardioVID Clinic, Medellín, Colombia Department of Internal Medicine, Faculty of Medicine, Universidad de Antioquia, Medellín, Colombia Universidad del Valle, Cali, Colombia Export Date: 14 December 2023 CODEN: CPCAE Correspondence Address: Gonzalez-Franco, J.Dirección km 14 vía Las Palmas, Colombia; email: juliana.gonzalezf@udea.edu.co LA - English DB - MTMT ER - TY - JOUR AU - Greene, S.J. AU - Butler, J. AU - Kosiborod, M.N. TI - Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure JF - AMERICAN JOURNAL OF MEDICINE J2 - AM J MED VL - 137 PY - 2024 IS - 2 SP - S25 EP - S34 SN - 0002-9343 DO - 10.1016/j.amjmed.2023.04.019 UR - https://m2.mtmt.hu/api/publication/34517147 ID - 34517147 N1 - Division of Cardiology, Duke University School of Medicine, Durham, NC, United States Duke Clinical Research Institute, Durham, NC, United States Baylor Scott and White Research Institute, Dallas, Texas, United States University of Mississippi, Jackson, MS, United States Saint Luke's Mid America Heart Institute, Kansas City, Mo, United States University of Missouri-Kansas City, Kansas City, Mo, United States Export Date: 19 January 2024 CODEN: AJMEA Correspondence Address: Butler, J.; Department of Medicine (L650), 2500 N. State St, United States; email: Javed.butler@bwshealth.org Chemicals/CAS: glucose, 50-99-7, 84778-64-3, 8027-56-3; sodium, 7440-23-5; Glucose; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters AB - Cardiovascular outcomes trials of sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated consistent signals of benefit in terms of both prevention and treatment of heart failure (HF), in patients with and without type 2 diabetes (T2D). In response to growing evidence of the benefits of SGLT2 inhibitors, including increased survival, reduced hospitalizations and improved patient-reported symptoms, functional status, and quality of life, the treatment landscape for HF has evolved. Importantly, these agents have also demonstrated safety and tolerability in individuals with HF across the spectrum of left ventricular ejection fraction, with improvements in clinical and patient-reported outcomes occurring as early as days to weeks after treatment initiation. For patients with heart failure with reduced ejection fraction (HFrEF), SGLT2 inhibitors are now increasingly recognized as foundational disease-modifying therapy. An updated joint guideline from the American College of Cardiology and American Heart Association now recommends including SGLT2 inhibitors for patients with HF across the spectrum of ejection fraction, irrespective of the presence of diabetes, and regardless of background therapy (Class 1 recommendation for HFrEF, Class 2a recommendation for HF with mildly reduced ejection fraction [HFmrEF] and HF with preserved ejection fraction [HFpEF]). The European Society of Cardiology also include a Class I recommendation to use SGLT2 inhibitors for patients with HFrEF to reduce the risk of hospitalization for HF and CV death, irrespective of T2D status. This chapter reviews published clinical trial data about the efficacy and safety of SGLT2 inhibitors among patients with HFrEF, HFpEF, and patients hospitalized for HF. © 2023 LA - English DB - MTMT ER - TY - JOUR AU - Green, J.B. AU - Everett, B.M. AU - Ghosh, A. AU - Younes, N. AU - Krause-Steinrauf, H. AU - Barzilay, J. AU - Desouza, C. AU - Inzucchi, S.E. AU - Pokharel, Y. AU - Schade, D. AU - Scrymgeour, A. AU - Tan, M.H. AU - Utzschneider, K.M. AU - Mudaliar, S. AU - Crandall, J.P. AU - McKee, M.D. AU - Behringer-Massera, S. AU - Brown-Friday, J. AU - Xhori, E. AU - Ballentine-Cargill, K. AU - Duran, S. AU - Estrella, H. AU - Gonzalez, De La Torre S. AU - Lukin, J. AU - Phillips, L.S. AU - Burgess, E. AU - Olson, D. AU - Rhee, M. AU - Wilson, P. AU - Raines, T.S. AU - Boers, J. AU - Costello, J. AU - Maher-Albertelli, M. AU - Mungara, R. AU - Savoye, L. AU - White, C.A. AU - Gullett, C. AU - Holloway, L. AU - Morehead, F. AU - Person, S. AU - Sibymon, M. AU - Tanukonda, S. AU - Adams, C. AU - Ross, A. AU - Balasubramanyam, A. AU - Gaba, R. AU - Gonzalez, Hattery E. AU - Ideozu, A. AU - Jimenez, J. AU - Montes, G. AU - Wright, C. AU - Hollander, P. AU - Roe, E. AU - Jackson, A. AU - Smiley, A. AU - Burt, P. AU - Estrada, L. AU - Chionh, K. AU - Ismail-Beigi, F. AU - Falck-Ytter, C. AU - Sayyed, Kassem L. AU - Sood, A. AU - Tiktin, M. AU - Kulow, T. AU - Newman, C. AU - Stancil, K.A. AU - Cramer, B. AU - Iacoboni, J. AU - Kononets, M.V. AU - Sanders, C. AU - Tucker, L. AU - Werner, A. AU - Maxwell, A. AU - McPhee, G. AU - Patel, C. AU - Colosimo, L. AU - Krol, A. AU - Goland, R. AU - Pring, J. AU - Alfano, L. AU - Kringas, P. AU - Hausheer, C. AU - Tejada, J. AU - Gumpel, K. AU - Kirpitch, A. AU - Schneier, H. AU - Abouassi, H. AU - Chatterjee, R. AU - Feinglos, M.N. AU - English, Jones J. AU - Khan, S.A. AU - Kimpel, J.B. AU - Zimmer, R.P. AU - Furst, M. AU - Satterwhite, B.M. AU - Thacker, C.R. AU - Evans, Kreider K. AU - Mariash, C.N. AU - Mather, K.J. AU - Ismail, H.M. AU - Lteif, A. AU - Mullen, M. AU - Hamilton, T. AU - Patel, N. AU - Riera, G. AU - Jackson, M. AU - Pirics, V. AU - Aguillar, D. AU - Howard, D. AU - Hurt, S. AU - Bergenstal, R. AU - Carlson, A. AU - Martens, T. AU - Johnson, M. AU - Hill, R. AU - Hyatt, J. AU - Jensen, C. AU - Madden, M. AU - Martin, D. AU - Willis, H. AU - Konerza, W. AU - Yang, S. AU - Kleeberger, K. AU - Passi, R. AU - Fortmann, S. AU - Herson, M. AU - Mularski, K. AU - Glauber, H. AU - Prihoda, J. AU - Ash, B. AU - Carlson, C. AU - Ramey, P.A. AU - Schield, E. AU - Torgrimson-Ojerio, B. AU - Arnold, K. AU - Kauffman, B. AU - Panos, E. AU - Sahnow, S. AU - Bays, K. AU - Berame, K. AU - Cook, J. AU - Ghioni, D. AU - Gluth, J. AU - Schell, K. AU - Criscola, J. AU - Friason, C. AU - Jones, S. AU - Nazarov, S. AU - Rassouli, N. AU - Puttnam, R. AU - Ojoawo, B. AU - Nelson, R. AU - Curtis, M. AU - Hollis, B. AU - Sanders-Jones, C. AU - Stokes, K. AU - El-Haqq, Z. AU - Kolli, A. AU - Tran, T. AU - Wexler, D. AU - Larkin, M.E. AU - Meigs, J. AU - Chambers, B. AU - Dushkin, A. AU - Rocchio, G. AU - Yepes, M. AU - Steiner, B. AU - Dulin, H. AU - Cayford, M. AU - Chu, K. AU - Demanbey, A. AU - Hillard, M. AU - Martin, K. AU - Thangthaeng, N. AU - Gurry, L. AU - Kochis, R. AU - Raymond, E. AU - Ripley, V. AU - Stevens, C. AU - Park, J. AU - Aroda, V. AU - Ghazi, A. AU - Magee, M. AU - Ressing, A. AU - Loveland, A. AU - Hamm, M. AU - Hurtado, M. AU - Kuhn, A. AU - Leger, J. AU - Manandhar, L. AU - Mwicigi, F. AU - Sanchez, O. AU - Young, T. AU - Garg, R. AU - Lagari-Libhaber, V. AU - Florez, H.J. AU - Valencia, W.M. AU - Marks, J. AU - Casula, S. AU - Oropesa-Gonzalez, L. AU - Hue, L. AU - Cuadot, A. AU - Nieto-Martinez, R. AU - Riccio, Veliz A.K. AU - Gutt, M. AU - Kendal, Y.J. AU - Veciana, B. AU - Ahmann, A. AU - Aby-Daniel, D. AU - Joarder, F. AU - Morimoto, V. AU - Sprague, C. AU - Yamashita, D. AU - Cady, N. AU - Rivera-Eschright, N. AU - Kirchhoff, P. AU - Morales, Gomez B. AU - Adducci, J. AU - Goncharova, A. AU - Hox, S.H. AU - Petrovitch, H. AU - Matwichyna, M. AU - Jenkins, V. AU - Broadwater, L. AU - Ishii, R.R. AU - Bermudez, N.O. AU - Hsia, D.S. AU - Cefalu, W.T. AU - Greenway, F.L. AU - Waguespack, C. AU - King, E. AU - Fry, G. AU - Dragg, A. AU - Gildersleeve, B. AU - Arceneaux, J. AU - Haynes, N. AU - Thomassie, A. AU - Pavlionis, M. AU - Bourgeois, B. AU - Hazlett, C. AU - Henry, R. AU - Boeder, S. AU - Pettus, J. AU - Diaz, E. AU - Garcia-Acosta, D. AU - Maggs, S. AU - Delue, C. AU - Stallings, A. AU - Castro, E. AU - Hernandez, S. AU - Krakoff, J. AU - Curtis, J.M. AU - Killean, T. AU - Khalid, M. AU - Joshevama, E. AU - Diaz, E. AU - Martin, D. AU - Tsingine, K. AU - Karshner, T. AU - Albu, J. AU - Pi-Sunyer, F.X. AU - Frances, S. AU - Maggio, C. AU - Ellis, E. AU - Bastawrose, J. AU - Gong, X. AU - Banerji, M.A. AU - August, P. AU - Lee, M. AU - Lorber, D. AU - Brown, N.M. AU - Josephson, D.H. AU - Thomas, L.L. AU - Tsovian, M. AU - Cherian, A. AU - Jacobson, M.H. AU - Mishko, M.M. AU - Kirkman, M.S. AU - Buse, J.B. AU - Diner, J. AU - Dostou, J. AU - MacHineni, S. AU - Young, L. AU - Bergamo, K. AU - Goley, A. AU - Kerr, J. AU - Largay, J.F. AU - Guarda, S. AU - Cuffee, J. AU - Culmer, D. AU - Fraser, R. AU - Almeida, H. AU - Coffer, S. AU - Debnam, E. AU - Kiker, L. AU - Morton, S. AU - Josey, K. AU - Fuller, G. AU - Garvey, W.T. AU - Cherrington, A.L. AU - Dyer, D. AU - Lawson, M.C.R. AU - Griffith, O. AU - Agne, A. AU - McCullars, S. AU - Cohen, R.M. AU - Craig, J. AU - Rogge, M.C. AU - Burton, K. AU - Kersey, K. AU - Wilson, C. AU - Lipp, S. AU - Vonder, Meulen M.B. AU - Adkins, C. AU - Onadeko, T. AU - Rasouli, N. AU - Baker, C. AU - Schroeder, E. AU - Razzaghi, M. AU - Lyon, C. AU - Penaloza, R. AU - Underkofler, C. AU - Lorch, R. AU - Douglass, S. AU - Steiner, S. AU - Sivitz, W.I. AU - Cline, E. AU - Knosp, L.K. AU - McConnell, J. AU - Lowe, T. AU - Herman, W.H. AU - Pop-Busui, R. AU - Martin, C. AU - Waltje, A. AU - Katona, A. AU - Goodhall, L. AU - Eggleston, R. AU - Kuo, S. AU - Bojescu, S. AU - Bule, S. AU - Kessler, N. AU - Lasalle, E. AU - Whitley, K. AU - Seaquist, E.R. AU - Bantle, A. AU - Harindhanavudhi, T. AU - Kumar, A. AU - Redmon, B. AU - Bantle, J. AU - Coe, M. AU - Mech, M. AU - Taddese, A. AU - Lesne, L. AU - Smith, S. AU - Kuechenmeister, L. AU - Shivaswamy, V. AU - Burbach, S. AU - Rodriguez, M.G. AU - Seipel, K. AU - Alfred, A. AU - Morales, A.L. AU - Eggert, J. AU - Lord, G. AU - Taylor, W. AU - Tillson, R. AU - Adolphe, A. AU - Burge, M. AU - Duran-Valdez, E. AU - Martinez, J. AU - Bancroft, A. AU - Kunkel, S. AU - Ali, Jamaleddin Ahmad F. AU - Hernandez, McGinnis D. AU - Pucchetti, B. AU - Scripsick, E. AU - Zamorano, A. AU - Defronzo, R.A. AU - Cersosimo, E. AU - Abdul-Ghani, M. AU - Triplitt, C. AU - Juarez, D. AU - Mullen, M. AU - Garza, R.I. AU - Verastiqui, H. AU - Wright, K. AU - Puckett, C. AU - Raskin, P. AU - Rhee, C. AU - Abraham, S. AU - Jordan, L.F. AU - Sao, S. AU - Morton, L. AU - Smith, O. AU - Osornio, Walker L. AU - Schnurr-Breen, L. AU - Ayala, R. AU - Kreymer, R.B. AU - Sturgess, D. AU - Kahn, S.E. AU - Alarcon-Casas, Wright L. AU - Boyko, E.J. AU - Tsai, E.C. AU - Trence, D.L. AU - Trikudanathan, S. AU - Fattaleh, B.N. AU - Montgomery, B.K. AU - Atkinson, K.M. AU - Kozedub, A. AU - Concepcion, T. AU - Moak, C. AU - Prikhodko, N. AU - Rhothisen, S. AU - Elasy, T.A. AU - Martin, S. AU - Shackelford, L. AU - Goidel, R. AU - Hinkle, N. AU - Lovell, C. AU - Myers, J. AU - Lipps, Hogan J. AU - McGill, J.B. AU - Salam, M. AU - Schweiger, T. AU - Kissel, S. AU - Recklein, C. AU - Clifton, M.J. AU - Tamborlane, W. AU - Camp, A. AU - Gulanski, B. AU - Pham, K. AU - Alguard, M. AU - Gatcomb, P. AU - Lessard, K. AU - Perez, M. AU - Iannone, L. AU - Magenheimer, E. AU - Montosa, A. AU - Cefalu, W.T. AU - Fradkin, J. AU - Burch, H.B. AU - Bremer, A.A. AU - Nathan, D.M. AU - Lachin, J.M. AU - Buse, J.B. AU - Kahn, S.E. AU - Larkin, M.E. AU - Tiktin, M. AU - Wexler, D. AU - Burch, H.B. AU - Bremer, A.A. AU - Lachin, J.M. AU - Bebu, I. AU - Butera, N. AU - Buys, C.J. AU - Fagan, A. AU - Gao, Y. AU - Gramzinski, M.R. AU - Hall, S.D. AU - Kazemi, E. AU - Legowski, E. AU - Liu, H. AU - Suratt, C. AU - Tripputi, M. AU - Arey, A. AU - Backman, M. AU - Bethepu, J. AU - Lund, C. AU - Mangat, Dhaliwal P. AU - McGee, P. AU - Mesimer, E. AU - Ngo, L. AU - Steffes, M. AU - Seegmiller, J. AU - Saenger, A. AU - Arends, V. AU - Gabrielson, D. AU - Conner, T. AU - Warren, S. AU - Day, J. AU - Huminik, J. AU - Soliman, E.Z. AU - Zhang, Z.M. AU - Campbell, C. AU - Hu, J. AU - Keasler, L. AU - Hensley, S. AU - Li, Y. AU - Herman, W.H. AU - Kuo, S. AU - Martin, C. AU - Waltje, A. AU - Mihalcea, R. AU - Min, D.J. AU - Perez-Rosas, V. AU - Prosser, L. AU - Resnicow, K. AU - Ye, W. AU - Shao, H. AU - Zhang, P. AU - Luchsinger, J. AU - Sanchez, D. AU - Assuras, S. AU - Groessl, E. AU - Sakha, F. AU - Chong, H. AU - Hillery, N. AU - Abdouch, I. AU - Bahtiyar, G. AU - Brantley, P. AU - Broyles, F.E. AU - Canaris, G. AU - Copeland, P. AU - Craine, J.J. AU - Fein, W.L. AU - Gliwa, A. AU - Hope, L. AU - Lee, M.S. AU - Meiners, R. AU - Meiners, V. AU - O'Neal, H. AU - Park, J.E. AU - Sacerdote, A. AU - Sledge, E. Jr AU - Soni, L. AU - Steppel-Reznik, J. AU - Turchin, A. AU - the, GRADE Study Research Group TI - Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study) JF - CIRCULATION J2 - CIRCULATION VL - 149 PY - 2024 IS - 13 SP - 993 EP - 1003 PG - 11 SN - 0009-7322 DO - 10.1161/CIRCULATIONAHA.123.066604 UR - https://m2.mtmt.hu/api/publication/34774113 ID - 34774113 N1 - Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, United States Divisions of Cardiovascular and Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville, MD, United States Division of Endocrinology, Kaiser Permanente of Georgia, Atlanta, United States Department of Endocrinology, Emory University School of Medicine, Atlanta, GA, United States Division of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha Va Medical Center, United States Section of Endocrinology, Yale School of Medicine, New Haven, CT, United States Division of Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC, United States Division of Endocrinology, University of New Mexico School of Medicine, Albuquerque, United States Va Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, United States Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, United States Department of Medicine, Va Puget Sound and University of Washington, Seattle, United States Va San Diego Healthcare System and University of California, San Diego, United States Export Date: 6 April 2024 CODEN: CIRCA Correspondence Address: Green, J.B.; C/o the Biostatistics Center, 6110 Executive Blvd, Ste 750, United States; email: grademail@bsc.gwu.edu Chemicals/CAS: cholesterol, 57-88-5; creatinine, 19230-81-0, 60-27-5; hemoglobin A1c, 62572-11-6 AB - BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). METHODS: A total of 5047 participants with a mean±SD age of 57.2±10.0 years, type 2 diabetes duration of 4.0±2.7 years, and low baseline prevalence of cardiovascular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a median of 5 years. Prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalization or revascularization), MACE-5 (MACE-4+coronary revascularization), MACE-6 (MACE-5+hospitalization for heart failure), and the individual components. MACE outcomes and hospitalization for heart failure in the liraglutide-treated group were compared with the other groups combined using Cox proportional hazards models. MACE-6 was also analyzed as recurrent events using a proportional rate model to compare all treatment groups. RESULTS: We observed no statistically significant differences in the cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or their individual components, by randomized treatment group. However, when compared with the other treatment groups combined, the liraglutide-treated group had a significantly lower risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54-0.91]; P=0.021), MACE-6 (adjusted hazard ratio, 0.70 [95% CI, 0.55-0.90]; P=0.021), and hospitalization for heart failure (adjusted hazard ratio, 0.49 [95% CI, 0.28-0.86]; P=0.022). Compared with the liraglutide group, significantly higher rates of recurrent MACE-6 events occurred in the groups treated with glimepiride (rate ratio, 1.61 [95% CI, 1.13-2.29]) or sitagliptin (rate ratio 1.75; [95% CI, 1.24-2.48]). CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01794143. © 2024 Lippincott Williams and Wilkins. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Gribkova, I.V. TI - New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration JF - RATIONAL PHARMACOTHERAPY IN CARDIOLOGY / RATSIONAL'NAYA FARMAKOTERAPIYA V KARDIOLOGII J2 - RATIONAL PHARMACOTHERAPY CARDIOLOGY VL - 20 PY - 2024 IS - 1 SP - 63 EP - 68 PG - 6 SN - 1819-6446 DO - 10.20996/1819-6446-2024-2954 UR - https://m2.mtmt.hu/api/publication/34799345 ID - 34799345 N1 - Export Date: 19 April 2024 Correspondence Address: Gribkova, I.V.; Research Institute for Healthcare Organization and Medical Management, Russian Federation; email: igribkova@yandex.ru LA - Russian DB - MTMT ER - TY - JOUR AU - Guaricci, A.I. AU - Sturdà, F. AU - Russo, R. AU - Basile, P. AU - Baggiano, A. AU - Mushtaq, S. AU - Fusini, L. AU - Fazzari, F. AU - Bertandino, F. AU - Monitillo, F. AU - Carella, M.C. AU - Simonini, M. AU - Pontone, G. AU - Ciccone, M.M. AU - Grandaliano, G. AU - Vezzoli, G. AU - Pesce, F. TI - Assessment and management of heart failure in patients with chronic kidney disease JF - HEART FAILURE REVIEWS J2 - HEART FAIL REV VL - 29 PY - 2024 SP - 379 EP - 394 PG - 16 SN - 1382-4147 DO - 10.1007/s10741-023-10346-x UR - https://m2.mtmt.hu/api/publication/34170050 ID - 34170050 N1 - University Cardiologic Unit, Interdisciplinary Department of Medicine, Polyclinic University Hospital, University of Bari Aldo Moro, Piazza Giulio Cesare 11, Bari, 70121, Italy Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, 70124, Italy Department of Perioperative Cardiology and Cardiovascular Imaging, Centro Cardiologico Monzino, IRCCS, Milan, 20138, Italy Nephrology and Dialysis Unit, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy Department of Nephrology and Dialysis, Vita Salute San Raffaele University, Milan, 20132, Italy Export Date: 3 October 2023 CODEN: HFREF Correspondence Address: Guaricci, A.I.; University Cardiologic Unit, Piazza Giulio Cesare 11, Italy; email: andreaigoren.guaricci@uniba.it LA - English DB - MTMT ER - TY - JOUR AU - Gunn, A.H. AU - Warraich, H.J. AU - Mentz, R.J. TI - Costs of care and financial hardship among patients with heart failure JF - AMERICAN HEART JOURNAL J2 - AM HEART J VL - 269 PY - 2024 SP - 94 EP - 107 PG - 14 SN - 0002-8703 DO - 10.1016/j.ahj.2023.12.001 UR - https://m2.mtmt.hu/api/publication/34502114 ID - 34502114 N1 - Department of Medicine, Duke University School of Medicine, Durham, NC, United States Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States Harvard Medical School, Boston, MA, United States Department of Medicine, Cardiology Section, VA Boston Healthcare System, Boston, MA, United States Division of Cardiology, Duke University School of Medicine, Durham, NC, United States Duke Clinical Research Institute, Durham, NC, United States Export Date: 15 January 2024 CODEN: AHJOA Correspondence Address: Gunn, A.H.; Department of Medicine, DUMC 3710, United States; email: alexander.gunn@duke.edu Funding text 1: The authors express gratitude for the work of Dr Samantha Kaplan, a medical librarian at the Duke Medical Center Library, for her assistance with search strategy optimization. AB - With the implementation of new therapies, more patients are living with heart failure (HF) as a chronic condition. Alongside these advances, out-of-pocket (OOP) medical costs have increased, and patients experience significant financial burden. Despite increasing interest in understanding and mitigating financial burdens, there is a relative paucity of data specific to HF. Here, we explore financial hardship in HF from the patient perspective, including estimated OOP costs for guideline-directed medical therapy for HF with reduced ejection fraction, hospitalizations, and total direct medical costs, as well as the consequences of high OOP costs. Studies estimate that high OOP costs are common in HF, and a large proportion are related to prescription drugs. Subsequently, the effects on patients can lead to worsening adherence, delayed care, and poor outcomes, leading to a financial toxicity spiral. Further, we summarize patients’ cost preferences and outline future research that is needed to develop evidence-based solutions to reduce costs in HF. © 2023 Elsevier Inc. LA - English DB - MTMT ER - TY - JOUR AU - Guo, L. AU - Xiao, X. TI - Guideline for the management of diabetes mellitus in the elderly in China (2024 edition) JF - CHINESE JOURNAL OF DIABETES MELLITUS J2 - CHINESE J DIABET MELLITUS VL - 16 PY - 2024 IS - 2 SP - 147 EP - 189 PG - 43 SN - 1674-5809 DO - 10.3760/cma.j.cn115791-20240112-00020 UR - https://m2.mtmt.hu/api/publication/34816479 ID - 34816479 N1 - Export Date: 24 April 2024 Correspondence Address: Guo, L.; Department of Endocrinology, China; email: glx1218@163.com Correspondence Address: Xiao, X.; Department of Endocrinology, China; email: xiaoxh2014@vip.163.com LA - Chinese DB - MTMT ER - TY - JOUR AU - Guo, L. AU - Xiao, X. TI - Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition) JF - AGING MEDICINE J2 - AGING MED VL - 7 PY - 2024 IS - 1 SP - 5 EP - 51 PG - 47 SN - 2475-0360 DO - 10.1002/agm2.12294 UR - https://m2.mtmt.hu/api/publication/34816478 ID - 34816478 N1 - Export Date: 24 April 2024 Correspondence Address: Guo, L.; National Center of Gerontology, China; email: glx1218@163.com Correspondence Address: Xiao, X.; National Center of Gerontology, China; email: xiaoxh2014@vip.163.com AB - With the deepening of aging in China, the prevalence of diabetes in older people has increased noticeably, and standardized diabetes management is critical for improving clinical outcomes of diabetes in older people. In 2021, the National Center of Gerontology, Chinese Society of Geriatrics, and Diabetes Professional Committee of Chinese Aging Well Association organized experts to write the first guideline for diabetes diagnosis and treatment in older people in China, the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2021 Edition). The guideline emphasizes that older patients with diabetes are a highly heterogeneous group requiring comprehensive assessment and stratified and individualized management strategies. The guideline proposes simple treatments and de-intensified treatment strategies for older patients with diabetes. This edition of the guideline provides clinicians with practical and operable clinical guidance, thus greatly contributing to the comprehensive and full-cycle standardized management of older patients with diabetes in China and promoting the extensive development of clinical and basic research on diabetes in older people and related fields. In the past 3 years, evidence-based medicine for older patients with diabetes and related fields has further advanced, and new treatment concepts, drugs, and technologies have been developed. The guideline editorial committee promptly updated the first edition of the guideline and compiled the Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition). More precise management paths for older patients with diabetes are proposed, for achieving continued standardization of the management of older Chinese patients with diabetes and improving their clinical outcomes. © 2024 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd. LA - English DB - MTMT ER - TY - JOUR AU - Hadjadj, S. AU - Cooper, M.E. AU - Steubl, D. AU - Petrini, M. AU - Hantel, S. AU - Mattheus, M. AU - Wanner, C. AU - Thomas, M.C. TI - Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial JF - KIDNEY MEDICINE J2 - Kidney Med VL - 6 PY - 2024 IS - 3 SN - 2590-0595 DO - 10.1016/j.xkme.2023.100783 UR - https://m2.mtmt.hu/api/publication/34742563 ID - 34742563 N1 - Institut du thorax, INSERM, CNRS, Université Nantes, CHU Nantes, Nantes, France Department of Diabetes, Monash University, Melbourne, Australia Boehringer Ingelheim International GmbH, Ingelheim, Germany, and Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany Export Date: 18 March 2024 Correspondence Address: Thomas, M.C.; Department of Diabetes, Level 5, 99 Commercial Rd, St Kilda Rd Central, Australia; email: Merlin.Thomas@monash.edu Chemicals/CAS: empagliflozin, 864070-44-0 Funding text 1: This analysis was sponsored by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance, who funded the EMPA-REG OUTCOME study and the current analysis. Employees from Boehringer Ingelheim were involved in study design; collection, analysis, and interpretation of data; reviewing and editing of the report; and the decision to submit the report for publication. AB - Rationale & Objective: Kidney function progressively declines in most patients with type 2 diabetes (T2DM). Many develop progressive chronic kidney disease (CKD), but some experience a more rapid decline, with a greater risk of kidney failure and cardiovascular disease. In EMPA-REG OUTCOME, empagliflozin was associated with slower kidney disease progression. This post hoc analysis evaluated the effect of empagliflozin (pooled doses) on the prevalence of a “rapid decliner” phenotype, defined by an annual estimated glomerular filtration rate (eGFR) decline of >3 mL/min/1.73 m2. Study Design: This was an exploratory analysis of EMPA-REG OUTCOME, a large randomized, double-blind, placebo-controlled trial in adults with T2DM, established cardiovascular disease and an eGFR of ≥30 mL/min/1.73 m2. Setting & Participants: Analysis was undertaken on 6,967 participants (99.2%) in whom serial eGFR data was available. Interventions: Patients were randomized (1:1:1) to empagliflozin 10 mg, 25 mg, or placebo in addition to standard of care. Outcomes: Annual change in eGFR over the maintenance phase of treatment (week 4 to last value on treatment) was calculated using linear regression models. Logistic regression analysis was used to investigate differences in rapid decline between the treatment groups. Results: Over the study period, a rapid decliner phenotype was observed in 188 (9.5%) participants receiving placebo and 134 (3.4%) receiving empagliflozin. After adjusting for other risk factors, this equated to a two-third reduction in odds (OR, 0.32; 95% CI, 0.25-0.40; P < 0.001) among participants receiving empagliflozin versus placebo. A comparable risk reduction was observed using a threshold of eGFR decline of >5 mL/min/1.73 m2/y (empagliflozin vs placebo, 43 [1.1%] vs 44 [2.2%] participants; OR, 0.47; 95% CI, 0.31-0.72; P < 0.001). Limitations: This is a post hoc analysis of a trial undertaken in participants with T2DM and CVD. Generalization of findings to other settings remains to be established. Conclusions: Patients receiving empagliflozin were significantly less likely to experience a rapid decline in eGFR over a median of 2.6 years of exposure to the study drug. Funding: The Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Trial Registration: clinicaltrials.gov ID: NCT01131676 Plain-Language Summary: In most people with type 2 diabetes, their kidney function starts to decline over time. However, in some people, this can happen more rapidly, which can increase their risk of kidney or cardiovascular disease. A major study, EMPA-REG OUTCOME, has shown that empagliflozin, which helps to control blood sugar in people with type 2 diabetes, also reduced the risk of cardiovascular disease events and slowed the progression of kidney disease, when compared with people in the study who received placebo. In this new research from the same major study empagliflozin, compared with a placebo, was shown to reduce the risk of people having a rapid decline in their kidney function over the 3 years of the study. © 2023 The Authors LA - English DB - MTMT ER - TY - JOUR AU - Harrington, J. AU - Mentz, R.J. AU - Rockhold, F.W. AU - Garg, J. AU - Butler, J. AU - De, Pasquale C.G. AU - Ezekowitz, J.A. AU - Lewis, G.D. AU - O’Meara, E. AU - Ponikowski, P. AU - Troughton, R.W. AU - Wong, Y.W. AU - Adamczyk, R. AU - Storie, T. AU - Blackman, N. AU - Hernandez, A.F. TI - Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial JF - CIRCULATION-HEART FAILURE J2 - CIRC-HEART FAIL VL - 17 PY - 2024 IS - 2 SP - 169 EP - 177 PG - 9 SN - 1941-3289 DO - 10.1161/CIRCHEARTFAILURE.123.010676 UR - https://m2.mtmt.hu/api/publication/34694316 ID - 34694316 N1 - Department of Medicine, Division of Cardiology, Duke University, Durham, NC, United States Duke Clinical Research Institute, Durham, NC, United States Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, United States Baylor Scott and White Research Institute, Dallas, TX, United States Department of Medicine, University of Mississippi, Jackson, United States Flinders Medical Centre, Flinders University, Adelaide, SA, Australia Canadian VIGOUR, Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) Centre, University of Alberta, Edmonton, AB, Canada Cardiology Division, Massachusetts General Hospital, Boston, United States Montreal Heart Institute, Université de MontréalQC, Canada Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland Christchurch Heart Institute, University of Otago, Christchurch, New Zealand Department of Medicine, The University of Queensland, Brisbane, QLD, Australia Department of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, United States American Regent Inc, Shirley, NY, United States Export Date: 29 February 2024 Correspondence Address: Mentz, R.J.; Department of Internal Medicine, 200 Trent Dr, 4th Floor, Orange Zone, Room 4221, United States; email: robert.mentz@duke.edu LA - English DB - MTMT ER - TY - JOUR AU - Harris, D.D. AU - Sabe, S.A. AU - Xu, C.M. AU - Sabra, M. AU - Broadwin, M. AU - Malhotra, A. AU - Li, J.W. AU - Abid, M.R. AU - Sellke, F.W. TI - Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia JF - SURGERY J2 - SURGERY (UNITED STATES) VL - 175 PY - 2024 IS - 2 SP - 265 EP - 270 PG - 6 SN - 0039-6060 DO - 10.1016/j.surg.2023.09.043 UR - https://m2.mtmt.hu/api/publication/34323200 ID - 34323200 N1 - Export Date: 14 November 2023 CODEN: SURGA Correspondence Address: Sellke, F.W.; Division of Cardiothoracic Surgery, 2 Dudley Street, MOC 360, United States; email: fsellke@lifespan.org AB - Background: Inflammation and disruption of cardiac metabolism are prevalent in the setting of myocardial ischemia. Canagliflozin, a sodium-glucose costransporter-2 inhibitor, has beneficial effects on the heart, though the precise mechanisms are unknown. This study investigated the effects of canagliflozin therapy on metabolic pathways and inflammation in ischemic myocardial tissue using a swine model of chronic myocardial ischemia. Methods: Sixteen Yorkshire swine underwent placement of an ameroid constrictor to the left circumflex artery to induce chronic ischemia. Two weeks later, pigs received either no drug (n = 8) or 300 mg canagliflozin (n = 8) daily. Five weeks later, pigs underwent terminal harvest and tissue collection. Results: Canagliflozin treatment was associated with a trend toward decreased expression of fatty acid oxidation inhibitor acetyl-CoA carboxylase and decreased phosphorylated/inactivated acetyl-CoA carboxylase, a promotor of fatty acid oxidation, compared with control ischemic myocardium (P =.08, P =.03). There was also a significant modulation in insulin resistance markers p-IRS1, p-PKCα, and phosphoinositide 3-kinase in ischemic myocardium of the canagliflozin group compared with the control group (all P <.05). Canagliflozin treatment was associated with a significant increase in inflammatory markers interleukin 6, interleukin 17, interferon-gamma, and inducible nitric oxide synthase (all P <.05). There was a trend toward decreased expression of the anti-inflammatory cytokines interleukin 10 (P =.16) and interleukin 4 (P =.31) with canagliflozin treatment. Conclusion: The beneficial effects of canagliflozin therapy appear to be associated with inhibition of fatty acid oxidation and enhancement of insulin signaling in ischemic myocardium. Interestingly, canagliflozin appears to increase the levels of several inflammatory markers, but further studies are required to better understand how canagliflozin modulates inflammatory signaling pathways. © 2023 Elsevier Inc. LA - English DB - MTMT ER - TY - JOUR AU - Hasan, I. AU - Rashid, T. AU - Jaikaransingh, V. AU - Heilig, C. AU - Abdel-Rahman, E.M. AU - Awad, A.S. TI - SGLT2 inhibitors: Beyond glycemic control JF - Journal of Clinical and Translational Endocrinology J2 - J Clin Transl Endocrinol VL - 35 PY - 2024 SN - 2214-6237 DO - 10.1016/j.jcte.2024.100335 UR - https://m2.mtmt.hu/api/publication/34777751 ID - 34777751 N1 - Export Date: 8 April 2024 LA - English DB - MTMT ER - TY - JOUR AU - Hepp, Tamás AU - Varjas, Norbert AU - Hévízi, Zsombor AU - Bodor, Alexandra AU - Benczúr, Béla TI - A csökkent ejekciós frakcióval járó krónikus szívelégtelenség gyógyszeres terápiája: vericiguát, a lehetséges ötödik pillér? JF - LEGE ARTIS MEDICINAE J2 - LEGE ART MED VL - 34 PY - 2024 IS - 1-2 SP - 8 EP - 15 PG - 8 SN - 0866-4811 DO - 10.33616/lam.34.0008 UR - https://m2.mtmt.hu/api/publication/34741073 ID - 34741073 AB - A krónikus szívelégtelenség incidenciája és prevalenciája világszerte növekszik, morbiditása és mortalitása továbbra is magas, a betegség megfelelő kezelése kiemelt jelentőségű. A csökkent balkamra-funkcióval járó szívelégtelenség (HFrEF) kezelése jelenleg négy alappillérre támaszkodik: ACEI/ARNI, β-blokkolók, MRA-k és legújabb csoportként az SGLT-2-gátlók, melyek mind - egyike igazoltan csökkenti a HFrEF-betegek mortalitását és morbiditását. A HFrEF gyógyszeres terápiájának viszonylag új terápiás lehetősége a szolúbilis guanilát-cikláz-stimulátor vericiguát, mely a szívelégtelenségben szenvedő betegekben károsodott NO-sGC-cGMP jelátviteli útba avatkozik be. A vericiguát nitrogén-monoxid jelenlététől függetlenül aktiválja a sGC enzimet, melynek következtében az intracelluláris cGMP-szint magas marad, amely javíthatja az endothelialis, myocardialis és vascularis funkciókat egyaránt. A vericiguát biztonságosságát és hatékonyságát a VICTORIA vizsgálatban igazolták. A közelmúltban szív elégtelenség miatt kórházba került, vagy parenteralis diuretikumterápiára szoruló, 45%-nál rosszabb ejekciós frakcióval járó krónikus szívelégtelen betegekben a vericiguát szignifikáns mértékben csökkentette a szívelégtelenség miatti hospitalizáció és a cardiovascularis halálozás összetett vég pontját placebóhoz képest. A relatívkockázat-csökkenés 10%, az abszolútkockázat-csökkenés 4,2% volt a vericiguát-csoportban. A VICTORIA vizsgálatban mutatott pozitív eredményeknek köszönhetően a vericiguát új gyógyszeres terápiás lehetőségként került be a 2021-ben bemutatott ESC Szívelégtelenség irányelvbe. Az ajánlás jelenleg IIb evidenciaszinttel javasolja a vericiguát alkalmazását olyan HFrEF-betegek esetén, akik a közelmúltban optimális gyógyszeres terápia ellenére szívelégtelenség progressziója miatt ellátásra szorultak. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Hirota, Yushi AU - Kakei, Yasumasa AU - Imai, Junta AU - Katagiri, Hideki AU - Ebihara, Ken AU - Wada, Jun AU - Suzuki, Junichi AU - Urakami, Tatsuhiko AU - Omori, Takashi AU - Ogawa, Wataru TI - A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01) JF - DIABETES THERAPY J2 - DIABTHERAP VL - 15 PY - 2024 SP - 533 EP - 545 PG - 13 SN - 1869-6953 DO - 10.1007/s13300-023-01526-x UR - https://m2.mtmt.hu/api/publication/34649636 ID - 34649636 N1 - Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan Clinical and Translational Research Center, Kobe University Hospital, Kobe, Japan Department of Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Miyagi, Japan Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan Division of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan Export Date: 29 February 2024 Correspondence Address: Ogawa, W.; Division of Diabetes and Endocrinology, 7-5-1 Kusunoki-cho, Chuo-ku, Japan; email: ogawa@med.kobe-u.ac.jp LA - English DB - MTMT ER - TY - JOUR AU - Hogan, George AU - Patel, Hiten AU - Patel, Nikhil R. TI - Are you giving men with heart failure the best care? JF - TRENDS IN UROLOGY & MENS HEALTH J2 - TRENDS IN UROLOGY & MENS HEALTH VL - 15 PY - 2024 IS - 1 SP - 11 EP - 16 PG - 6 SN - 2044-3730 DO - 10.1002/tre.948 UR - https://m2.mtmt.hu/api/publication/34603292 ID - 34603292 AB - Heart failure is a leading cause of morbidity and mortality worldwide. Management involves a comprehensive multidisciplinary approach focusing on symptom control, preventing disease progression and improving patients' quality of life. Significant advances in recent years, including the introduction of combination angiotensin receptor-neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors, have led to an improvement in long-term prognosis. LA - English DB - MTMT ER - TY - JOUR AU - Hojná, S. AU - Malínská, H. AU - Hüttl, M. AU - Vaňourková, Z. AU - Marková, I. AU - Miklánková, D. AU - Hrdlička, J. AU - Papoušek, F. AU - Neckář, J. AU - Kujal, P. AU - Behuliak, M. AU - Rauchová, H. AU - Kadlecová, M. AU - Sedmera, D. AU - Neffeová, K. AU - Zábrodská, E. AU - Olejníčková, V. AU - Zicha, J. AU - Vaněčková, I. TI - Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet JF - BIOMEDICINE & PHARMACOTHERAPY J2 - BIOMED PHARMACOTHER VL - 174 PY - 2024 SN - 0753-3322 DO - 10.1016/j.biopha.2024.116520 UR - https://m2.mtmt.hu/api/publication/34795677 ID - 34795677 N1 - Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic 3rd Faculty of Medicine, Charles University, Prague, Czech Republic 1st Faculty of Medicine, Charles University, Prague, Czech Republic Export Date: 17 April 2024 CODEN: BIPHE Correspondence Address: Vaněčková, I.; Laboratory of Experimental Hypertension, Videnska 1083, Czech Republic; email: ivana.vaneckova@fgu.cas.cz AB - A combination of liver and heart dysfunction worsens the prognosis of human survival. The aim of this study was to investigate whether empagliflozin (a sodium-glucose transporter-2 inhibitor) has beneficial effects not only on cardiac and renal function but also on hepatic function. Adult (6-month-old) male spontaneously hypertensive rats (SHR) were fed a high-fat diet (60% fat) for four months to induce hepatic steatosis and mild heart failure. For the last two months, the rats were treated with empagliflozin (empa, 10 mg.kg-1.day-1 in the drinking water). Renal function and oral glucose tolerance test were analyzed in control (n=8), high-fat diet (SHR+HF, n=10), and empagliflozin-treated (SHR+HF+empa, n=9) SHR throughout the study. Metabolic parameters and echocardiography were evaluated at the end of the experiment. High-fat diet feeding increased body weight and visceral adiposity, liver triglyceride and cholesterol concentrations, and worsened glucose tolerance. Although the high-fat diet did not affect renal function, it significantly worsened cardiac function in a subset of SHR rats. Empagliflozin reduced body weight gain but not visceral fat deposition. It also improved glucose sensitivity and several metabolic parameters (plasma insulin, uric acid, and HDL cholesterol). In the liver, empagliflozin reduced ectopic lipid accumulation, lipoperoxidation, inflammation and pro-inflammatory HETEs, while increasing anti-inflammatory EETs. In addition, empagliflozin improved cardiac function (systolic, diastolic and pumping) independent of blood pressure. The results of our study suggest that hepatoprotection plays a decisive role in the beneficial effects of empagliflozin in preventing the progression of cardiac dysfunction induced by high-fat diet feeding. © 2024 The Authors LA - English DB - MTMT ER - TY - JOUR AU - Horiuchi, Y. AU - Asami, M. AU - Yahagi, K. AU - Oshima, A. AU - Gonda, Y. AU - Yoshiura, D. AU - Komiyama, K. AU - Yuzawa, H. AU - Tanaka, J. AU - Aoki, J. AU - Tanabe, K. TI - Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 6 SN - 2077-0383 DO - 10.3390/jcm13061670 UR - https://m2.mtmt.hu/api/publication/34795719 ID - 34795719 N1 - Export Date: 17 April 2024 Correspondence Address: Horiuchi, Y.; Division of Cardiology, Japan; email: yooouyou@gmail.com AB - (1) Background: In patients with heart failure (HF) and impaired nutritional status or decreased muscle mass, sodium-glucose cotransporter-2 inhibitors (SGLT2is) may worsen these conditions and result in poor prognosis, especially worsening of frailty. We aimed to investigate the relationship between SGLT2is and clinical outcomes, including frailty-related events, in patients with HF and malnutrition, frailty, sarcopenia, or cachexia. (2) Methods: In this retrospective observational cohort study, a global federated health research network provided data on patients with HF and malnutrition, frailty, sarcopenia, or cachexia from January 2016 to December 2021. We investigated the incidence of the composite endpoint of death or frailty-related events within one year. (3) Results: Among 214,778 patients included in the analysis, 4715 were treated with SGLT2is. After propensity score matching, 4697 patients in the SGLT2is group were matched with 4697 patients in the non-SGLT2is groups. The incidence of the composite endpoint, mortality, and frailty-related events was lower in the SGLT2is group than in the non-SGLT2is group (composite endpoint, 65.6% versus 77.6%, p < 0.001; mortality, 17.4% vs. 35.5%, p < 0.001; frailty-related events, 59.4% vs. 64.3%, p < 0.001). (4) Conclusions: Patients with HF and malnutrition, frailty, sarcopenia, or cachexia had a high incidence of death and frailty-related events. SGLT2is were associated with a lower incidence of these events. © 2024 by the authors. LA - English DB - MTMT ER - TY - JOUR AU - Hsu, C.-Y. AU - Yeh, C.-Y. AU - Yen, T.-Y. AU - Chen, C.-C. AU - Chen, J.-F. AU - Chu, C.-H. AU - Huang, C.-N. AU - Lin, C.-L. AU - Lin, S.-Y. AU - Liu, F.-H. AU - Ou, H.-Y. AU - Wang, C.-Y. TI - The expert consensus on care and education for patients with diabetic kidney disease in Taiwan JF - PRIMARY CARE DIABETES J2 - PRIM CARE DIABETES VL - In press PY - 2024 SN - 1751-9918 DO - 10.1016/j.pcd.2024.02.003 UR - https://m2.mtmt.hu/api/publication/34742622 ID - 34742622 N1 - Export Date: 18 March 2024 Correspondence Address: Ou, H.-Y.; Endocrinology and Metabolism Division, Taiwan; email: mikonlon@gmail.com Funding text 1: The authors would like to thank all colleagues who contributed to this study. AB - Increasing prevalence of type 2 DM (T2DM) and diabetic kidney disease (DKD) has posed a great impact in Taiwan. However, guidelines focusing on multidisciplinary patient care and patient education remain scarce. By literature review and expert discussion, we propose a consensus on care and education for patients with DKD, including general principles, specifics for different stages of chronic kidney disease (CKD), and special populations. (i.e. young ages, patients with atherosclerotic cardiovascular disease or heart failure, patients after acute kidney injury, and kidney transplant recipients). Generally, we suggest performing multidisciplinary patient care and education in alignment with the government-led Diabetes Shared Care Network to improve the patients’ outcomes for all patients with DKD. Also, close monitoring of renal function with early intervention, control of comorbidities in early stages of CKD, and nutrition adjustment in advanced CKD should be emphasized. © 2024 The Authors LA - English DB - MTMT ER - TY - JOUR AU - Htoo, P.T. AU - Tesfaye, H. AU - Schneeweiss, S. AU - Wexler, D.J. AU - Everett, B.M. AU - Glynn, R.J. AU - Schmedt, N. AU - Koeneman, L. AU - Déruaz-Luyet, A. AU - Paik, J.M. AU - Patorno, E. TI - Effectiveness and safety of empagliflozin: final results from the EMPRISE study JF - DIABETOLOGIA J2 - DIABETOLOGIA VL - In press PY - 2024 SP - In press SN - 0012-186X DO - 10.1007/s00125-024-06126-3 UR - https://m2.mtmt.hu/api/publication/34766721 ID - 34766721 N1 - Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, United States Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, MA, United States Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States Global Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany Global Medical Affairs, Lilly Deutschland GmbH, Bad Homburg vor der Höhe, Germany Division of Renal (Kidney) Medicine, Brigham and Women’s Hospital, Boston, MA, United States Export Date: 3 April 2024 CODEN: DBTGA Correspondence Address: Patorno, E.; Division of Pharmacoepidemiology and Pharmacoeconomics, United States; email: epatorno@bwh.harvard.edu AB - Aims/hypothesis: Limited evidence exists on the comparative safety and effectiveness of empagliflozin against alternative glucose-lowering medications in individuals with type 2 diabetes with the broad spectrum of cardiovascular risk. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) cohort study was designed to monitor the safety and effectiveness of empagliflozin periodically for a period of 5 years with data collection from electronic healthcare databases. Methods: We identified individuals ≥18 years old with type 2 diabetes who initiated empagliflozin or dipeptidyl peptidase-4 inhibitors (DPP-4i) from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we identified four a priori-defined effectiveness outcomes: (1) myocardial infarction (MI) or stroke; (2) hospitalisation for heart failure (HHF); (3) major adverse cardiovascular events (MACE); and (4) cardiovascular mortality or HHF. Safety outcomes included lower-limb amputations, non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), severe hypoglycaemia, retinopathy progression, and short-term kidney and bladder cancers. We estimated HRs and rate differences (RDs) per 1000 person-years, overall and stratified by age, sex, baseline atherosclerotic cardiovascular disease (ASCVD) and heart failure. Results: We identified 115,116 matched pairs. Compared with DPP-4i, empagliflozin was associated with lower risks of MI/stroke (HR 0.88 [95% CI 0.81, 0.96]; RD −2.08 [95% CI (−3.26, −0.90]), HHF (HR 0.50 [0.44, 0.56]; RD −5.35 [−6.22, −4.49]), MACE (HR 0.73 [0.62, 0.86]; RD −6.37 [−8.98, −3.77]) and cardiovascular mortality/HHF (HR 0.57 [0.47, 0.69]; RD −10.36 [−12.63, −8.12]). Absolute benefits were larger in older individuals and in those with ASCVD/heart failure. Empagliflozin was associated with an increased risk of DKA (HR 1.78 [1.44, 2.19]; RD 1.59 [1.08, 2.09]); decreased risks of AKI (HR 0.62 [0.54, 0.72]; RD −2.39 [−3.08, −1.71]), hypoglycaemia (HR 0.75 [0.67, 0.84]; RD −2.46 [−3.32, −1.60]) and retinopathy progression (HR 0.78 [0.63, 0.96)]; RD −9.49 [−16.97, −2.10]); and similar risks of other safety events. Conclusions/interpretation: Empagliflozin relative to DPP-4i was associated with risk reductions of MI or stroke, HHF, MACE and the composite of cardiovascular mortality or HHF. Absolute risk reductions were larger in older individuals and in those who had history of ASCVD or heart failure. Regarding the safety outcomes, empagliflozin was associated with an increased risk of DKA and lower risks of AKI, hypoglycaemia and progression to proliferative retinopathy, with no difference in the short-term risks of lower-extremity amputation, non-vertebral fractures, kidney and renal pelvis cancer, and bladder cancer. Graphical Abstract: (Figure presented.) © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. LA - English DB - MTMT ER - TY - JOUR AU - Huang, C.-Y. AU - Lee, J.-K. TI - Effects of SGLT2 Inhibitors with and without Metformin in High-Risk, Treatment-Naïve Patients with Diabetes JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 5 SN - 2077-0383 DO - 10.3390/jcm13051387 UR - https://m2.mtmt.hu/api/publication/34777755 ID - 34777755 N1 - Export Date: 8 April 2024 LA - English DB - MTMT ER - TY - JOUR AU - Huang, Y. AU - Zhou, H. AU - Fang, C. AU - Ma, L. AU - Zhang, Y. AU - Rong, W. AU - Liu, X. AU - Ye, H. TI - Cost-Effectiveness of New Quadruple Therapy Compared with Standard Treatment for Patients with Heart Failure in China JF - JOURNAL OF CARDIOVASCULAR PHARMACOLOGY J2 - J CARDIOVASC PHARM VL - 83 PY - 2024 IS - 1 SP - 86 EP - 92 PG - 7 SN - 0160-2446 DO - 10.1097/FJC.0000000000001476 UR - https://m2.mtmt.hu/api/publication/34536402 ID - 34536402 N1 - Department of Pharmacy, Ningbo Medical Center, Li Huili Hospital, Ningbo University, Ningbo, Zhijiang, China The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, Hunan, China Department of Cardiology, Ningbo Medical Center, Li Huili Hospital, Ningbo University, Ningbo, Zhijiang, China Export Date: 27 January 2024 CODEN: JCPCD Correspondence Address: Liu, X.; The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Caie North Road No. 233, Changsha, China; email: liuxiaoli0923@sina.com Correspondence Address: Ye, H.; Department of Cardiology, Xingning Road No. 57, Ningbo, China; email: lindayenbzjch@163.com Chemicals/CAS: dapagliflozin, 461432-26-8; empagliflozin, 864070-44-0; Sodium-Glucose Transporter 2 Inhibitors Funding text 1: Supported by the 2021 Zhejiang Pharmaceutical Association Hospital Pharmacy Special Scientific Research Funding Project (No. 2021ZYY41), the Pharmacoeconomics and Health Technology Assessment Fund Project of Zhejiang Pharmaceutical Association (No. 2022JYZ12) and NINGBO Medical & Health Leading Academic Discipline Project (No. 2022-F06). AB - Abstract:This study aimed to compare the cost-effectiveness of the new quadruple therapy regimen of adding sodium-glucose-linked transporter 2 (SGLT2) inhibitors, with standard treatment for patients with heart failure (HF) in China. From the payer's perspective, the dates of cardiovascular event recurrences were extracted from a meta-analysis including 6 trials, combined with the treatment cost for patients with HF in China to construct a Markov model. The outcomes included per capita medical costs and incremental cost-effectiveness ratio, using quality-adjusted life years (QALYs) data. Single-factor, probability sensitivity analysis, and scenario analysis were used to explore the potential uncertainties of the model. The per capita costs of the new quadruple therapy regimen and standard treatment were $87441.26 and $87087.54, respectively. The new regimen was associated with a mean of 21.44 QALYs gained, compared with 18.60 QALYs gained with the standard treatment. The incremental cost-effectiveness ratio was $124.03 per QALY gained. The sensitivity analysis revealed that changes in the parameters within the set range did not affect the model results. In China, compared with standard treatment, the new quadruple therapy regimen with SGLT2 inhibitors reduce the frequency of cardiovascular events among patients with HF, and it has economic advantages. © 2024 Lippincott Williams and Wilkins. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Hu, Wei-Syun AU - Lin, Cheng-Li TI - Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study JF - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY J2 - N-S ARCH PHARMACOL VL - 397 PY - 2024 SP - 575 EP - 581 PG - 7 SN - 0028-1298 DO - 10.1007/s00210-023-02623-1 UR - https://m2.mtmt.hu/api/publication/34169712 ID - 34169712 N1 - Funding Agency and Grant Number: Ministry of Science and Technology [MOST 1112321-B-039005]; China Medical University [CMU110-AWARD-01]; China Medical University Hospital [DMR-HHC-1104, DMR-111105]; Health Data Science Center, China Medical University Hospital Funding text: This study is supported in part by the Ministry of Science and Technology (MOST 111-2321-B-039-005), China Medical University (CMU110-AWARD-01), and China Medical University Hospital (DMR-HHC-110-4, DMR-111-105). We are grateful to Health Data Science Center, China Medical University Hospital for providing administrative, technical, and funding support. The funders had no role in the study design, data collection and analysis, the decision to publish, or preparation of the manuscript. No additional external funding was received for this study. AB - To compare the potential role of sodium-glucose cotransporter-2 inhibitors (SGLT2I) in the development of psychiatric disease among patients with type 2 diabetes mellitus (DM). Using a large population-based database, SGLT2I users and non-SGLT2I users were 1:1 matched according to the covariates of sex, age, comorbidities, adapted diabetes complications severity index (DCSI), medications, and index year using propensity score matching and a logistic regression model. We calculated the incidence of major psychiatric disorders and adjusted hazard ratios (HR) with 95% confidence interval (CI) for SGLT2I users and the non- SGLT2I users using a Cox proportional hazards model. SGLT2I were associated with a lower risk for psychiatric disorders than those not treated with SGLT2I (HR 0.80 and 95% CI 0.72-0.88). Among patients with DM, SGLT2I were associated with a lower risk of psychiatric disease. LA - English DB - MTMT ER - TY - JOUR AU - Hu, W.-S. AU - Lin, C.-L. TI - Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus—a retrospective analysis of nationwide medical claims data JF - NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY J2 - N-S ARCH PHARMACOL VL - 397 PY - 2024 SP - 1623 EP - 1631 PG - 9 SN - 0028-1298 DO - 10.1007/s00210-023-02685-1 UR - https://m2.mtmt.hu/api/publication/34170072 ID - 34170072 N1 - School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, 2, Yuh-Der Road, Taichung, 40447, Taiwan Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan Export Date: 3 October 2023 CODEN: NSAPC Correspondence Address: Hu, W.-S.; School of Medicine, Taiwan; email: weisyunhu@gmail.com LA - English DB - MTMT ER - TY - JOUR AU - Iwakura, Katsuomi AU - Onishi, Toshinari AU - Okamura, Atsunori AU - Koyama, Yasushi AU - Tanaka, Nobuaki AU - Okada, Masato AU - Fujii, Kenshi AU - Seo, Masahiro AU - Yamada, Takahisa AU - Yano, Masamichi AU - Hayashi, Takaharu AU - Yasumura, Yoshio AU - Nakagawa, Yusuke AU - Tamaki, Shunsuke AU - Nakagawa, Akito AU - Sotomi, Yohei AU - Hikoso, Shungo AU - Nakatani, Daisaku AU - Sakata, Yasushi AU - Watanabe, Tetsuya AU - Higuchi, Yoshiharu AU - Masuda, Masaharu AU - Asai, Mitsutoshi AU - Mano, Toshiaki AU - Fuji, Hisakazu AU - Masuda, Daisaku AU - Shutta, Ryu AU - Yamashita, Shizuya AU - Sairyo, Masami AU - Abe, Haruhiko AU - Ueda, Yasunori AU - Matsumura, Yasushi AU - Nagai, Kunihiko AU - Nishino, Masami AU - Tanouchi, Jun AU - Arita, Yoh AU - Ogasawara, Nobuyuki AU - Ishizu, Takamaru AU - Ichikawa, Minoru AU - Takano, Yuzuru AU - Rin, Eisai AU - Shinoda, Yukinori AU - Tachibana, Koichi AU - Hoshida, Shiro AU - Izumi, Masahiro AU - Yamamoto, Hiroyoshi AU - Kato, Hiroyasu AU - Nakatani, Kazuhiro AU - Yasuga, Yuji AU - Nishio, Mayu AU - Hirooka, Keiji AU - Yoshimura, Takahiro AU - Kashiwase, Kazunori AU - Hasegawa, Shinji AU - Tani, Akihiro AU - Okumoto, Yasushi AU - Makino, Yasunaka AU - Kijima, Yoshiyuki AU - Kitao, Takashi AU - Fujita, Masashi AU - Harada, Koichiro AU - Kumada, Masahiro AU - Nakagawa, Osamu AU - Araki, Ryo AU - Yamada, Takayuki AU - Matsuoka, Yuki AU - Sato, Taiki AU - Sunaga, Akihiro AU - Oeun, Bolrathanak AU - Kida, Hirota AU - Dohi, Tomoharu AU - Akazawa, Yasuhiro AU - Nakamoto, Kei AU - Okada, Katsuki AU - Sera, Fusako AU - Kioka, Hidetaka AU - Ohtani, Tomohito AU - Takeda, Toshihiro AU - Mizuno, Hiroya TI - The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 14 PY - 2024 IS - 1 PG - 12 SN - 2045-2322 DO - 10.1038/s41598-024-52101-8 UR - https://m2.mtmt.hu/api/publication/34613005 ID - 34613005 N1 - Division of Cardiology, Sakurabashi Watanabe Hospital, 2-4-32, Umeda, Kita-ku, Osaka, 5300001, Japan Department of Cardiovascular Medicine, Sakai City Medical Center, Sakai, Japan Division of Cardiology, Osaka General Medical Center, Osaka, Japan Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan Cardiovascular Division, Osaka Police Hospital, Osaka, Japan Division of Cardiology, Amagasaki Chuo Hospital, Amagasaki, Japan Division of Cardiology, Kawanishi City Medical Center, Kawanishi, Japan Department of Cardiology, Rinku General Medical Center, Izumisano, Japan Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine, Toon, Japan Department of Medical Informatics, Osaka University Graduate School of Medicine, Osaka, Japan Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan Cardiovascular Medicine, Nara Medical University, Kashihara, Japan Kansai Rosai Hospital, Amagasaki, Japan Kobe Ekisaikai Hospital, Kobe, Japan National Hospital Organization Osaka National Hospital, Osaka, Japan Ikeda Municipal Hospital, Ikeda, Japan Japan Community Health Care Organization Osaka Hospital, Osaka, Japan Higashiosaka City Medical Center, Higashiosaka, Japan Kawachi General Hospital, Higashiosaka, Japan Yao Municipal Hospital, Yao, Japan Kinki Central Hospital, Itami, Japan Japan Community Health Care Organization, Osaka Minato Central Hospital, Osaka, Japan Sumitomo Hospital, Osaka, Japan Saiseikai Senri Hospital, Suita, Japan National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan Kano General Hospital, Osaka, Japan Kinan Hospital, Tanabe, Japan Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan Japan Community Health Care Organization, Hoshigaoka Medical Center, Hirakata, Japan Minoh City Hospital, Minoh, Japan Osaka International Cancer Institute, Osaka, Japan Suita Municipal Hospital, Suita, Japan Toyonaka Municipal Hospital, Toyonaka, Japan Otemae Hospital, Osaka, Japan Export Date: 29 February 2024 Correspondence Address: Iwakura, K.; Division of Cardiology, 2-4-32, Umeda, Kita-ku, Japan; email: iwakura@mac.com AB - The coexistence of heart failure is frequent and associated with higher mortality in patients with type 2 diabetes (T2DM), and its management is a critical issue. The WATCH-DM risk score is a tool to predict heart failure in patients with type 2 diabetes mellitus (T2DM). We investigated whether it could estimate outcomes in T2DM patients with heart failure with preserved ejection fraction (HFpEF). The WATCH-DM risk score was calculated in 418 patients with T2DM hospitalized for HFpEF (male 49.5%, age 80 +/- 9 years, HbA1c 6.8 +/- 1.0%), and they were divided into the äverage or lower" (<= 10 points), "high" (11-13 points) and "very high" (>= 14 points) risk groups. We followed patients to observe all-cause death for 386 days (median). We compared the area under the curve (AUC) of the WATCH-DM score for predicting 1-year mortality with that of the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score and of the Barcelona Bio-Heart Failure Risk (BCN Bio-HF). Among the study patients, 108 patients (25.8%) had average or lower risk scores, 147 patients (35.2%) had high risk scores, and 163 patients (39.0%) had very high risk scores. The Cox proportional hazard model selected the WATCH-DM score as an independent predictor of all-cause death (HR per unit 1.10, 95% CI 1.03 to 1.19), and the äverage or lower" risk group had lower mortality than the other groups (p = 0.047 by log-rank test). The AUC of the WATCH-DM for 1-year mortality was 0.64 (95% CI 0.45 to 0.74), which was not different from that of the MAGGIC score (0.72, 95% CI 0.63 to 0.80, p = 0.08) or that of BCN Bio-HF (0.70, 0.61 to 0.80, p = 0.25). The WATCH-DM risk score can estimate prognosis in T2DM patients with HFpEF and can identify patients at higher risk of mortality. LA - English DB - MTMT ER - TY - JOUR AU - Jain, Sneha S. AU - Yu, Jie AU - Arnott, Clare AU - Neal, Bruce AU - Perkovic, Vlado AU - Neuen, Brendon L. AU - Jardine, Meg AU - Mahaffey, Kenneth W. TI - Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial JF - INTERNATIONAL JOURNAL OF CARDIOLOGY J2 - INT J CARDIOL VL - 395 PY - 2024 PG - 5 SN - 0167-5273 DO - 10.1016/j.ijcard.2023.131444 UR - https://m2.mtmt.hu/api/publication/34501925 ID - 34501925 N1 - Funding Agency and Grant Number: Janssen Research & Development, LLC Funding text: The CANVAS Program and the CREDENCE trial were sponsored by Janssen Research & Development, LLC. AB - Background: Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that has been shown to reduce cardio-vascular events in diabetic patients with and without heart failure (HF). Whether the clinical benefits and safety profile of canagliflozin are different in those on a beta blocker and an angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (BB + RAASi) is unknown.Methods: We pooled participants with HF at baseline from the CANVAS Program and CREDENCE trial and assessed major adverse cardiovascular events and its components; hospitalization for heart failure (HHF); HHF or CV death; all-cause mortality; a renal composite; and a combined renal and CV composite.Results: Of 14,543 participants, 2113 had HF at baseline, and 1280 were on BB + RAASi. In those with a history of HF, participants on BB + RAASi therapy were more likely to have coronary atherosclerotic disease (82 vs 72%, p < 0.001), history of myocardial infarction (42 vs 29%, p < 0.001), higher mean body mass index (34 vs 32 kg/ m(2), p < 0.001), and lower mean estimated glomerular filtration rate (67 vs 70 mL/min/1.73 m(2), p < 0.01). They were also more likely to be on insulin, a statin, antithrombotic agent, and a diuretic (all p < 0.001). In unadjusted analysis and when adjusted for selected baseline factors, there was no heterogeneity in canagliflozin treatment effect except for HHF/CV death in those on baseline BB + RAASi vs. those not on baseline BB + RAASi (Phe-terogeneity = 0.02).Conclusion: Canagliflozin mostly improved CV and kidney outcomes in participants with a history of HF irrespective of use of BB + RAASi at baseline, with possible greater benefit on HHF/CV death in participants on BB + RAASi. LA - English DB - MTMT ER -